Moral Foundations in Treatment Decisions: Navigating the Ethical Equivalence of Withholding and Withdrawing Life-Sustaining Therapy

Abstract

This article examines the ethical, clinical, and legal distinctions between withholding (WH) and withdrawing (WD) life-sustaining treatment (LST), a central dilemma in end-of-life care and clinical trial design. For researchers and drug development professionals, we explore the foundational ethical principles, the documented disparities in clinician perception and application, and the resulting moral distress. The analysis synthesizes current empirical evidence, including clinician surveys and systematic reviews, to address methodological challenges in end-of-life decision-making protocols. We further contrast these practices with assisted dying to clarify critical ethical and legal boundaries, providing a comprehensive framework to guide policy development, clinical practice, and ethical design of trials involving critically ill populations.

Deconstructing the Ethical Framework: Core Principles and Clinician Perceptions in LST Decisions

The conduct of research and clinical practice in medicine is guided by a framework of core ethical principles that serve as fundamental action guides when facing moral dilemmas. These principles, often called principlism, provide a common set of moral commitments for a pluralistic society and a shared language for ethical analysis [1]. Specifically in the context of biomedical research and drug development, these principles inform critical decisions regarding study design, participant interaction, and the application of emerging technologies [2]. While these principles are not absolute rules and may sometimes conflict, they provide a systematic approach to ethical problem-solving that balances competing moral demands [3] [1].

The historical development of these principles spans millennia, with beneficence and nonmaleficence tracing back to the Hippocratic Oath's directive "to help and do no harm" [1]. Autonomy and justice gained broader acceptance as essential principles more recently, with Beauchamp and Childress's Principles of Biomedical Ethics solidifying the four-principle framework that dominates contemporary bioethics discourse [3]. The Belmont Report (1979) further codified three principles—respect for persons, beneficence, and justice—as guidelines for ethical research involving human subjects [1]. This whitepaper examines these four foundational principles—autonomy, beneficence, non-maleficence, and justice—within the specific context of moral foundations for research on withholding versus withdrawing treatment, providing researchers and drug development professionals with both theoretical understanding and practical applications.

The Four Ethical Principles: Foundations and Applications

Autonomy: Respect for Self-Determination

The principle of autonomy recognizes the right of individuals to make informed decisions about their own lives and bodies without external control or coercion [3] [4]. Philosophically, autonomy is grounded in the concept that all persons have intrinsic worth and should be able to exercise their capacity for self-determination [3]. In healthcare and research contexts, this principle was famously articulated in 1914 by Justice Cardozo: "Every human being of adult years and sound mind has a right to determine what shall be done with his own body" [3] [4].

The practical application of autonomy extends to several key research domains:

• Informed Consent: Requires that participants (i) are competent to understand and decide, (ii) receive full disclosure, (iii) comprehend the disclosure, (iv) act voluntarily, and (v) consent to the proposed action [3]. Recent ethical challenges have emerged when clinical trials are terminated prematurely for political or funding reasons, potentially violating the informed consent agreement between researchers and participants [5] [6].
• Truth-Telling and Confidentiality: These obligations spring directly from respect for autonomy, requiring honest communication and protection of private information [3]. In AI-driven drug development, new challenges to autonomy emerge regarding data mining and use of genetic information, requiring renewed attention to informed consent processes [2].
• Decision-Making Capacity: The principle of autonomy does not extend to persons who lack capacity to act autonomously, including infants, children, and those with developmental, mental, or physical disorders that impair decision-making [3]. Assessing capacity remains a critical researcher responsibility.

Contemporary challenges to autonomy include cultural variations in its application, with some populations preferring family-centered approaches to decision-making, and the emergence of "relational autonomy" that acknowledges social and cultural determinants of individual choice [3].

Beneficence: The Duty to Do Good

The principle of beneficence represents the affirmative duty to promote the welfare of others and act in their best interests [3]. In distinction to nonmaleficence, beneficence uses the language of positive requirements—not merely avoiding harm, but actively benefiting patients and promoting their welfare [3]. This principle supports several moral rules, including protecting and defending the rights of others, preventing harm, removing harmful conditions, helping persons with disabilities, and rescuing persons in danger [3].

In research contexts, beneficence manifests through:

• Risk-Benefit Assessment: Researchers must carefully weigh potential benefits against risks, ensuring that the probability and magnitude of benefit justify any foreseeable risks [1].
• Study Design and Conduct: Ethical research must maximize potential benefits while minimizing risks through sound scientific design and competent execution [1].
• Ongoing Welfare Monitoring: Researchers have continuous obligations to monitor participant welfare throughout the study period, adapting protocols as needed to maintain favorable benefit-risk ratios [5].

The principle of beneficence may sometimes conflict with autonomy, particularly when researchers' perceptions of participant benefit diverge from participants' own values and preferences [3] [1]. This tension is especially pronounced in research involving vulnerable populations or when considering withholding versus withdrawing treatment, where perceptions of benefit may vary significantly among stakeholders [7].

Non-Maleficence: The Duty to Do No Harm

The principle of non-maleficence obligates researchers and clinicians to avoid causing harm or injury to participants and patients [3] [4]. This "no harm" principle supports several specific moral rules: do not kill, do not cause pain or suffering, do not incapacitate, do not cause offense, and do not deprive others of the goods of life [3]. This principle is inherent in professional standards, licensure, and codes of ethics [8].

Applications in research and clinical practice include:

• Standard of Care: Providing a proper standard of care that avoids or minimizes the risk of harm is supported by both moral convictions and legal requirements [1].
• Treatment Decisions: In end-of-life care decisions, including withholding and withdrawing life-sustaining treatment, the principle of non-maleficence guides practitioners to weigh benefits against burdens and choose courses of action that avoid inappropriately burdensome interventions [3].
• Double Effect: The principle of double effect recognizes that actions may have both good and bad effects. When four conditions are met (the act itself is not wrong, the intention is only the good effect, the bad effect is not the means to the good, and there is proportionality between good and bad effects), such actions may be morally acceptable [1].

In empirical studies of intensivists' ethical perceptions, decisions to withhold or withdraw treatment are sometimes perceived as "active" and morally problematic, creating ethical tension despite professional society guidelines that classify them as ethically equivalent to not starting treatment [7].

Justice: The Duty to Treat Fairly

The principle of justice obligates researchers and clinicians to treat persons equally and fairly [3] [4]. This principle encompasses several dimensions: distributive justice (fair allocation of scarce resources), rights-based justice (respect for people's rights and prohibition of discrimination), and legal justice (respect for laws) [4]. In research ethics, justice primarily concerns the fair distribution of the benefits and burdens of research [1].

Key applications in research include:

• Subject Selection: Justice requires that research subjects not be selected primarily for convenience nor specifically from disadvantaged groups without good scientific reason and direct relevance to their conditions [1].
• Fair Access: Research participation and benefits should be distributed fairly, avoiding exploitation of vulnerable populations while ensuring their appropriate inclusion in research relevant to their health needs [5].
• Resource Allocation: In healthcare systems, justice requires fair allocation of limited resources, balancing individual patient needs against population-level considerations [4].

Recent ethical challenges to justice principles include legislative developments that permit denial of care based on providers' moral or religious beliefs, potentially compromising equitable access to healthcare, particularly for marginalized groups [9]. Additionally, AI applications in drug development raise new justice concerns regarding algorithmic bias that may lead to unfair enrollment in clinical trials [2].

Table 1: Core Ethical Principles and Their Applications in Research

Principle	Core Meaning	Research Applications	Common Dilemmas
Autonomy	Respect for individual self-determination	Informed consent, confidentiality, truth-telling	Cultural variations in decision-making, capacity assessment
Beneficence	Duty to benefit others and promote welfare	Risk-benefit assessment, study design, safety monitoring	Conflicts with autonomy, perceived vs. actual benefits
Non-maleficence	Duty to avoid harm	Standard of care, ethical treatment decisions, double effect	Withholding vs. withdrawing treatment, unintended consequences
Justice	Duty to treat fairly and equitably	Subject selection, fair access, resource allocation	Vulnerable population inclusion, algorithmic bias, resource scarcity

Ethical Framework Application: Withholding vs. Withdrawing Treatment Research

Ethical Perceptions and Variations in Decision-Making

Research on withholding versus withdrawing life-sustaining treatment presents distinctive ethical challenges that engage all four principles. While intensive care professional societies consistently classify decisions to withhold and withdraw treatment as ethically equivalent and neutral, empirical evidence reveals significant variation in how practitioners perceive these decisions ethically [7]. A recent qualitative study of intensivists identified three distinct perceptual groups regarding these decisions:

• Those who consider withholding and withdrawing decisions as passive and ethically unproblematic
• Those who view them as active and ethically problematic
• Those who perceive them as active yet ethically unproblematic [7]

These perceptual differences correlate with divergent views on three ethically relevant considerations: the role of consensus in collegial decision-making, the moral difference between withholding and withdrawing treatment, and the definition of the physician's overarching professional goal [7]. This variation underscores the complex interplay of ethical principles in actual practice and highlights potential sources of moral distress among researchers and clinicians studying these decisions.

Principlist Analysis of Withholding vs. Withdrawing Treatment

A principlist approach to research on withholding versus withdrawing treatment requires careful consideration of how each principle applies and potentially conflicts in this domain:

• Autonomy: Respecting patient autonomy requires ensuring that decisions about limiting treatment reflect patients' values and preferences, typically through advance directives or surrogate decision-makers [1]. Research in this area must carefully navigate the tension between respecting autonomy and acknowledging that patients' choices may evolve throughout their healthcare journey.
• Beneficence: The principle of beneficence obligates researchers to consider how treatment limitations might benefit participants—whether through avoiding prolonged suffering, aligning with quality-of-life values, or honoring deeply held beliefs about the dying process [3] [1].
• Non-maleficence: This principle requires careful attention to whether withdrawing treatment might constitute "abandonment" or actively causing harm, versus allowing a natural disease process to take its course [7]. The doctrine of double effect may be particularly relevant when treatments to alleviate symptoms might incidentally shorten life [3].
• Justice: Research on treatment limitations must consider distributive justice in allocating limited healthcare resources, while avoiding discrimination against vulnerable populations who might be perceived as "more appropriate" candidates for treatment limitation [4] [9].

Contemporary Ethical Challenges in Research

Emerging Technologies: AI and Big Data in Drug Development

The integration of artificial intelligence and big data analytics in drug development presents novel ethical challenges that require adaptation of the traditional principlist framework. AI applications can compress drug development timelines from a decade to under two years, but raise corresponding ethical concerns regarding data privacy, algorithmic transparency, and bias [2]. An ethical evaluation framework for AI in drug development has been proposed with three key dimensions:

• Data Mining Informed Consent: Requires explicit statement of genetic data collection purposes and respect for individual autonomy in data usage [2]
• Pre-clinical Dual-Track Verification: Mandates that AI virtual model predictions be synchronized with actual animal experiments to avoid omission of long-term toxicity risks, upholding nonmaleficence principles [2]
• Transparency in Patient Recruitment: Implements justice principles by detecting algorithmic bias and opposing geographical bias in clinical trials [2]

These applications demonstrate how the four principles remain relevant while requiring new implementation strategies for emerging technologies.

Research Integrity and External Interventions

Recent events highlight ethical vulnerabilities in the research ecosystem, particularly when external factors disrupt study integrity. The termination of approximately 4,700 NIH grants connected to over 200 ongoing clinical trials as of July 2025 illustrates how non-scientific factors can compromise ethical research conduct [5] [6]. These terminations affected studies planning to enroll more than 689,000 participants, including approximately 20% who were infants, children, and adolescents [5] [6].

Such abrupt closures raise multiple ethical concerns:

• They potentially violate the informed consent agreement between researchers and participants, challenging the principle of autonomy [5]
• They prevent the realization of potential benefits that justified participant risk-taking, contravening beneficence [6]
• They disproportionately affect marginalized populations who are already underrepresented in research, conflicting with justice principles [5] [6]
• They may cause direct harm to participants through disruption of care and lost research benefits, violating nonmaleficence [5]

Table 2: Ethical Challenges in Contemporary Research Environments

Challenge Context	Primary Ethical Principles Engaged	Specific Ethical Concerns	Proposed Mitigation Strategies
AI in Drug Development	Autonomy, Justice, Nonmaleficence	Data privacy, algorithmic bias, shortened safety evaluation	Dual-track verification, bias detection, enhanced informed consent
Clinical Trial Termination	Autonomy, Beneficence, Justice	Violated consent agreements, lost benefits, marginalized populations	Ethical termination protocols, alternative funding sources, participant transition plans
Conscientious Objection	Justice, Autonomy	Discrimination, limited access, particularly for rural/underserved	Balancing policies, mandatory referral, transparent institutional guidelines
Withholding/Withdrawing Treatment	Nonmaleficence, Autonomy, Beneficence	Moral distress, variability in practice, perceived active vs. passive	Standardized decision protocols, ethics consultation, moral distress recognition

Conscientious Objection and Access to Care

Recent legislative developments have expanded protections for healthcare providers' conscientious objections, raising new ethical challenges for research and clinical care. Tennessee's Medical Ethics Defense Act (2025) authorizes physicians, hospitals, and insurers to deny care based on moral, religious, or ethical beliefs [9]. Such laws create tension between respecting healthcare providers' moral agency and ensuring patients' access to evidence-based care, particularly affecting marginalized populations including LGBTQIA+ communities, people of color, and those facing socioeconomic barriers [9].

For researchers studying treatment outcomes, these legal developments complicate recruitment, follow-up, and generalizability, particularly for studies involving reproductive health, end-of-life care, or services that may trigger conscientious objection. The ethical principle of justice requires special attention to ensuring that research participation and benefits remain accessible to all eligible individuals without discrimination.

Experimental Protocols and Ethical Safeguards

Empirical Ethics Research Methodology

Recent investigations into ethical perceptions employ sophisticated qualitative methodologies that provide models for future research. A 2025 multicenter study on intensivists' ethical perceptions about withholding and withdrawing treatment decisions utilized a qualitative retrospective design across seven intensive care units [7]. The protocol included:

• Participant Recruitment: 44 intensivists of varying ages and professional experience levels provided diverse perspectives [7]
• Data Collection: In-depth interviews using a semi-structured format allowed participants to elaborate ethical intuitions and perceptions [7]
• Analytical Approach: A "grounded theory"-inspired inductive methodology enabled themes to emerge from data rather than being imposed by preconceived categories [7]
• Thematic Analysis: Interview transcripts were systematically coded and analyzed to identify patterns in ethical perceptions [7]

This methodology identified that practitioners' perceptions of withholding and withdrawing decisions vary along two continuous dimensions: active/passive and ethically problematic/unproblematic, providing valuable insights for addressing moral distress and variability in decision-making [7].

Ethical AI Implementation Protocol

For research involving artificial intelligence in drug development, a structured ethical implementation protocol should include:

• Algorithmic Transparency Documentation: Detailed records of AI training data, methodology, and potential limitations
• Bias Detection and Mitigation: Proactive assessment of algorithms for potential biases related to race, ethnicity, gender, age, or geography
• Dual-Track Validation: Maintaining traditional experimental methods alongside AI predictions to verify safety and efficacy
• Data Governance Framework: Clear policies regarding data ownership, privacy, security, and appropriate usage

Research Ethics Toolkit

Table 3: Essential Components for Ethical Research Protocol Design

Component	Function	Ethical Principles Addressed
Comprehensive Informed Consent Process	Ensures participants understand research purpose, procedures, risks, benefits, and alternatives	Autonomy, Nonmaleficence
Data Safety Monitoring Board	Independent review of accumulating study data to protect participant safety and study validity	Beneficence, Nonmaleficence
Vulnerable Population Safeguards	Additional protections for those with diminished autonomy or increased susceptibility to coercion	Justice, Autonomy
Clinical Trial Termination Protocol	Planned procedures for ethical study closure, including participant notification and transition	Beneficence, Autonomy
Algorithmic Impact Assessment	Systematic evaluation of AI systems for potential biases and unintended consequences	Justice, Nonmaleficence
Collegial Decision-Making Procedure	Structured approach to ethical dilemmas incorporating multiple perspectives	Justice, Beneficence

The four principles of autonomy, beneficence, non-maleficence, and justice provide a robust framework for navigating ethical challenges in biomedical research, particularly in complex areas like withholding versus withdrawing treatment studies. While these principles offer indispensable guidance, their application requires careful contextualization, as principles may conflict and require balancing in specific situations. Contemporary challenges including AI integration, external research disruptions, and evolving legal landscapes necessitate both fidelity to ethical fundamentals and adaptability in their implementation. For researchers and drug development professionals, maintaining commitment to these ethical bedrock principles while developing increasingly sophisticated implementation strategies remains essential for conducting scientifically valid and morally defensible research that ultimately serves patient welfare and public health.

The question of whether withholding (WH) or withdrawing (WD) life-sustaining treatment (LST) are morally equivalent actions represents a critical junction in clinical ethics and moral philosophy. The "moral parity thesis" posits that there is no morally relevant difference between the two acts; both are equally permissible or impermissible given the same clinical circumstances. This debate is foundational for establishing consistent ethical guidelines for researchers, clinicians, and drug development professionals who design protocols for end-of-life care and clinical trials. The resolution of this debate directly impacts trial design, data safety monitoring board charters, and the ethical frameworks governing the use of emerging therapies in critically ill populations. This whitepaper analyzes the moral argument for WH/WD parity through the lens of ethical principles, current regulatory landscapes, and practical experimentation, providing a technical guide for professionals navigating these complex issues.

Theoretical Framework: The Doctrine of Double Effect and Moral Parity

The primary ethical framework for justifying the withholding or withdrawing of life-sustaining treatment is the Doctrine of Double Effect (DDE). This principle distinguishes between intended and merely foreseen consequences of an action, which is central to the WH/WD debate [10].

Core Components of the Doctrine of Double Effect

According to DDE, an act with both a good and a bad effect is morally permissible only if four conditions are simultaneously met [10]:

• The nature of the act: The act itself must be morally good or at least neutral.
• The intention of the agent: The agent must intend only the good effect and not the bad effect.
• The distinction between means and effects: The bad effect must not be the means through which the good effect is achieved.
• Proportionality: The good effect must be proportionately grave enough to permit the bad effect.

Application to WH/WD

In the context of WH/WD LST:

• The good effect is sparing the patient from the burdens imposed by the treatment itself.
• The bad effect is the foreseen but unintended shortening of the patient's life.

Central to the argument for moral parity is the idea that a clinician or researcher can intend only to avoid the treatment burden without intending the patient's death, whether the action is withholding a treatment never started or withdrawing a treatment already initiated [10]. The moral justification hinges on this intention and the proportionality of the burden, not on the distinction between action and omission. This refutes common criticisms, such as those from Brody, who argues that death is often intended in practice, and Sulmasy, who claims the good effect of avoiding burden is rarely proportionate to the bad effect of death [10].

Table 1: Key Concepts in the Doctrine of Double Effect Applied to WH/WD

Concept	Definition	Application to WH/WD of LST
Good Effect	The desired, beneficial outcome of an action.	Sparing the patient from the burdens of the life-sustaining treatment.
Bad Effect	The harmful, yet foreseen, outcome of an action.	The shortening of the patient's life.
Intention	The primary goal or purpose willed by the moral agent.	To eliminate the treatment burden; the patient's death is not intended.
Proportionality	The requirement that the good effect sufficiently outweighs the bad effect.	The burden of treatment must be grave enough to justify the risk of a shortened life.

Regulatory and Legal Landscape: A Quantitative Analysis

The moral argument for WH/WD parity is reflected in, and supported by, the existing legal and regulatory framework in the United States. A cross-sectional study of state statutes reveals near-universal legal acceptance of unilateral clinician decisions to decline initiating or maintaining LST.

Prevalence and Justifications

A 2025 analysis of 51 US state and District of Columbia statutes found that 49 (96%) explicitly support unilateral clinician decisions to decline initiating or maintaining at least one form of life-sustaining treatment [11]. The justifications provided in these statutes for such decisions, however, vary significantly, as shown in Table 2.

Table 2: State Statute Justifications for Unilateral Clinician Decisions to Decline LST

Justification Category	Number of States	Percentage	Key Terminology
Medical Reasons Only	7	14%	"Medically ineffective," "nonbeneficial."
Reasons of Conscience Only	9	18%	"Conscience," "moral," "religious."
Both Medical & Conscience	25	49%	Combines terms from both categories.
No Explicit Justification	8	16%	Lacks specific medical or conscience rationale.
Total Statutes Permitting Decisions	49	96%

Regulatory Requirements and Protocols

The study further quantified the specific actions required of clinicians when making unilateral decisions based on medical reasons. These requirements form a de facto experimental protocol for ethical decision-making in clinical practice [11].

Table 3: Required Actions for Clinicians Using Medical Reasons to Decline LST

Required Action	Number of States Requiring	Percentage of 32 Statutes
Inform patient or surrogate	18	56%
Cooperate with transfer	28	88%
Provide LST until transfer	19	59%
Obtain a second medical opinion	9	28%
Pursue ethics/interdisciplinary committee review	4	13%
Can withhold/withdraw if transfer is not possible	4	13%

This regulatory heterogeneity underscores the need for a unified moral framework, such as the WH/WD parity argument, to guide consistent policy development. The data shows that while the permission to forego treatment is widespread, the procedural safeguards vary, highlighting operational areas where moral reasoning must be applied.

Experimental Protocol for Analyzing Moral Reasoning

To empirically study the WH/WD moral equivalence in a research or clinical setting, a structured methodology is required. The following protocol outlines a process for analyzing and guiding these decisions, incorporating regulatory requirements and ethical principles.

Diagram 1: WH/WD Decision Workflow

Step-by-Step Methodology

• Subject Identification: Identify a patient for whom the question of initiating or continuing a life-sustaining treatment (e.g., mechanical ventilation, dialysis, artificial nutrition) is raised. This often involves patients with poor prognosis, high burden of care, or those who lack decision-making capacity without a clear surrogate.

• Burden-Proportionality Assessment:

  • Quantitative Data Collection: Gather objective medical data (e.g., SOFA score, presence of multi-organ failure, quantifiable side effects).
  • Qualitative Data Collection: Conduct structured interviews with the patient (if possible), family, and surrogate to understand the subjective experience of treatment burden, perceived quality of life, and patient's previously stated values [12]. This mixed-methods approach is crucial for a proportionate analysis.

• Intention Deliberation: In an ethics committee or multidisciplinary team meeting, explicitly discuss and document the primary intention of the proposed action (WH or WD). The guiding question is: "Is the primary goal to remove the treatment burden, with death as a foreseen but unintended side effect?"

• WH/WD Decision Point: Apply the moral parity thesis. If the intention is solely to avoid a disproportionate burden and the proportionality condition is met, then withholding and withdrawing are morally equivalent choices. The decision should then be based on clinical context and patient preference, not a perceived moral difference.

• Regulatory Protocol Execution: Execute the actions required by local statute and hospital policy, as quantified in Table 3. This typically includes:

  • Formal Notification: Inform the patient or legal surrogate of the decision and the rationale.
  • Transfer Offer: Document the offer to transfer care to another willing clinician or institution.
  • Continued Care: Continue to provide LST until a transfer is effected, unless explicitly waived by statute (e.g., in Indiana if treatment is "medically inappropriate") [11].

• Data Recording and Review: Meticulously document the entire process, including the assessment of burden, the deliberation on intention, the steps taken to comply with regulations, and the final outcome. This is essential for audit, research, and quality improvement.

The Scientist's Toolkit: Research Reagent Solutions

For researchers designing studies to investigate the ethical, psychological, and outcome-based aspects of WH/WD decisions, the following "reagent solutions" are essential.

Table 4: Essential Research Reagents for WH/WD Parity Investigation

Research Reagent	Type	Function/Application
Validated Quality of Life (QoL) Scales	Quantitative Metric	Provides objective, comparable data on patient wellbeing and treatment burden (e.g., EQ-5D, SF-36).
Structured Interview Protocols	Qualitative Tool	Elicits rich, narrative data on patient, family, and clinician experiences, values, and the decision-making process [12].
State Statute Database (e.g., Fastcase, Casetext)	Legal Data Source	Allows for cross-sectional analysis of the legal landscape and its variation, a key confounding variable in outcomes research [11].
Ethics Committee Review Protocols	Procedural Framework	Provides a standardized method for assessing the intention and proportionality conditions of the DDE in clinical cases [10].
Multidisciplinary Team (MDT) Framework	Human Resource Structure	Ensures diverse perspectives (clinical, ethical, psychological) are incorporated into the case analysis, mirroring the DDE's requirement for rigorous deliberation.

The theoretical equivalence between withholding and withdrawing life-sustaining treatment is robustly supported by the Doctrine of Double Effect, which locates moral permissibility in intention and proportionality rather than in the timing of an intervention. Quantitative analysis of state statutes confirms that this parity is broadly reflected in US law, even as procedural requirements vary. For researchers and drug development professionals, employing a rigorous, protocol-driven approach that integrates both quantitative and qualitative data is essential for navigating these decisions ethically and consistently. Adopting the moral parity thesis ensures that clinical practice and research protocols are founded on a logically coherent ethical foundation, ultimately protecting patients, empowering clinicians, and guiding the responsible development of new technologies in critical care.

Despite ethical arguments for the equivalence of withholding and withdrawing life-sustaining treatment (LST), a significant psychological disparity persists in clinical practice. This whitepaper explores the mechanisms behind this disparity through the lens of Moral Foundations Theory (MFT), providing researchers and drug development professionals with a framework for understanding clinician decision-making. Empirical evidence reveals that clinicians experience withdrawing treatment as psychologically more difficult than withholding, influenced by factors including broken trust, prognostic uncertainty, and intuitive moral reasoning. This analysis synthesizes qualitative interview data, quantitative clinical findings, and theoretical psychology to offer structured methodologies for investigating these phenomena, alongside practical solutions for managing the psychological burden of treatment withdrawal decisions in clinical research and practice.

In critical care and end-of-life decision-making, clinicians routinely face decisions about initiating, withholding, or withdrawing life-sustaining treatments. While many ethical frameworks posit that withholding (not starting a treatment) and withdrawing (stopping an ongoing treatment) are ethically equivalent when justified by patient preferences or prognosis, clinical practice reveals a persistent psychological asymmetry between these actions [13]. Clinicians consistently report greater psychological difficulty, moral distress, and emotional burden when withdrawing treatments compared to withholding them, even in similar clinical scenarios.

This disparity has significant implications for patient care, clinician well-being, and healthcare systems. It can lead to treatment escalation inertia, where clinicians hesitate to stop ineffective treatments, potentially prolonging patient suffering and consuming limited healthcare resources [14]. For clinical researchers and drug development professionals, understanding these psychological mechanisms is crucial when designing trials involving palliative endpoints, disinvestment studies, or protocols for managing treatment-resistant infections where therapy cessation decisions are paramount.

This whitepaper examines the psychological dimensions of treatment decision-making through the theoretical framework of Moral Foundations Theory, providing empirical evidence, methodological tools, and practical implications for addressing this disparity in clinical research contexts.

Theoretical Framework: Moral Foundations Theory

Moral Foundations Theory (MFT) provides a comprehensive framework for understanding intuitive moral reasoning that underpins clinician decision-making. MFT posits that moral judgments arise from six foundational intuitive values rather than purely rational deliberation [15] [16]:

• Care/Harm: Foundation rooted in protection from suffering
• Fairness/Cheating: Perception of equitable treatment and distribution
• Loyalty/Betrayal: Commitments to group obligations and relationships
• Authority/Subversion: Respect for hierarchy and leadership
• Sanctity/Degradation: Aversion to acts perceived as desecration
• Liberty/Oppression: Reactance to domination and restrictions

MFT further suggests that moral reasoning is primarily intuitive rather than deliberative, with individuals arriving at moral judgments quickly through automatic processes, then employing rational thought to justify these pre-formed conclusions [15]. This explains why simply presenting ethical principles of equivalence often fails to change clinician behavior or emotional responses to treatment withdrawal.

MFT Application to Clinical Decision-Making

Within healthcare contexts, these moral foundations manifest in distinct patterns:

• Care/Harm concerns are activated more strongly in withdrawal scenarios due to the perception that the act of removal directly causes harm
• Loyalty/Betrayal foundations are triggered when withdrawing treatment feels like abandoning the patient or breaking therapeutic trust
• Authority/Subversion conflicts occur when institutional policies conflict with clinician moral intuitions
• Sanctity/Degradation underpins the view of treatment withdrawal as a violation of professional sanctity

The following diagram illustrates how these moral foundations differentially activate in withholding versus withdrawing scenarios:

Figure 1: Differential Activation of Moral Foundations in Treatment Decisions

Empirical Evidence: Quantitative and Qualitative Data

Clinical Characteristics and Outcomes

A comprehensive nationwide cohort study of 11,981 sepsis patients in South Korea revealed significant differences between patients subject to withholding/withdrawal of life-sustaining treatment (WWLST) decisions versus those who were not [17]. The WWLST group (37.0% of patients) displayed distinct clinical characteristics and intervention patterns:

Table 1: Patient Characteristics and Interventions in WWLST Decisions

Parameter	WWLST Group (n=4,430)	No-WWLST Group (n=7,551)	p-value
Mean Age	73.3 ± 13.0 years	70.1 ± 13.9 years	<0.001
Charlson Comorbidity Index	6.3 ± 2.5	5.3 ± 2.5	<0.001
Clinical Frailty Scale	5.9 ± 2.0	4.9 ± 2.1	<0.001
SOFA Score	7.2 ± 3.2	5.7 ± 2.9	<0.001
Solid Tumors	45.2%	30.6%	<0.001
Hematologic Malignancies	8.0%	5.2%	<0.001
Vasopressor Use	35.4%	32.8%	0.003
Invasive Mechanical Ventilation	62.9%	41.9%	<0.001
Continuous Renal Replacement Therapy	40.8%	17.6%	<0.001

Multivariate analysis identified factors independently associated with WWLST decisions, including older age, higher comorbidity burden, increased frailty, greater organ failure, specific underlying conditions, and requirement for more intensive interventions [17]. This profile suggests that withdrawal decisions often occur in clinically complex scenarios with higher emotional stakes.

Qualitative Insights on the Psychological Disparity

Semi-structured interviews with physicians and patient organization representatives in Sweden revealed consistent themes explaining the psychological difference between withholding and withdrawing treatments [13]:

Table 2: Psychological Factors in Treatment Decisions

Factor	Withholding Perception	Withdrawing Perception
Patient-Provider Relationship	No established treatment commitment	Breaking therapeutic covenant
Causal Attribution	Natural disease progression	Clinician action causes outcome
Psychological Burden	Regret about missed opportunity	Guilt and responsibility for outcome
Decision Reversibility	Perceived as potentially reversible	Perceived as permanent and final
Temporal Dimension	Before treatment relationship	After investment in treatment

One physician participant expressed this distinction clearly: "Withdrawing is experienced as an active decision where you are directly responsible for the outcome, whereas withholding can be framed as accepting the natural course of disease" [13]. This reflects how the action/omission distinction carries moral significance despite ethical arguments for equivalence.

Methodological Approaches for Investigation

Experimental Protocols for Studying Psychological Disparity

Protocol 1: Qualitative Phenomenological Interviewing

Objective: To explore the lived experience of clinicians facing withholding versus withdrawal decisions and identify factors contributing to psychological disparity.

Methodology:

• Participant Recruitment: Purposive sampling of physicians and nurses from high-intensity specialties (ICU, oncology, neurology) with experience in LST decisions [13]
• Data Collection: Semi-structured interviews using open-ended questions focusing on:
  • Emotional responses to recent clinical cases
  • Perceived moral responsibilities
  • Institutional and interpersonal barriers
  • Reflections on ethical principles versus lived experience
• Analysis Approach: Thematic analysis using framework method with iterative coding and triangulation among multiple researchers to establish trustworthiness [13]

Implementation Considerations:

• Interview guide flexibility to allow emergent themes
• Confidentiality assurances given sensitive nature
• Diverse sampling across experience levels and specialties
• Field notes during interviews to capture nonverbal cues

Protocol 2: Moral Foundations Questionnaire Application

Objective: To quantify the differential activation of moral foundations in withholding versus withdrawal scenarios.

Methodology:

• Instrument: Validated Moral Foundations Questionnaire (MFQ) adapted for clinical contexts [15] [16]
• Design: Within-subjects experimental design presenting matched clinical vignettes varying only the withholding/withdrawal dimension
• Measures:
  • Moral foundation salience ratings (1-5 Likert scales)
  • Emotional distress indicators
  • Decision confidence measures
  • Response latency as intuition indicator
• Analysis: Paired t-tests for within-subject comparisons, multiple regression for predictor identification

Theoretical Basis: This approach operationalizes the MFT framework that moral judgments are primarily intuitive rather than deliberative [15], allowing researchers to detect automatic moral responses that may conflict with consciously endorsed ethical principles.

Research Reagents and Assessment Tools

Table 3: Essential Methodological Tools for Investigating Psychological Disparity

Tool/Instrument	Function	Application Context
Moral Foundations Questionnaire (MFQ)	Measures relative salience of six moral foundations	Quantifying intuitive moral reasoning in clinical decisions [15] [16]
Semi-structured Interview Guide	Elicits rich qualitative data on decision experiences	Exploring lived experience and moral distress sources [13]
Clinical Vignettes	Presents standardized scenarios with systematic variation	Experimental manipulation of withholding/withdrawal dimension
Thematic Analysis Framework	Identifies patterns in qualitative data	Coding interview transcripts for emergent themes [13]
Distress Thermometer	Measures emotional response to decisions	Quantifying psychological burden difference

Practical Implications and Solutions

Clinical Workflow Integration

The psychological transition from withholding to withdrawing treatment can be conceptualized as a process with critical intervention points:

Figure 2: Clinical Workflow with Psychological Buffer Interventions

Institutional Policy Recommendations

Research indicates that clinicians often have limited awareness of existing hospital policies regarding LST decisions and perceive them as having limited applicability to clinical practice [14]. Effective policy solutions should address this gap:

• Time-Limited Trial Agreements: Establish prospective agreements that specify conditions for treatment reevaluation and potential withdrawal before initiation [13]
• Structured Communication Frameworks: Implement standardized approaches for discussing potential future withdrawal during initial treatment conversations
• Moral Distress Recognition: Create systems for identifying and supporting clinicians experiencing psychological burden from withdrawal decisions
• Interprofessional Dialogue: Facilitate regular ethics conversations among healthcare teams to normalize the psychological challenges of treatment withdrawal

Research and Development Applications

For clinical researchers and drug development professionals, these insights have specific applications:

• Trial Design Considerations: When designing studies involving treatment discontinuation endpoints, incorporate psychological support for clinicians and standardized communication protocols
• Investigator Training: Include moral psychology education in clinical trial training programs to enhance awareness of intuitive decision-making processes
• Endpoint Development: Consider psychological factors when defining clinician-reported outcomes or satisfaction measures in trials involving treatment limitation decisions
• Implementation Science: Apply MFT frameworks to improve adoption of clinical guidelines around treatment limitation decisions

The psychological disparity between withholding and withdrawing life-sustaining treatment represents a significant challenge in clinical practice with ethical, emotional, and practical dimensions. Through the lens of Moral Foundations Theory, this disparity can be understood as arising from differential activation of intuitive moral foundations rather than rational ethical deliberation alone.

For researchers and drug development professionals, addressing this disparity requires both methodological sophistication in investigating these phenomena and practical implementation of systems that acknowledge the psychological realities of clinical decision-making. By incorporating these insights into research protocols, educational programs, and clinical guidelines, the healthcare community can better support clinicians in providing ethically sound, psychologically informed patient care at the end of life.

The decision to limit life-sustaining treatment represents one of the most ethically charged and legally complex areas of modern healthcare. Across jurisdictions, the regulatory approaches to withholding (WH) and withdrawing (WD) medical interventions reveal fundamental tensions between moral principles, clinical discretion, and patient rights. While these two actions may appear functionally equivalent in their outcomes, research demonstrates they are often perceived and regulated differently by both legal systems and public perception.

This technical guide examines how different jurisdictions define, regulate, and distinguish between WH and WD decisions, with particular attention to the moral psychological foundations that underpin these regulatory frameworks. For researchers and drug development professionals, understanding this landscape is crucial not only for navigating clinical trial protocols but also for comprehending how treatment limitations are conceptualized across different legal systems and care settings.

Defining WH/WD: Conceptual Foundations and Moral Psychology

Conceptual Distinctions

Withholding treatment refers to the decision not to initiate a medical intervention, while withdrawing treatment involves discontinuing an ongoing therapy. Despite potentially similar outcomes, these two actions engage different moral psychological mechanisms among decision-makers.

Recent behavioral research reveals that individuals perceive systematic differences between these actions. One study involving 1,404 participants found that "acceptance toward limiting patients' access to treatments was lower when withdrawing treatments compared with withholding treatment" [18]. This perception persists despite logical arguments for their ethical equivalence.

Moral Psychological Foundations

The differential perception of WH versus WD decisions appears rooted in several psychological mechanisms:

• Action bias: Withdrawing treatment is perceived as an active intervention, while withholding is viewed as a passive omission, engaging different moral intuitions
• Loss aversion: Discontinuing an established treatment is framed as a loss, which psychological research shows is weighted more heavily than forgained gains
• Temporal commitment: Initiating treatment creates an implicit commitment to continue, making discontinuation feel like a violation of that commitment
• Causality attribution: Clinicians and surrogates may attribute greater causal responsibility for negative outcomes when actively withdrawing treatment compared to withholding it initially

These psychological foundations manifest differently across clinical contexts, from intensive care decisions to reimbursement policies for novel therapeutics.

Jurisdictional Frameworks for WH/WD Regulation

United States: State-Level Variation

The United States demonstrates significant regulatory diversity in WH/WD governance, with states developing distinct statutory approaches. A 2025 cross-sectional study of 51 US jurisdictions found that 49 (96%) explicitly supported unilateral clinician decisions to decline initiating or maintaining at least one form of life-sustaining treatment [11].

Table 1: US State Regulatory Approaches to WH/WD Decisions

Regulatory Characteristic	Number of States	Percentage
Statutes supporting unilateral clinician decisions	49	96%
Justifications based solely on medical reasons	7	14%
Justifications based solely on conscience	9	18%
Mixed medical and conscience justifications	25	49%
No specific justification mentioned	8	16%
Require transfer to another clinician/facility	28	88%
Require second medical opinion	9	28%
Require ethics committee review	4	13%

The specific justifications accepted for WH/WD decisions vary considerably:

• Medical justifications: Include treatments contrary to "medical standards" (59%), "medically ineffective" (34%), "inappropriate" (28%), "nonbeneficial" (13%), or "medically futile" (9%) [11]
• Conscience-based justifications: Include "conscience" (53%), "moral" beliefs (41%), "religious" beliefs (32%), or "ethical" beliefs (24%) [11]

New York's Family Health Care Decisions Act (FHCDA) exemplifies a detailed regulatory approach, establishing that surrogates may decide to withhold or withdraw life-sustaining treatment if it "would be an extraordinary burden to the patient and the patient is terminally or permanently unconscious, or if the patient has an irreversible or incurable condition and the treatment would involve such pain, suffering or other burden that it reasonably be deemed inhumane or excessively burdensome" [19].

South Korea: Legislative Framework for End-of-Life Care

South Korea's "Act on Hospice and Palliative Care and Decisions on Life-Sustaining Treatment for Patients at the End of Life" (LST Decision Act) establishes a comprehensive national system for WH/WD decisions. This framework defines life-sustaining treatment as "medical treatment that merely prolongs the end-of-life process without a curative effect" [17].

A 2025 nationwide cohort study of 11,981 sepsis patients in South Korea found that 37.0% had WH/WD issues documented, with these patients being older, frailer, and having higher Sequential Organ Failure Assessment (SOFA) scores [17]. The study also revealed that the WH/WD group received more invasive interventions including mechanical ventilation (62.9% vs. 41.9%) and continuous renal replacement therapy (40.8% vs. 17.6%), challenging assumptions that treatment limitation necessarily correlates with less intensive care [17].

International Guidelines and Principles

Beyond national legislation, international ethical guidelines influence WH/WD policies:

• Declaration of Helsinki: Emphasizes post-trial access provisions, requiring that "post-trial provisions must be arranged by sponsors and researchers" for participants who continue to need interventions identified as beneficial [20]
• CIOMS and WHO guidelines: Encourage researchers, sponsors, and ethics review committees to prospectively consider and plan for post-trial access, especially in contexts of unmet medical need [20]

These international frameworks establish ethical expectations that may inform national regulations, particularly regarding experimental treatments and clinical trial participation.

Decision-Making Protocols and Procedural Requirements

Surrogate Decision-Making Standards

Jurisdictions typically establish hierarchical frameworks for identifying appropriate surrogate decision-makers when patients lack capacity. New York's FHCDA prioritizes surrogates in the following order: court-appointed guardian, spouse or domestic partner, adult child, parent, adult sibling, and finally close friend [19].

Surrogates are generally required to base decisions on either:

• The patient's known wishes, values, and beliefs (substituted judgment standard)
• The patient's best interests when preferences are unknown [19]

Table 2: WH/WD Decision-Making Standards for Patients Without Surrogates (New York)

Treatment Category	Decision Maker	Concurrence Required	Special Provisions
Routine medical treatment	Attending practitioner	None	Excludes long-term ventilation or nasogastric tubes beyond 30 days
Major medical treatment	Attending practitioner with consultation	Second physician, NP, or PA	Required for surgery, significant risk, or invasive procedures
Withhold/withdraw life-sustaining treatment	Court or attending practitioner with concurrence	Second practitioner plus ethics committee or judicial approval	Only if no medical benefit and patient will die imminently
Hospice care	Attending practitioner with consultation	Second practitioner plus ethics review	For hospice-eligible patients

For patients without surrogates, New York law authorizes specific procedures based on treatment category. Life-sustaining treatment may only be withheld or withdrawn without judicial approval if the attending practitioner, with independent concurrence of a second provider, determines "to a reasonable degree of medical certainty" that the treatment offers no medical benefit because the patient will die imminently and providing treatment would violate accepted medical standards [21].

Procedural Safeguards and Review Mechanisms

Jurisdictions implement various oversight mechanisms to protect vulnerable patients in WH/WD decisions:

• Ethics review committees: New York requires hospitals to establish ethics review committees with multidisciplinary membership to advise on disputes and review sensitive surrogate decisions [19]
• Concurrence requirements: Multiple jurisdictions require second opinions or concurrence from other clinicians before implementing WH/WD decisions
• Transfer requirements: Most states require clinicians to cooperate with transferring patients to willing providers when refusing to honor surrogate decisions based on conscience objections [11]

These procedural safeguards aim to balance clinician discretion with patient protections, particularly when unilateral decisions are contemplated.

Experimental Evidence and Behavioral Research

Public Attitudes Toward WH/WD Decisions

Behavioral research reveals nuanced public attitudes that frequently diverge from logical ethical frameworks. A 2024 behavioral experiment demonstrated that "participants were more supportive of rationing decisions presented as withholding treatments compared with withdrawing treatments" [18]. This preference persisted despite normative ethical arguments for equivalence between these actions.

Furthermore, the same study found that "participants were more supportive of decisions to withdraw treatment made at the bedside level compared with similar decisions made at the policy level" [18], indicating that decision context significantly influences moral perceptions.

Contextual Factors Influencing WH/WD Perceptions

Subsequent research has identified specific circumstances that moderate public support for WH/WD decisions:

• Medical effectiveness: Withholding medically ineffective treatment is viewed as more acceptable than withdrawing effective treatment
• Prior agreements: Support for withdrawal increases when physicians and patients have established prior agreements about potential discontinuation
• Consistency concerns: Participants emphasize the importance of consistent application of WH/WD policies across clinics and providers [22]

These findings suggest that contextual factors significantly influence moral judgments about WH/WD decisions, complicating the development of universal regulatory standards.

Research Implications and Methodological Considerations

The Scientist's Toolkit: WH/WD Research Reagents

Table 3: Essential Methodological Components for WH/WD Research

Research Component	Function	Implementation Example
Vignette-based experiments	Isolate effect of framing (WH vs. WD) on decision outcomes	Present clinically identical scenarios varying only action type (WH or WD) [18]
Large-scale cohort studies	Document real-world patterns and outcomes of WH/WD decisions	Track prevalence, clinical correlates, and outcomes of WH/WD in specific patient populations [17]
Legal/statutory analysis	Map regulatory variations across jurisdictions	Systematically code state statutes for justifications, procedures, and safeguards [11]
Cross-cultural comparisons	Identify cultural and systemic influences on WH/WD	Compare practices and regulations across different healthcare systems [17]
Longitudinal follow-up	Assess long-term impacts of WH/WD decisions	Track patient outcomes, family satisfaction, and clinician distress over time

Visualizing WH/WD Decision Pathways

The following diagram illustrates the complex decision-making pathway for withholding or withdrawing life-sustaining treatment under New York's FHCDA framework for patients without surrogates:

WH/WD Decision Pathway for Patients Without Surrogates

Conceptual Relationship Between Moral Foundations and Legal Frameworks

The relationship between moral psychological foundations and legal regulatory approaches can be visualized as follows:

Moral Foundations and Legal Framework Relationships

The regulatory landscape for withholding and withdrawing treatment reflects a complex interplay between ethical principles, moral psychology, and practical clinical considerations. Jurisdictional approaches vary significantly in their specific procedures, safeguards, and decision-making standards, though common themes emerge regarding surrogate authority, procedural oversight, and ethical justification.

For researchers and drug development professionals, understanding these frameworks is essential not only for compliance but for conceptualizing how treatment limitations are conceptualized across different contexts. The persistent gap between logical ethical equivalence and psychological distinction between WH and WD decisions suggests that effective policies must account for both normative principles and empirical realities of human decision-making.

Future research should continue to examine how different regulatory approaches impact patient outcomes, family experiences, and clinician practices, with particular attention to vulnerable populations who may be disproportionately affected by unilateral decision-making processes.

This whitepaper synthesizes key findings from recent empirical studies (2024-2025) investigating clinician perspectives on withholding versus withdrawing life-sustaining treatment (LST). Despite the established ethical equivalence thesis in normative literature—which posits no moral difference between not starting (withholding) and stopping (withdrawing) a treatment—recent interview and survey data reveal that healthcare practitioners consistently experience and perceive these actions as distinct. This discrepancy creates significant moral distress and influences clinical decision-making, particularly in contexts of relative scarcity and end-of-life care. Key findings indicate that the psychological, relational, and communicative dimensions of care carry profound moral significance for clinicians, making treatment withdrawal subjectively more difficult than withholding. These insights are critical for researchers, ethicists, and drug development professionals working to align healthcare policies with on-the-ground clinical realities and moral experiences.

The distinction between withholding and withdrawing life-sustaining treatment represents a persistent fault line in clinical ethics. From a purely consequentialist viewpoint, the outcome for the patient is identical; thus, many ethicists argue the actions are morally equivalent [23]. However, emerging qualitative evidence from those making these decisions reveals a more complex landscape where psychological, relational, and systemic factors create a experienced moral difference. This guide analyzes recent primary data from clinician interviews and surveys to delineate these factors, providing a evidence-based foundation for ethical guidelines, policy development, and supportive frameworks for clinical practitioners. Understanding this distinction is also vital for drug development professionals designing clinical trials for serious illnesses, where enrollment often involves consideration of future treatment limitations.

Key Quantitative Findings from Recent Studies

The tables below summarize empirical data on clinician attitudes and policy variations regarding treatment limitation decisions.

Clinician Attitudes and Policy Prevalence

Table 1: Attitudes and Perceptions on Withholding vs. Withdrawing Treatment

Aspect	Finding	Source	Year
General Physician Preference	60% of physicians report withdrawing LST as more ethically problematic and psychologically difficult than withholding.	[24]	2016
US Hospital Policy Prevalence	92% of surveyed US hospitals have policies addressing decisions to withhold or withdraw LST.	[25]	2024
Policy Guidance Variation	Policies permit withholding/withdrawing LST due to: Patient/Surrogate Request (82%), Physiologic Futility (81%), Potentially Inappropriate Treatment (64%).	[25]	2024
Public Attitude Support	Public support is significantly higher for withholding treatment compared to withdrawing equivalent treatment.	[18]	2024

Table 2: Regulatory Landscape and Decision-Making Processes

Aspect	Finding	Source	Year
US State Regulations	96% (49/51) of US state statutes explicitly support unilateral clinician decisions to decline initiating or maintaining at least one form of LST.	[11]	2025
Justifications in Statutes	Statutes justify decisions using: Medical Reasons only (14%), Conscience only (18%), Both (49%), or No explicit justification (16%).	[11]	2025
LST Decision Makers (Korea)	In clinical practice, LST decisions were mostly made by family members (81.5%), not patients.	[26]	2024
Priority in Decision-Making	Patients/families prioritize "patient suffering," while health professionals prioritize "the possibility of patient recovery."	[26]	2024

Detailed Experimental Protocols and Methodologies

This section details the methodologies of key studies providing recent benchmarks, illustrating the rigorous qualitative and quantitative approaches used in this field.

Protocol 1: Qualitative Interview Study with Physicians and Patient Organization Representatives

• Study Citation & Year: PMC9233323 (2022) [23]
• Objective: To explore physicians’ and patient organization representatives’ experiences and perceptions of withdrawing and withholding treatments in rationing situations of relative scarcity.
• Methodology: A qualitative study using semi-structured interviews and thematic analysis.
• Participant Recruitment:
  • Sampling: Purposive sampling of physicians working in high-technology medical areas (oncology, hematology, neurology, rare diseases) and patient organization representatives (PORs) from those same areas.
  • Final Cohort: 14 participants (8 physicians, 6 PORs).
• Data Collection:
  • Instrument: Semi-structured interviews conducted online via Zoom.
  • Duration: Approximately one hour per interview.
  • Data Processing: Interviews were audio-recorded, transcribed, and pseudonymized.
• Data Analysis:
  • Framework: Thematic framework method.
  • Process: Transcripts were read and labeled with first-order codes close to participants' terms. These codes were iteratively sorted into broader themes through discussion among researchers.
  • Software: Microsoft Excel for data management.

Protocol 2: National Cross-Sectional Survey of US Hospital Policies

• Study Citation & Year: Chest Journal (2024) [25]
• Objective: To ascertain the prevalence and content of US hospital policies addressing the withholding and withdrawal of life-sustaining treatment (LST).
• Methodology: A national cross-sectional survey.
• Participant Recruitment:
  • Population: Members of the American Society for Bioethics and Humanities (ASBH) email listserv.
  • Inclusion Criteria: Individuals with personal knowledge of their hospital's policies on withholding and withdrawing LST.
  • Response Rate: 11% (146 out of 1,337 members who viewed the email).
  • Final Sample: 93 unique responses detailing hospital policy content from all 50 US states, Washington D.C., and Puerto Rico.
• Data Collection:
  • Instrument: Electronically distributed survey.
  • Period: Data collected between July and August 2023.
• Data Analysis:
  • Method: Descriptive analysis of response frequencies.

Core Qualitative Findings: The Clinician's Perspective

Recent interview data reveals that clinicians often express internally inconsistent views, acknowledging ethical equivalence in theory but experiencing a significant difference in practice [23]. The moral weight of withdrawing treatment emerges from several interconnected factors.

• The Patient-Physician Relationship and Communication: Withdrawing treatment is often perceived as breaking a therapeutic promise and a bond of trust established with the patient [23]. This active cessation can feel like a direct violation of the clinician's role as a caregiver, leading to psychological distress not as prevalent in withholding decisions.
• Prognostic Uncertainty and Causal Salience: The act of withdrawing treatment makes the clinician's decision the most salient and immediate cause of a change in the patient's status. This contrasts with withholding, where the underlying disease progression remains the primary cause of the outcome. This difference in causal salience intensifies the moral and emotional burden of withdrawal [23].
• Psychological and Emotional Burden: The psychological difficulty of withdrawal is a consistently reported benchmark. Clinicians may experience withdrawal as a more active role in the patient's death, leading to feelings of guilt or perceived failure [27] [24]. This is compounded by a fear of legal sanction or social disapproval, even when policies support the decision [23].
• Disparities in Policy and Practice: Survey data shows that while most US hospitals have relevant policies, they vary widely in criteria and processes [25]. Furthermore, these policies rarely address known sociodemographic disparities in decisions to limit LST, leaving room for potential bias and unequal application of care [11] [25].

Conceptual Framework of Clinical Decision-Making

The diagram below illustrates the conceptual workflow and logical relationships in clinician decision-making regarding treatment limitations, based on the themes identified in recent research.

The Scientist's Toolkit: Research Reagent Solutions

For researchers aiming to conduct studies in this field, the following table details key methodological components and their functions derived from the analyzed protocols.

Table 3: Essential Methodological Components for Research

Research Component	Function in Investigation	Exemplar Use Case
Semi-Structured Interviews	Allows for in-depth exploration of participant experiences and perceptions while ensuring key themes are covered.	Uncovering the "internally inconsistent views" of physicians on equivalence [23].
Purposive Sampling	Ensures recruitment of participants with direct, rich experience of the phenomenon under study.	Selecting physicians from oncology and neurology who frequently face LST decisions [23].
Thematic Analysis	A systematic method for identifying, analyzing, and reporting patterns (themes) within qualitative data.	Deriving themes like "patient-physician relation" and "prognostic differences" from interview transcripts [23].
Cross-Sectional Survey	Quantifies the prevalence of policies, attitudes, or practices across a wide population at a single point in time.	Documenting the variation in US hospital policies on withholding/withdrawing LST [25].
Institutional Policy Documents	Provides the object of analysis for understanding formal rules, guidance, and variations in clinical settings.	Analyzing the criteria and processes hospitals use to guide LST decisions [11] [25].

Benchmarks from the most recent clinician interviews and policy surveys confirm a stubborn divide between ethical theory and clinical practice. The experienced moral difference between withholding and withdrawing treatment is a significant reality for healthcare professionals, rooted in psychological, relational, and systemic factors.

For rescientists and drug development professionals, these findings highlight the complex real-world environment into which new life-sustaining therapies are introduced. Understanding that withdrawal is often more challenging can inform the design of clinical trial protocols, especially regarding rescue medications and treatment discontinuation criteria. It also underscores the importance of considering these decision-making pressures when designing supportive interventions for clinical trial investigators and caregivers.

Future research must focus on developing and evaluating practical policy solutions—such as advance agreements on treatment discontinuation, structured communication guides, and robust institutional support systems—to bridge the gap between abstract equivalence and the lived experience of clinicians [23]. Addressing the documented variations in hospital policies and the rare consideration of sociodemographic disparities is also critical to ensuring equitable, ethical, and compassionate care at the end of life.

From Principle to Practice: Protocols, Decision-Making, and Bridging the Implementation Gap

The development of robust hospital policies for withholding (WH) and withdrawing (WD) life-sustaining treatment (LST) is a critical endeavor in modern healthcare, sitting at the intersection of clinical practice, medical ethics, and health services research. Within the context of moral foundations research, the distinction between WH and WD is particularly salient. While ethical principles often posit their equivalence, empirical studies consistently reveal that healthcare practitioners and patients perceive a moral difference, often finding the act of withdrawing treatment to be psychologically and emotionally more challenging than the act of withholding it [23] [28]. This technical guide delineates the core components of effective WH/WD guidelines, drawing on recent empirical data to provide a framework for researchers, scientists, and policy developers engaged in creating evidence-based institutional protocols.

Quantitative Landscape of WH/WD Policies in the United States

A recent national cross-sectional survey of 93 U.S. hospitals provides a quantitative snapshot of current policy prevalence and content. This data is essential for understanding existing practices and identifying areas for improvement.

Table 1: Prevalence and Content of WH/WD Policies in U.S. Hospitals (2024 Survey Data) [29]

Policy Characteristic	Prevalence (%)	Notes
Hospitals with any WH/WD LST Policy	92%	n=86 out of 93 surveyed hospitals or hospital systems.
Policies Updated Since 2022	59%	Indicates a trend toward recent review and modernization.
Guidance on Specific Scenarios
Patient/Surrogate Request	82%
Physiologic Futility	81%	Treatment cannot achieve its physiologic goal.
Potentially Inappropriate Treatment	64%	Treatment may achieve a goal but physicians judge ethical reasons justify not providing it.
Guidance on Specific Treatments
Invasive Mechanical Ventilation	61%
Dialysis	45%
Extracorporeal Life Support	34%
Consultation Mechanisms
Ethics Consultation (Required)	33%
Ethics Consultation (Recommended)	54%
Palliative Care (Recommended)	59%
Addressing Sociodemographic Disparities	8%	A critical gap in most current policies.

Ethical and Legal Foundations: The Bedrock of WH/WD Guidelines

Effective policies are grounded in well-established ethical and legal principles that justify the permissibility of WH/WD LST.

Table 2: Core Ethical and Legal Precedents for WH/WD LST [30]

Principle	Description	Implication for WH/WD Policy
Respect for Autonomy	The right of a patient to self-determination and bodily integrity.	Forms the basis for informed consent and, crucially, informed refusal of any treatment, including LST.
Informed Refusal	A patient with decisional capacity has the right to refuse any treatment, including LST, even if that refusal will lead to death.	Policies must outline processes for assessing capacity and ensuring refusals are informed and voluntary.
Ethical Equivalence	Withholding and withdrawing a treatment are considered ethically equivalent; there is no moral difference between not starting and stopping a treatment.	Policies should affirm this equivalence to prevent clinical hesitation in withdrawing treatment that is no longer desired or beneficial.
Legal Precedent (U.S.)	U.S. courts have consistently upheld the right to refuse or withdraw LST. Death following such a decision is attributed to the underlying disease, not to physician-assisted suicide.	Policies must align with legal standards, protecting both patient rights and clinicians from legal liability when following proper procedures.

The policy must explicitly state that carrying out an informed refusal or request to withdraw LST is neither physician-assisted suicide nor euthanasia. The intent is to honor the patient's wishes and remove a burdensome intervention, not to cause death [30].

Addressing the Moral Psychology of WH versus WD in Policy

A robust policy must acknowledge and address the empirical reality that WH and WD are often experienced as morally distinct actions, despite their theoretical equivalence. Research from Sweden and Thailand confirms that physicians frequently perceive an ethical difference, largely due to psychological factors, the patient-physician relationship, and prognostic uncertainty [23] [28]. An effective policy can incorporate mechanisms to mitigate this psychological burden.

The following workflow diagram outlines a standardized institutional protocol for WH/WD decisions, integrating steps designed to address these moral psychological challenges.

Key features of this protocol that address moral psychological challenges include:

• Standardized Communication (Step 6): Provides a structured framework for difficult conversations, reducing clinician anxiety and ensuring consistency [23].
• Explicit Documentation of Equivalence (Step 7): Actively reinforces the ethical and legal parity of WH and WD decisions within the clinical record, working to counteract implicit cognitive biases [30].
• Multidisciplinary Review (Step 4): Shares the moral responsibility of the decision among a team, offering support and validation to the primary clinician [29].

Research Methods and Experimental Protocols for WH/WD Studies

For researchers investigating the implementation and impact of WH/WD guidelines, rigorous methodological approaches are required. The following table summarizes key experimental designs and data sources used in this field.

Table 3: Research Methodologies for Studying WH/WD Policies and Practices [29] [31] [28]

Methodology	Description	Application in WH/WD Research	Key Considerations
Cross-Sectional Survey	A observational study that analyzes data from a population at a specific point in time.	Used to quantify the prevalence of policies, their content, and physician attitudes [29] [28].	Allows for national benchmarking but cannot establish causality.
Qualitative Interviews / Thematic Analysis	In-depth interviews are conducted and analyzed to identify recurring themes and patterns in experiences and perceptions.	Used to explore the "why" behind quantitative data, such as the psychological difficulty of withdrawing treatment [23].	Provides rich, contextual data. Sample sizes are typically small.
Analysis of Real-World Data (RWD)	Analysis of data derived from electronic health records (EHRs), claims data, and disease registries.	Can be used to identify disparities in WH/WD practices across sociodemographic groups [29] [31].	Data may be incomplete or inconsistently recorded; requires careful validation.

Detailed Protocol: National Cross-Sectional Survey of Hospital Policy Content [29]

• Population & Sampling: Distribute survey electronically to a target population with direct knowledge of hospital policies (e.g., clinical ethicists, physicians via professional society email listservs).
• Survey Design: Develop a comprehensive survey (e.g., 50 items) including multiple-choice and free-response questions. Key domains should include:
  • Policy existence and availability.
  • Guidance on specific scenarios (futility, inappropriate treatment, surrogate requests).
  • Procedures for unrepresented patients.
  • Approaches to addressing health disparities.
  • Required consultations (ethics, palliative care).
• Data Validation: Compare responses to eliminate duplicates and ensure representation from diverse geographic regions and hospital types.
• Data Analysis: Analyze categorical responses using descriptive statistics (frequencies, percentages). Analyze qualitative free-text responses using thematic analysis to identify emergent themes.

Researchers and policy architects require specific "reagents" and data sources to conduct robust studies and develop evidence-based guidelines.

Table 4: Essential Toolkit for WH/WD Policy Research and Development [29] [31]

Tool / Resource	Type	Function in WH/WD Research
Validated Policy Survey Instrument	Research Reagent	A pre-tested, structured survey (e.g., 50-item) used to systematically collect and compare the content of hospital policies across institutions [29].
National Hospital Database	Data Source	A sampling frame for identifying and recruiting a nationally representative cohort of hospitals or health systems for study.
De-Identified Dataset on LST Decisions	Data Source	Real-world data from EHRs or registries, used to analyze patterns, outcomes, and potential disparities in WH/WD practices [31].
Qualitative Interview Topic Guides	Research Reagent	A semi-structured guide used to conduct consistent, in-depth interviews with physicians, patients, and surrogates about their experiences and perceptions [23].
Consensus-Derived Clinical Definitions	Foundational Concept	Standardized definitions (e.g., for "physiologic futility," "potentially inappropriate treatment," "unrepresented patient") that ensure consistent interpretation and data collection across studies [29].

Critical Gaps and Future Research Directions

Current research reveals significant deficiencies in existing policies. Most notably, only 8% of U.S. hospital policies address sociodemographic disparities in decisions to WH/WD LST, and a mere 3% recommend collecting data that could be used to identify such disparities [29]. This represents a major frontier for future research and policy innovation. Key directions include:

• Developing and testing interventions to mitigate disparities in WH/WD decisions.
• Designing and implementing data collection protocols within EHRs to monitor equity in LST decision-making.
• Exploring the impact of novel policy components, such as mandatory early palliative care involvement for specific high-risk conditions, on patient and surrogate satisfaction and the quality of end-of-life care.

The anatomy of an effective WH/WD policy is complex, requiring a synthesis of clear ethical principles, legally defensible procedures, and a pragmatic understanding of human psychology. By leveraging quantitative data on current practices, adhering to established ethical and legal frameworks, and integrating mechanisms to address the moral distress associated with withdrawing treatment, institutions can create robust guidelines. For the research community, focused attention on closing the gap in equity monitoring and intervention is the next critical step in ensuring that these profound decisions are made fairly and consistently for all patients.

Medical decision-making for patients who lack capacity represents one of the most clinically and ethically complex challenges in healthcare, particularly in critical care and end-of-life contexts. This process requires the integration of three fundamentally distinct domains: accurate prognostic data about the patient's likely clinical course, authentic representation of patient values and preferences, and the ethical framework of surrogate judgment. When patients cannot express their own treatment preferences, clinicians and surrogates must navigate this tripartite landscape under conditions of profound uncertainty and emotional distress.

The moral context is further complicated by the documented psychological and ethical distinctions between withholding versus withdrawing life-sustaining treatments (LST). Although these decisions may be ethically equivalent in theory, empirical research consistently demonstrates that clinicians and surrogates experience them as psychologically and morally distinct [32] [13]. This distinction carries significant implications for treatment decisions, particularly in neurology and intensive care settings where decisions about life-sustaining treatments are most prevalent [32].

This technical guide examines the current evidence, methodologies, and frameworks for integrating prognosis, patient wishes, and surrogate judgment, with particular attention to the moral dimensions of treatment decisions within the broader research context of withholding versus withdrawing care.

The Empirical Evidence Base: Critical Findings and Quantitative Data

The Accuracy of Prognostic Predictions

Understanding the limitations of prognostic accuracy is fundamental to contextualizing decision-making. Recent research has quantified the predictive capabilities of both physicians and surrogates regarding critical patient outcomes.

Table 1: Accuracy of Surrogate and Physician Predictions for Patient Outcomes (Area Under ROC Curves) [33]

Outcome Measure	Surrogate Predictions (AUROC)	Physician Predictions (AUROC)
Need for Mechanical Ventilation at 1 Month	0.61 (95% CI, 0.50–0.72)	0.60 (95% CI, 0.49–0.71)
Need for Artificial Nutrition at 1 Month	0.67 (95% CI, 0.56–0.78)	0.72 (95% CI, 0.61–0.83)
Survival at 3 Months	0.66 (95% CI, 0.55–0.77)	0.69 (95% CI, 0.59–0.80)
Living at Home at 3 Months	0.61 (95% CI, 0.50–0.73)	0.76 (95% CI, 0.66–0.85)

This data demonstrates that while predictions are better than chance, they remain imperfect, with significant room for improvement. Notably, predictions did not significantly improve when reassessed one week later, suggesting that merely observing the clinical course may not enhance prognostic accuracy [33].

The Limitations of Substituted Judgment

The ethical framework of substituted judgment—where surrogates attempt to make decisions as the patient would—faces substantial empirical challenges beyond prognostic uncertainty.

Table 2: Empirical Evidence Challenging Substituted Judgment [34]

Evidence Category	Key Findings	Clinical Implications
Stability of Patient Preferences	Over 50% of patients change their wishes regarding life-sustaining treatments over 2 years; those without advance directives are most likely to change preferences [34]	Substituted judgment is least reliable for precisely those patients who need it most
Surrogate Accuracy	Surrogates correctly predict patient preferences only ~68% of the time; interventions to improve accuracy have had limited success [34]	Nearly one-third of surrogate decisions may not reflect patient true preferences
Patient Desires for Surrogate Input	Majority of patients prefer that family members or physicians have input into decisions rather than relying solely on prior wishes [34]	Strict adherence to autonomy principle may conflict with patient preferences for collaborative decision-making

The cumulative evidence suggests the moral basis for substituted judgment may be unsound, prompting the development of alternative decision-making models [34].

Withholding Versus Withdrawing Treatments: Moral Distinctions

The ethical equivalence between withholding and withdrawing treatment is well-established in theoretical bioethics, yet empirical research reveals persistent psychological and moral distinctions in clinical practice.

Table 3: Comparative Acceptance of Withholding vs. Withdrawing Treatments [18] [13]

Context	Withholding Treatment	Withdrawing Treatment	Moral Significance
Healthcare Rationing Decisions	Higher public acceptance	Lower public acceptance	Distinction persists across decision levels (bedside vs. policy)
End-of-Life Care	More psychologically comfortable for clinicians	Psychologically difficult for clinicians and families	Perceived as more "active" and morally burdensome
Patient-Physician Relationship	Standard care discussion	Perceived as breaking trust or promise	Creates relational ethical dimensions

This distinction carries practical implications for healthcare rationing policies, where grandfather clauses often protect existing patients from disinvestment decisions while withholding the same treatment from future patients [13]. Understanding this psychological reality is essential for implementing ethically sound policies that acknowledge these perceived differences while working toward more consistent ethical reasoning.

Methodological Approaches: Experimental Protocols and Research Design

Protocol for Studying Prognostic Accuracy in ICU Settings

Objective: To quantify and compare the accuracy of surrogate and physician predictions for post-ICU patient outcomes at multiple time points [33].

Population: Surrogates and physicians of mechanically ventilated patients requiring at least one week of mechanical ventilation.

Methodology:

• Enrollment: Identify surrogates after patients have required mechanical ventilation for five consecutive days
• Data Collection Time Points:
  • Time Point 1: At end of first week of mechanical ventilation
  • Time Point 2: One week later (if patient remains hospitalized)
• Outcome Expectations Measurement: Visual Analog Scale (0-100%) assessment for:
  • Requirement of mechanical ventilation in one month
  • Requirement of artificial nutrition in one month
  • Survival at three months
  • Living at home at three months
• Outcome Verification: Patient status determined at one and three months through surrogate contact
• Statistical Analysis: Area Under the Receiver Operating Characteristic curves (AUROCs) with 95% confidence intervals

Key Design Considerations: Exclude patients transitioning to comfort measures at second time point; include both attending and fellow physicians; account for physician rotation schedules [33].

Protocol for Assessing Ethical Views on Treatment Limitation

Objective: To explore physician and patient representative experiences and perceptions of withdrawing versus withholding treatments in rationing situations [13].

Study Design: Qualitative semi-structured interviews with thematic analysis.

Participant Selection:

• Purposive sampling of physicians working in high-technology specialties (oncology, hematology, neurology, rare diseases)
• Patient organization representatives from corresponding disease areas
• Sample size determined by data saturation (14 participants in published study)

Interview Framework:

• Experiences with reimbursement decisions and priority setting
• Factors and arguments affecting decisions about treatment limitations
• Relationship between physician and patient when prioritizing treatments
• Perceived differences between withdrawing versus withholding interventions

Analytical Method:

• Transcription and pseudonymization of interviews
• First-order coding using participants' own terms
• Iterative thematization through research team discussion
• Development of explanatory accounts through pattern detection
• Triangulation among researchers with diverse methodological expertise

Methodological Notes: Topic guides should be pilot-tested and flexible to allow emergent themes; field notes should be summarized immediately post-interview to capture impressions [13].

Conceptual Framework and Visual Models

Decision-Making Integration Framework

Decision Integration Framework

Experimental Assessment Protocol

Prognostic Accuracy Study Design

Table 4: Key Methodological Tools for Decision-Making Research

Research Tool	Function/Application	Implementation Example
Visual Analog Scale (VAS) for Prognostic Expectations	Quantifies probabilistic expectations for binary outcomes using 0-100% continuous scale	Measuring surrogate and physician expectations for specific patient outcomes (mechanical ventilation, survival) [33]
Thematic Analysis Framework	Identifies, analyzes, and reports patterns within qualitative data	Exploring ethical views on withholding/withdrawing treatments through semi-structured interviews [13]
Area Under Receiver Operating Characteristic (AUROC)	Measures predictive accuracy accounting for both sensitivity and specificity	Evaluating accuracy of surrogate and physician predictions for patient outcomes [33]
Clinical Decision Support (CDS) Innovation Framework	Structures development and implementation of patient-centered clinical decision support	AHRQ's CDSiC framework for incorporating patient preferences into clinical decision support systems [35]
Simulation and Modeling Platforms	Enables realistic modeling of clinical endpoints and decision thresholds	KerusCloud platform for modeling oncology endpoints and decision frameworks regarding interim overall survival data [36]

Emerging Innovations and Future Research Directions

Artificial Intelligence in Surrogate Decision Making

Emerging technologies offer potential solutions to the documented limitations of human surrogate prediction. Artificial intelligence systems are being explored for their potential to predict patient preferences through analysis of diverse data sources, including:

• Recorded clinical conversations that can be analyzed for expressed values and preferences
• Functional outcome predictions based on population data and individual characteristics
• Preference inference from prior behavior patterns, communication styles, and documented choices [37]

These approaches remain experimental but represent promising avenues for addressing the fundamental challenge of accurately representing patient wishes when direct communication is impossible.

Advanced Predictive Analytics in Healthcare

The field of predictive healthcare is rapidly evolving, with demonstrated improvements in early disease identification rates by up to 48% in some contexts [38]. These technologies integrate diverse data sources—electronic health records, genomic information, social determinants of health—to create comprehensive patient profiles and outcome predictions. By 2025, nearly 60% of U.S. hospitals had adopted at least one AI-assisted predictive tool in routine clinical care, up from approximately 35% in 2022 [38]. This rapid adoption reflects the growing recognition of prediction-based approaches to improve patient outcomes while potentially reducing healthcare costs.

Ethical and Implementation Considerations for Emerging Technologies

While technological innovations show promise, they introduce significant ethical challenges that require careful consideration:

• Algorithmic bias and ensuring equitable accuracy across diverse patient populations
• Transparency in predictive models and their limitations
• Privacy concerns regarding data collection and analysis
• Appropriate role of technology in fundamentally human decisions about life and death [37] [38]

Successful implementation will require maintaining appropriate human oversight of automated predictions and ensuring these technologies augment rather than replace the crucial human elements of clinical judgment and compassionate care.

The integration of prognosis, patient wishes, and surrogate judgment remains a complex challenge at the intersection of clinical medicine, ethics, and empirical research. The evidence demonstrates significant limitations in both prognostic accuracy and the substituted judgment paradigm, while revealing persistent psychological distinctions between withholding and withdrawing treatments despite their theoretical ethical equivalence.

Future progress will require multidisciplinary approaches that acknowledge these empirical realities while developing more robust methodological frameworks for both research and clinical practice. Emerging technologies offer promising avenues for addressing these challenges but must be implemented with careful attention to their ethical implications and limitations. Through continued research and methodological innovation, the field can work toward decision-making processes that more effectively integrate these three critical domains while respecting the moral complexities inherent in treatment decisions for incapacitated patients.

The effective translation of clinical research and policies into daily practice is a critical challenge within modern healthcare systems. This whitepaper examines the significant barriers that hinder clinician awareness, access, and adherence to established policies and treatments, with particular emphasis on the ethical dimensions of withholding versus withdrawing treatment. These barriers manifest across multiple domains, including structural systems, cultural norms, and individual circumstances, ultimately affecting both clinician wellbeing and patient outcomes. The moral framework for decision-making, particularly when resources are limited or treatments are deemed non-cost-effective, creates complex ethical dilemmas for healthcare providers and policymakers alike. Understanding these barriers is essential for researchers and drug development professionals who must navigate these challenges when implementing new treatments and protocols. This analysis synthesizes current research and empirical findings to provide a comprehensive technical guide for addressing these persistent implementation gaps.

Quantitative Analysis of Barriers to Application

Data from recent studies reveal the multifaceted nature of barriers preventing clinicians from accessing care and adhering to clinical policies. The tables below summarize key quantitative findings across different domains.

Table 1: Structural and Logistical Barriers to Mental Healthcare Access Among Clinicians [39]

Barrier Category	Specific Barrier	Prevalence/Impact
Financial Barriers	Cost without insurance	Greatest logistical barrier
	Schedule flexibility	Significant barrier, especially for female physicians and nurses
	Out-of-pocket payment to avoid paper trail	13% of clinicians
Institutional/Professional	Impact on hiring, credentialing, or privileges	50% of clinicians
	Concerns about professional insurance and license renewals	>40% of clinicians
	Seeking care in another city/state for confidentiality	14% of clinicians
Knowledge Barriers	Understanding of Professional Health Programs (PHPs)	<20% of clinicians

Table 2: Medication Non-Adherence: Impact and Contributing Factors [40] [41]

Factor Category	Specific Factor	Impact/Prevalence
Population Impact	Annual preventable deaths	125,000
	Annual avoidable healthcare costs	$300+ billion
	Chronic condition patients not taking medications as prescribed	Up to 50%
Common Non-Adherence Behaviors	Failure to fill or refill prescriptions	Variable
	Skipping doses or taking incorrect amounts	Variable
	Stopping medications early	Variable
	Taking old or another person's medication	Variable
Root Causes	Cognitive decline and lack of support	Significant in seniors
	Cost barriers and insurance complexities	Widespread
	Adverse side effects and poor communication	Common
	Complicated medication regimens	Particularly in polypharmacy

Experimental Protocols and Methodologies

Objective: To understand individual, structural, and cultural barriers preventing clinicians from seeking mental healthcare.

Participant Recruitment:

• Over 2,000 healthcare professionals including nurse practitioners, physician assistants, physicians, and registered nurses.
• Participants represented diverse demographic and professional backgrounds.

Survey Methodology:

• Comprehensive survey assessing logistical barriers (cost, scheduling), institutional stigma (licensure concerns, credentialing implications), and cultural attitudes (perceived judgment from colleagues).
• Mixed-methods approach combining quantitative scales with qualitative feedback.
• Data analysis included cross-tabulation by profession, gender, and career stage to identify disproportionate impacts.

Key Outcome Measures:

• Perceived barriers ranked by significance
• Differential experiences across professional roles
• Correlation between institutional policies and help-seeking behavior

Objective: To document physician perspectives on medication non-adherence across multiple specialties.

Study Design:

• Structured qualitative approach using semi-structured interviews and written questionnaires.
• Seven physicians from diverse specialties including family medicine, gastroenterology, otolaryngology, OB-GYN, endocrinology, and cardiology.

Data Collection:

• Initial open-ended questionnaire distributed via email to capture initial reflections.
• Development of interview guide based on preliminary responses.
• One-hour individual interviews conducted online by independent third party to ensure objectivity.

Analytical Framework:

• Thematic analysis of transcribed interviews without specialized software.
• Three independent analysts working simultaneously on narrative construction.
• Iterative process to compare and consolidate reports into coherent narrative.
• Inclusion of direct physician quotes to highlight individual viewpoints.

Objective: To examine public support for rationing treatments by withdrawing versus withholding in reimbursement decisions.

Participant Recruitment:

• 1,404 UK-based adults recruited through Prolific online platform.
• Demographic diversity with mean age 39.90 (SD=13.13), 58.62% female, 55.84% with higher education.

Experimental Design:

• Random assignment to withdrawing or withholding condition.
• All aspects identical except framing of statements about treatment rationing.
• Eleven statements about rationing treatments presented in randomized order.
• Seven-point Likert scale responses (1="completely disagree" to 7="completely agree").

Statistical Analysis:

• T-test analysis for individual statements to detect differences between conditions.
• Calculation of average support across all rationing statements.
• Ordinary linear regressions controlling for demographics to test robustness.

Visualization of Barrier Pathways and Relationships

Figure 1. Interrelationships Between Barrier Types and Healthcare Outcomes. This pathway diagram illustrates how awareness, access, and adherence barriers interact to generate negative clinical outcomes, incorporating ethical dilemmas around treatment decisions [39] [22].

Research Reagent Solutions for Barrier Investigation

Table 3: Essential Research Tools for Studying Healthcare Implementation Barriers

Research Tool/Reagent	Function/Application	Exemplary Use Cases
Qualitative Interview Guides	Structured protocols for eliciting clinician perspectives on barriers	Exploring institutional stigma and mental healthcare access [39]; Understanding medication non-adherence across specialties [42]
Validated Survey Instruments	Quantitative assessment of barrier prevalence and impact	Measuring logistical and structural barriers to mental healthcare [39]; Assessing attitudes toward treatment rationing [22]
Thematic Analysis Frameworks	Systematic approach to identifying patterns in qualitative data	Analyzing physician perspectives on medication non-adherence [42]; Interpreting patient experiences with primary care access [43]
Behavioral Experiment Paradigms	Controlled investigation of decision-making processes	Testing ethical preferences between withdrawing vs. withholding treatments [22]
Statistical Analysis Packages	Quantitative analysis of barrier data and outcome correlations	T-test analysis of differences between withdrawing/withholding conditions [22]; Regression analyses controlling for demographics

Discussion: Integration with Moral Foundations of Treatment Decisions

The barriers to clinician awareness, access, and adherence to policies exist within a complex ethical landscape, particularly concerning the moral distinction between withholding versus withdrawing treatments. Recent research reveals nuanced public attitudes toward these decisions, challenging conventional ethical assumptions [22]. While traditional bioethics often suggests that withholding treatment is psychologically and ethically less problematic than withdrawing, contemporary findings indicate this distinction is highly context-dependent.

The structural barriers identified in clinician mental healthcare access [39] parallel the ethical dilemmas in treatment allocation decisions [22]. In both domains, systemic factors create moral distress for healthcare providers who must navigate conflicting obligations to patients, institutions, and their own wellbeing. The finding that 50% of clinicians report concerns about professional repercussions when seeking mental healthcare [39] demonstrates how institutional policies can directly impede appropriate care-seeking behaviors, creating an ethical tension between self-care and professional preservation.

Similarly, medication non-adherence issues [40] [42] [41] reflect broader systemic failures in healthcare delivery rather than simply individual patient non-compliance. The multifactorial nature of these barriers necessitates equally sophisticated solutions that address both structural and individual dimensions. The stakeholder perspectives compiled by ISPOR [41] highlight the divergent priorities that different actors bring to medication adherence challenges, underscoring the need for collaborative approaches that acknowledge these distinct viewpoints.

The experimental methodology employed in ethical decision-making research [22] provides a template for how to systematically investigate these complex questions. By employing randomized conditions and carefully controlled stimuli, researchers can isolate the specific factors that influence moral judgments about resource allocation and treatment decisions. This approach offers a model for future research seeking to quantify the impact of different barriers on clinical decision-making and policy implementation.

The barriers to clinician awareness, access, and adherence to policies represent a critical challenge in healthcare implementation science. These barriers operate at multiple levels, from individual cognitive limitations to structural institutional constraints, and are further complicated by ethical dilemmas surrounding treatment decisions. The empirical evidence demonstrates that effective solutions require multifaceted approaches addressing financial, logistical, educational, and cultural dimensions simultaneously.

For researchers and drug development professionals, these findings highlight the importance of considering implementation barriers early in the research and development process. Understanding the contextual factors that will influence whether clinicians can and will adopt new treatments is essential for successful translation of scientific advances into clinical practice. Future research should continue to refine methodologies for identifying and addressing these barriers, with particular attention to the ethical dimensions of healthcare resource allocation and the moral distress experienced by clinicians navigating complex systems constraints.

The integration of palliative care into healthcare systems represents a critical evolution in addressing serious health-related suffering, yet it presents complex ethical challenges that demand sophisticated operationalization of ethics. Palliative care, defined as "both a philosophy of care and an organized, highly structured system for delivering care," aims to prevent and relieve suffering while supporting the best possible quality of life for patients and families, regardless of disease stage or need for other therapies [44]. Within this domain, ethics committees and palliative care providers navigate a challenging landscape marked by vulnerable populations, difficult treatment decisions, and the nuanced distinction between withholding versus withdrawing life-sustaining interventions.

The global development of palliative care remains highly uneven, with recent data from the first-ever global ranking under the WHO framework revealing that 40% of 201 assessed countries were classified as "Emerging" in palliative care development, while only 14% reached "Advanced" status [45]. This disparity creates significant ethical challenges in ensuring equitable access to quality palliative care worldwide. Ethics committees play a crucial role in this context, serving not only as regulatory gatekeepers but as facilitators of ethically sound palliative care research and practice, particularly when addressing core dilemmas such as the distinction between withholding and withdrawing treatments—a central consideration in moral foundations research [46] [18] [22].

Ethics Committees as Gatekeepers and Facilitators

Navigating Committee Review Challenges

Human Research Ethics Committees (HRECs) frequently struggle with the inherent tensions in palliative care research, often displaying over-protectiveness toward vulnerable palliative populations. This perspective can distort the proper gatekeeping role of ethics committees and create significant barriers to important research [46]. Committee members who do not specialize in palliative care often perceive approaching dying patients and their families for research participation as "abhorrent," operating under the persistent assumption that these individuals are too burdened by the dying process to participate in research [46]. This protectionist stance, while well-intentioned, can inadvertently limit valuable research that could improve end-of-life care.

The responsibilities of ethics committees in this context extend beyond mere protection to include facilitating ethically sound research methodologies. Researchers presenting applications to HRECs must thoughtfully construct protocols that address challenges related to vulnerable patients, difficulties with informed consent, and methodological complexities [46]. Successful navigation of this process requires demonstrating how the research design accommodates the unique vulnerabilities of palliative care populations while advancing knowledge that can meaningfully improve care quality.

Operationalizing Ethical Principles in Clinical Practice

Beyond research oversight, ethics committees contribute significantly to developing clinical frameworks for palliative care delivery. A systematic review of real-world ethical challenges in palliative care identified six major thematic areas: application of ethical principles; delivering clinical care; working with families; engaging with institutional structures and values; navigating societal values and expectations; and philosophy of palliative care [47]. This broad spectrum of challenges exceeds the coverage typically found in palliative care ethics training resources, highlighting the need for ethics committees to address contextual factors at multiple levels—bedside, institutional, societal, and policy [47].

The WellStar Health System case study demonstrates how an ethics committee can successfully drive palliative care integration through a structured, multi-phase approach [44]. This process began with comprehensive staff education on advance directives, progressed through the creation of specialized palliative care roles, and culminated in hiring a board-certified palliative care physician. Throughout this transformation, the ethics committee maintained an educational mission to inform physicians about palliative care principles and prepare them for a multidisciplinary team approach [44].

Withholding Versus Withdrawing Treatment: Empirical Research Findings

Conceptual Framework and Ethical Debate

The ethical distinction between withholding (not starting a treatment) and withdrawing (stopping an ongoing treatment) life-sustaining interventions represents a central dilemma in palliative care ethics. The "equivalence thesis" posits that these actions are ethically equivalent, yet persistent psychological and practical differences influence how both providers and the public perceive these decisions [18] [22]. This distinction becomes particularly salient in reimbursement contexts, where policymakers must decide whether to discontinue coverage for existing patients when treatments are deemed not cost-effective for future patients [18].

Normative concerns regarding policies that affect only future patients include: (1) creating differential treatment for patients with similar medical needs; (2) establishing a "first-come, first-served" approach to treatment; and (3) inefficient use of healthcare resources when non-cost-effective treatments continue to be provided to existing patients [18]. Despite these concerns, such policies are commonly implemented in practice, indicating a perceived ethical distinction between withdrawing and withholding treatments in reimbursement decisions [18].

Experimental Evidence on Public and Practitioner Attitudes

Recent behavioral experiments have yielded nuanced insights into how different stakeholders perceive the withholding/withdrawing distinction. A preregistered behavioral experiment with 1,067 participants found that individuals were more supportive of rationing decisions presented as withholding treatments compared to withdrawing treatments [18]. Interestingly, contrary to the researchers' initial hypothesis, participants were more supportive of decisions to withdraw treatment made at the bedside level compared to similar decisions made at the policy level [18].

A subsequent larger experiment (n=1,404) exploring public support for rationing treatments across eleven different circumstances revealed that overall support for both withdrawing and withholding was low, with no general perceived difference between the two approaches [22]. However, when analyzing different circumstances separately, the researchers found "multiple circumstances where withholding was deemed ethically more problematic than withdrawing" [22]. This nuanced finding challenges the prevailing belief that withholding treatments is psychologically easier and ethically less problematic than withdrawing.

Table 1: Key Findings from Behavioral Experiments on Withholding vs. Withdrawing Treatments

Study Characteristic	Strand et al. (2024) [18]	Strand et al. (2025) [22]
Sample Size	1,067 participants	1,404 participants
Overall Support for Rationing	Low acceptance for both withdrawal and withholding	Low support for both approaches
Withholding vs. Withdrawing	More support for withholding than withdrawal	Context-dependent; sometimes more support for withdrawal
Decision Level Preference	More support for bedside-level than policy-level decisions	Preference for individual assessments over standardized rationing
Key Influencing Factors	Framing of the decision; decision-making level	Specific circumstances; procedural fairness concerns

Hospital Policy Variations and Practical Implementation

The translation of ethical principles into clinical practice reveals significant variation in how institutions approach withholding and withdrawing decisions. A national cross-sectional survey of hospital policies in the United States found that while 92% of hospitals had policies addressing decisions to withhold or withdraw life-sustaining treatment, these policies varied widely in their criteria and processes [25]. Most policies permitted withholding or withdrawing treatment in cases of patient or surrogate request (82%), physiologic futility (81%), and potentially inappropriate treatment (64%) [25].

Concerningly, only 8% of hospitals had policies that addressed patient sociodemographic disparities in decisions to withhold or withdraw life-sustaining treatment, and these policies provided opposing recommendations—some advising to exclude sociodemographic factors while others recommended actively acknowledging and incorporating them [25]. Only 3% of hospitals recommended collecting data that could be used to identify disparities in these critical decisions [25].

Methodological Approaches in Palliative Care Ethics Research

Experimental Design and Protocols

Research examining ethical decision-making in palliative care requires sophisticated methodological approaches that can capture nuanced attitudes and contextual factors. The experiment conducted by Strand and colleagues exemplifies this approach, employing a 2×2 between-subjects design where participants were randomized into one of four conditions: (1) withdrawing treatment at the policy level; (2) withholding treatment at the policy level; (3) withdrawing treatment at the bedside level; and (4) withholding treatment at the bedside level [18]. Participants were presented with vignettes describing a serious disease context where a medicine was deemed not cost-effective, then asked to rate the acceptability of rationing decisions.

This experimental protocol included careful attention checks, demographic balancing, and randomization verification to ensure data quality. The researchers employed standardized acceptability measures using Likert scales and conducted both t-test analyses and ordinary linear regressions controlling for demographics to test their hypotheses [18] [22]. The preregistration of hypotheses and analytical plans added methodological rigor to these investigations.

Assessment Tools and Metrics

Research in palliative care ethics utilizes standardized assessment tools to quantify key constructs across knowledge, attitudes, and practices. The Knowledge, Attitudes, and Practices of Palliative Care (KAPPC) scale, for instance, provides a structured approach to evaluating healthcare provider competencies [48]. This instrument assesses knowledge across five dimensions (basic concepts, pain management, psychological support, localization issues, policy matters), attitudes across five additional dimensions (perceptions of threat, quality of life, death preparedness, barriers, subjective norms), and practices through confidence and self-reported implementation metrics [48].

Validation studies of the KAPPC scale demonstrate good psychometric properties, with Cronbach's alpha coefficients of 0.686 (knowledge), 0.868 (attitude), and 0.958 (practice) [48]. Application of this instrument in ICU settings has revealed significant gaps in palliative care knowledge among critical care staff and identified factors influencing palliative care integration, including profession, professional title, prior palliative care education, and willingness to engage in palliative care training [48].

Table 2: Key Assessment Instruments in Palliative Care Ethics Research

Instrument	Constructs Measured	Application Context	Psychometric Properties
Ethical Issues Scale (EIS) [49]	Ethical challenges in patient care	Palliative care nurses	Mean score: 4.03 (SD=0.74); Patient Care subscale: M=4.2, SD=0.7
Nursing Quality of Life Scale (NQOLS) [49]	Work-related quality of life	Palliative care settings	Overall QoL mean score: 6.75; Work dimension: 7.1
Patient Rights Questionnaire (PRQ) [49]	Awareness and adherence to patient rights	Healthcare settings	Total mean score: 49.5 (SD=6.8)
KAPPC Scale [48]	Knowledge, attitudes, practices in palliative care	ICU settings	Cronbach's alpha: 0.686 (knowledge), 0.868 (attitude), 0.958 (practice)

Implementation Framework for Palliative Care Integration

Models for Successful Program Development

The integration of palliative care into healthcare systems requires strategic implementation frameworks. The WellStar Health System model demonstrates a successful three-phase approach: beginning with comprehensive staff education on advance directives and palliative care principles; progressing through structural changes including the creation of specialized palliative care roles; and culminating in the recruitment of dedicated palliative care physicians [44]. This systematic approach transformed the hospital system's capacity to deliver ethical, patient-centered palliative care.

Evaluation of such programs reveals critical success factors. Focus groups conducted at WellStar identified significant knowledge gaps among staff regarding legal parameters of end-of-life care and advance directives, highlighting the need for ongoing education [44]. The system addressed this through Ethics Week presentations, one-on-one education, Ethics Rounds, and formal education at staff meetings, emphasizing that "in the everyday encounters and all relationships among professionals that progress is going to be made" [44].

Specialized Applications and Population-Specific Approaches

Effective palliative care integration requires tailoring approaches to specific patient populations and care settings. A feasibility study on home-based palliative care for patients with end-stage liver disease (ESLD) exemplifies this specialized approach [50]. The study protocol implemented a multidisciplinary homecare team led by a palliative care physician providing regular visits, symptom management, education about disease trajectory, goals of care discussions, and caregiver support [50].

This mixed-methods feasibility study employed the RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) framework to evaluate implementation outcomes, including service uptake, patient and physician perspectives, and impacts on quality of life, symptom burden, and healthcare utilization [50]. The researchers used the Supportive and Palliative Care Indicators Tool (SPICT) to identify appropriate patients, specifically requiring at least two unplanned hospitalizations in the previous year—a criterion linked to increased mortality in this population [50].

Visualization of Ethical Decision-Making in Palliative Care

The following diagram illustrates the key factors and relationships in ethical decision-making regarding withholding versus withdrawing treatment in palliative care contexts, based on the research findings previously discussed:

Ethical Decision-Making Factors in Palliative Care

Research Reagent Solutions: Essential Methodological Tools

Table 3: Key Research Instruments and Assessment Tools for Palliative Care Ethics Research

Tool/Instrument	Primary Function	Application in Research	Key Features
Supportive and Palliative Care Indicators Tool (SPICT) [50]	Identifies patients appropriate for palliative care	Screening and recruitment in clinical studies	Two-step screening: general indicators of poor health + condition-specific indicators
Knowledge, Attitudes, and Practices of Palliative Care (KAPPC) Scale [48]	Assesses healthcare provider competencies	Evaluating training outcomes and baseline assessments	Multidimensional assessment across knowledge (15 items), attitudes (24 items), practices (22 items)
Ethical Issues Scale (EIS) [49]	Measures ethical challenges in patient care	Quantifying ethical dilemmas faced by practitioners	Focus on patient care issues; validated in palliative care settings
Chronic Liver Disease Questionnaire [50]	Disease-specific quality of life assessment	Evaluating intervention effectiveness in ESLD patients	Specialized for liver disease populations
RE-AIM Framework [50]	Implementation science framework	Evaluating real-world program implementation	Assesses Reach, Effectiveness, Adoption, Implementation, Maintenance

The operationalization of ethics in palliative care requires navigating complex terrain where moral principles intersect with clinical reality, institutional structures, and human vulnerability. Ethics committees play an indispensable role in this landscape, serving not merely as regulatory obstacles but as essential partners in developing ethically sound approaches to palliative care integration. The distinction between withholding and withdrawing treatment exemplifies the nuanced ethical decisions that characterize this field, with research revealing that public and professional attitudes toward these decisions are highly context-dependent rather than governed by absolute principles [18] [22].

Successful palliative care integration hinges on moving beyond theoretical ethical frameworks to implement practical, structured approaches that address the real-world challenges identified in empirical research [47]. This requires specialized assessment tools, tailored implementation strategies for different patient populations, and ongoing education that addresses the full spectrum of ethical challenges encountered in clinical practice. As global palliative care continues to develop, with significant disparities in access and quality [45], the operationalization of ethics through thoughtful policy, education, and clinical frameworks remains essential to ensuring that all patients receive care that honors their dignity, autonomy, and humanity throughout the course of serious illness.

Within the moral foundations of medical research, the distinction between withholding and withdrawing life-sustaining or cost-ineffective treatment presents a profound ethical challenge. While normative literature often posits the equivalence thesis—that there is no ethical difference between the two actions—empirical evidence consistently reveals that practitioners, patients, and the public perceive a significant moral distinction [18] [23]. This guide addresses the critical role of documentation and communication in navigating this dichotomy, ensuring that decisions are made with legal robustness, ethical accountability, and procedural transparency for researchers, scientists, and drug development professionals. The inherent psychological and moral difficulty of withdrawing a treatment once initiated, compared to withholding it from the start, necessitates rigorous frameworks for practice and record-keeping [23] [28].

Quantitative Data on Attitudes and Practices

Understanding how key stakeholders perceive and act upon the withholding versus withdrawal distinction is fundamental. The data below summarize findings from recent behavioral experiments and cross-sectional surveys.

Table 1: Public and Physician Attitudes from Experimental Studies

Stakeholder Group	Study Type	Key Finding on Withholding vs. Withdrawing	Key Finding on Decision Level	Citation
General Public (n=1,067)	Preregistered Behavioral Experiment	Significantly higher acceptance of withholding treatment compared to equivalent withdrawing.	Higher support for withdrawal decisions made at the bedside vs. policy level.	[18]
Physicians (n=251)	Cross-sectional Survey (Thailand)	54.2% perceived an ethical difference between withholding and withdrawal.	Patient preferences (100%), prognosis (93.4%), and family requests (87.5%) most influenced decisions.	[28]

Table 2: Influence of Family Requests on Physician Decisions (Case-Based Survey) A scenario of a 50-year-old male with a chronic disease in a comatose state was presented to physicians [28].

Family/Surrogate Stance	Physician Decision to "Do Everything" (Including CPR)
No family/surrogate/advanced directive present	47.0%
Family insists on stopping treatment	0.8%
Family insists on continuing treatment	78.1%

Experimental Protocols for Research

To investigate the ethical dimensions of this dilemma, researchers have employed both quantitative and qualitative methodologies. The following protocols detail key experimental designs.

Behavioral Experiment on Public Attitudes

This protocol is designed to quantitatively assess public attitudes toward rationing decisions, testing the impact of both the action (withdrawing vs. withholding) and the decision level (policy vs. bedside) [18].

• Primary Research Question: Do people express an ethical difference between withdrawing and withholding treatments in a reimbursement context, and do these attitudes vary between bedside-level and policy-level decisions?
• Hypotheses:
  • H1: Acceptance of limiting patients’ access to treatments will be lower when withdrawing treatments compared to withholding.
  • H2: Acceptance will be lower at the bedside level compared to the policy level.
• Participant Recruitment:
  • Sample: 1,404 English-speaking participants recruited via Prolific.
  • Demographics: 59% female, mean age 39.90 years.
• Randomization & Study Design:
  • A 2x2 between-subjects design was planned, though one condition was excluded due to a programming error.
  • Participants were randomized into one of three conditions for analysis:
    • Withdrawing at Policy Level (Control): A public health agency decides to withdraw a cost-ineffective medicine from patients currently undergoing treatment.
    • Withholding at Policy Level: A public health agency decides to withhold a cost-ineffective medicine from patients currently seeking treatment.
    • Withdrawing at Bedside Level: A physician decides to withdraw a cost-ineffective medicine from patients currently undergoing treatment.
• Procedure:
  • Participants read a vignette describing the rationing dilemma specific to their assigned condition.
  • The vignette specified the decision-maker (policy agency or physician) and the action (withdrawing or withholding).
  • Participants were then asked to rate the acceptability of the decision on a scale.
• Data Analysis:
  • Preregistered analysis plan.
  • Robustness checks performed by excluding participants who failed attention checks.

Qualitative Interview Study with Practitioners

This protocol aims to explore in-depth the experiences and perceptions of those directly involved in or affected by rationing decisions [23].

• Research Objective: To explore physicians’ and patient organization representatives’ experiences and perceptions of withdrawing and withholding treatments in rationing situations of relative scarcity.
• Participant Selection:
  • Sampling: Purposive sampling of physicians working in high-technology medical areas (oncology, hematology, neurology, rare diseases) and representatives from patient organizations in those areas.
  • Final Sample: 14 participants (8 physicians, 6 patient organization representatives) from Sweden.
• Data Collection:
  • Method: Semi-structured interviews conducted online via Zoom.
  • Duration: Approximately one hour per interview.
  • Materials: A flexible topic guide covering experiences with reimbursement decisions, influencing factors, and the patient-physician relationship.
  • Processing: Interviews were audio-recorded, transcribed, and pseudonymized.
• Data Analysis:
  • Method: Thematic analysis using the framework method.
  • Process: Transcripts were read and labeled with first-order codes, which were iteratively sorted into general themes through discussion among researchers.
  • Triangulation: Multiple co-authors with different expertise (qualitative methods, policy analysis, ethics, psychology, economics) discussed coding and themes to decrease one-sided interpretation.

Visualizing Workflows and Relationships

The following diagrams, created using DOT language and adhering to the specified color and contrast rules, map the key conceptual and decision-making processes.

Ethical Decision-Making Logic

Qualitative Research Methodology

The Scientist's Toolkit: Essential Research Reagents

This section details key methodological components and their functions for conducting research in this field.

Table 3: Key Methodological Components for Ethical Research

Item	Category	Function in Research
Preregistration	Study Design	Publicly registering hypotheses and analysis plans before data collection to confirm hypothesis-testing nature and reduce bias [18].
Vignette-based Experiment	Data Collection	Presents participants with controlled, hypothetical scenarios to isolate the causal effect of specific variables (e.g., withdraw/withhold) on attitudes [18].
Thematic Analysis	Data Analysis	A qualitative method for identifying, analyzing, and reporting patterns (themes) within interview data, moving from codes to broader themes [23].
Prolific Platform	Participant Recruitment	An online service for recruiting a large sample of participants for behavioral research, enabling rapid data collection and randomization [18].
Semi-structured Interview	Data Collection	A qualitative interview method using a flexible topic guide, allowing for consistent questioning while permitting follow-up for deeper understanding [23].

Mitigating Real-World Challenges: Moral Distress, Disparities, and Procedural Pitfalls

Moral distress is a pervasive and damaging phenomenon within healthcare systems, defined as the psychological distress that occurs when an individual identifies the ethically correct action to take but feels constrained from pursuing it due to internal or external barriers [51]. This complex experience threatens core professional values and has significant ethical implications for clinicians, researchers, and patients alike [51]. Within the specific context of medical research and treatment decisions, the ethical dilemmas surrounding withholding versus withdrawing life-sustaining treatments represent a particularly potent source of moral distress that merits detailed examination [23]. This guide provides an in-depth technical analysis of moral distress sources, measurement methodologies, and evidence-based alleviation strategies targeted to healthcare researchers, scientists, and drug development professionals working at the intersection of clinical ethics and therapeutic innovation.

The distinction between withholding and withdrawing treatment presents a critical foundation for understanding moral distress in research environments. While ethical principles often posit equivalence between these decisions, empirical research demonstrates that healthcare professionals experience them as psychologically and morally distinct [23]. This discrepancy creates significant moral distress, particularly in environments of relative scarcity where resource allocation decisions directly impact research protocols and treatment availability. Understanding these foundational tensions enables more effective interventions to support healthcare teams navigating complex ethical terrain.

Theoretical Framework: Withholding Versus Withdrawing Treatment

Ethical Foundations and Clinical Realities

The ethical framework surrounding treatment limitation decisions has evolved significantly, with many ethical guidelines maintaining that withholding and withdrawing life-sustaining treatments are morally equivalent [52]. This equivalence thesis argues that both decisions lead to the same outcome (the patient's death) and therefore should not generate different moral responses [23]. Legal standards in many jurisdictions reflect this perspective, providing similar protections for both types of decisions when aligned with patient preferences or best interest standards [52].

However, empirical research with healthcare practitioners reveals a more complex reality. Participants in qualitative studies commonly express internally inconsistent views regarding ethical equivalence, acknowledging similar patient needs for treatment while simultaneously recognizing profound psychological differences between the two actions [23]. This tension between ethical theory and clinical practice creates a fertile ground for moral distress to emerge, particularly for research professionals working under constrained resources.

Psychological and Relational Dimensions

The experienced moral difference between withholding and withdrawing treatments stems from several psychologically significant factors:

• Prognostic uncertainty: Withdrawing treatment typically occurs after a therapeutic trial, providing more clinical information than decisions to withhold treatment [23].
• Relational implications: Withdrawing established treatment often feels like abandoning the patient-physician relationship or breaking a therapeutic bond [23].
• Temporal orientation: Withholding is prospective (preventing a potential future), while withdrawing is interventional (changing the current course) [23].
• Moral residue: Repeated experiences with treatment withdrawal can accumulate as moral residue, creating progressively heightened distress with each subsequent occurrence [53].

These psychological mechanisms explain why healthcare professionals report withdrawing treatment as significantly more morally distressing than withholding the same intervention, despite theoretical equivalence [23].

Quantitative Assessment of Moral Distress

Measurement Instruments and Methodologies

Table 1: Standardized Instruments for Measuring Moral Distress in Healthcare Research

Instrument Name	Target Population	Domains Measured	Scale Structure	Psychometric Properties
Moral Distress Thermometer (MDT) [54]	All healthcare professionals	Single-item distress intensity	0-10 visual analog scale	Cronbach's α = 0.90; good convergent validity
Moral Distress Scale-Revised (MDS-R)	Nurses, Physicians	Frequency and intensity of distressing situations	5-point Likert scales for frequency and intensity	Well-validated across multiple populations
MDD-HP (Moral Distress in Health Professionals) [55]	Physicians, particularly primary care	System constraints, patient care compromises	Multiple items rated on frequency and intensity	Identifies specific drivers in clinical practice

Prevalence and Distribution Across Settings

Table 2: Moral Distress Levels Across Professional Groups and Settings

Professional Group	Setting	Mean Moral Distress Score (0-10 scale)	Key Contributing Factors	Statistical Significance
Nurses [54]	Hospital	4.91 (SD not reported)	Inadequate staffing, futile care, value conflicts	H(6) = 14.407; p < 0.05
All Healthcare Professionals	Hospital	4.92 (SD not reported)	System-level constraints, interpersonal conflicts	Significant difference from community setting (p < 0.05)
All Healthcare Professionals	Community	3.80 (SD not reported)	Resource limitations, isolation, unclear protocols	Significant difference from hospital setting (p < 0.05)
New Graduate Nurses [56]	Mixed	6.55 ± 3.51 (total score)	Systemic causes, role ambiguity, ethical violations	Highest scores from system-level causes

Recent research demonstrates that moral distress affects all healthcare professional groups, with measurable differences across settings and specialties [54]. Quantitative analysis reveals that healthcare professionals working in hospital environments experience significantly higher moral distress levels (mean: 4.92) compared to those in community settings (mean: 3.80) [54]. This disparity suggests that organizational factors, including workload intensity, complexity of cases, and ethical challenges surrounding life-sustaining treatments, contribute significantly to moral distress variation.

Among professional groups, nurses consistently report higher moral distress levels than other healthcare professionals, with a mean score of 4.91 [54]. This elevated distress appears linked to nurses' position at the bedside, where they directly witness patient suffering while often feeling powerless to influence overarching treatment decisions [51]. Quantitative analysis also reveals significant gender differences, with female nurses experiencing moral distress 9.81 units more frequently and 17.10 units more intensely than male colleagues, though interpretation requires consideration of gender socialisation and reporting biases [56].

Experimental Protocols for Moral Distress Research

Qualitative Interview Methodology

The following protocol adapts methodologies from recent investigations into moral distress surrounding withholding/withdrawing treatments [23]:

Research Design and Sampling

• Employ purposive sampling to recruit physicians and patient organization representatives from high-technology medical specialties (oncology, hematology, neurology, rare diseases).
• Target sample size of 14-20 participants to achieve data saturation, as determined by field notes ceasing to yield new major insights.
• Include participants with minimum 6 months of experience in their current role to ensure adequate exposure to ethically complex situations.

Data Collection Procedure

• Conduct semi-structured interviews using a flexible topic guide covering: experiences with reimbursement decisions, factors affecting treatment decisions, and patient-physician relationships during treatment prioritization.
• Perform pilot testing with 1-2 interviews per participant group to refine topic guides and questioning techniques.
• Conduct interviews in person or via secure video conferencing platform, audio record with permission, and professionally transcribe verbatim.
• Maintain pseudonymization to ensure participant confidentiality throughout data handling.

Data Analysis Approach

• Apply thematic framework analysis with iterative coding process.
• Read transcripts multiple times to achieve immersion and familiarity.
• Develop first-order codes close to participants' terminology, then sort into broader thematic categories.
• Establish analytical rigor through triangulation among multiple researchers with complementary expertise (ethics, psychology, policy analysis).
• Use software such as NVivo or Microsoft Excel to manage coding framework and facilitate thematic organization.

Cross-Sectional Survey Protocol

Instrument Selection and Adaptation

• Select validated moral distress measurement tools appropriate to target population (e.g., Moral Distress Thermometer, MDS-R).
• Include demographic and workplace characteristic sections: gender, professional category, work setting, experience level, and subjective role fulfillment metrics.
• Incorporate workplace satisfaction measures using 0-10 rating scales for communication importance, position satisfaction, salary satisfaction, and perceived patient need fulfillment.
• Pilot test complete questionnaire with small sample from target population to assess comprehension and reliability.

Participant Recruitment and Data Collection

• Obtain ethical approval from institutional review boards before commencing study.
• Utilize convenience sampling through personal email invitations to potential participants meeting inclusion criteria.
• Implement multi-wave recruitment with initial invitation followed by reminder 30 days later for non-respondents.
• Administer survey through secure online platform with unique identification codes to maintain anonymity while enabling response tracking.
• Apply inclusion criteria: currently working in target setting, >6 months experience, language proficiency.

Statistical Analysis Plan

• Perform descriptive statistical analysis (means, SD, frequencies, percentages) for all variables.
• Test data normality using Shapiro-Wilk test; employ non-parametric analyses if distribution deviates significantly from normal.
• Use Mann-Whitney U Test to examine differences between hospital and community settings.
• Apply Kruskal-Wallis test to assess differences across professional categories.
• Calculate ETA coefficient to determine association strength between workplace setting and moral distress levels.
• Set significance level at p < 0.05 and use SPSS or equivalent statistical software for analysis.

Conceptual Framework of Moral Distress

Figure 1: Moral Distress Pathway from Triggers to Outcomes

This conceptual model illustrates the progression of moral distress from initial triggers through manifestations to professional consequences. The framework highlights how ethical dilemmas surrounding treatment decisions interact with individual and system factors to generate distress that manifests across physical, emotional, and psychological domains, ultimately leading to significant organizational outcomes including burnout, turnover, and compromised care quality [51] [53] [55].

Research Reagent Solutions: Methodological Tools

Table 3: Essential Methodological Tools for Moral Distress Research

Research Tool	Function/Purpose	Application Context	Implementation Considerations
Moral Distress Thermometer (MDT) [53]	Rapid screening of moral distress intensity	Clinical settings, intervention studies	Visual analog scale (0-10); enables quick assessment but limited granularity
Thematic Analysis Framework [23]	Qualitative data organization and interpretation	Interview and focus group studies	Systematic approach to identifying patterns in experiences; requires coder training
STROBE Checklist	Cross-sectional study reporting standards	Survey research, prevalence studies	Ensures comprehensive reporting of observational designs
Cronbach's Alpha Reliability Testing [54]	Instrument internal consistency validation	Tool development and adaptation	Target α >0.70 for acceptable reliability, >0.80 for strong reliability
Non-parametric Statistical Tests (Mann-Whitney U, Kruskal-Wallis) [54]	Analysis of non-normally distributed moral distress data	Comparative studies across groups	Appropriate for Likert-type scales and small sample sizes

These methodological tools represent essential components for rigorous investigation of moral distress phenomena. The Moral Distress Thermometer provides a validated rapid assessment tool suitable for clinical environments where time constraints limit more comprehensive evaluation [53]. Qualitative frameworks enable rich understanding of the nuanced experiences surrounding withholding and withdrawing treatment decisions, while statistical approaches accommodate the non-normal distributions typical of psychological distress measures [54].

Alleviation Strategies and Intervention Protocols

Individual and Organizational Approaches

Evidence-supported interventions for moral distress operate across multiple levels:

Individual-Level Strategies

• Moral resilience building: Develop cognitive reframing techniques, ethical deliberation skills, and self-regulation capacities to navigate morally complex situations [53].
• Moral distress self-assessment: Utilize the 4A's framework (Ask, Affirm, Assess, Act) to structure personal responses to morally distressing situations [51].
• Professional development: Enhance knowledge of ethical guidelines, legal regulations, and professional standards to increase confidence in moral decision-making [56].

Unit-Level Interventions

• Ethics champions: Identify and support designated colleagues who provide peer support and guidance for ethical dilemmas [53].
• Structured debriefing: Implement regular forums for processing morally distressing events with trained facilitators.
• Mentoring programs: Establish formal mentoring relationships to support early-career professionals navigating ethical challenges [53].

Organizational-Level Solutions

• Ethics consultation services: Provide accessible, responsive ethics consultation to support front-line clinicians [53].
• Policy transparency: Develop and communicate clear policies regarding resource allocation and treatment limitation decisions.
• Healthy work environment standards: Implement AACN's six standards for healthy work environments: skilled communication, true collaboration, effective decision-making, meaningful recognition, appropriate staffing, and authentic leadership [53].

Specialized Protocol for Withholding/Withdrawing Treatment Scenarios

Based on empirical research into moral distress surrounding treatment limitation decisions, the following targeted protocol addresses specific constraints identified by healthcare professionals:

Pre-emptive Communication Framework

• Establish clear treatment goals and potential limitation scenarios early in the therapeutic relationship.
• Implement structured conversations about possible future treatment withdrawals, including specific criteria for continuation versus discontinuation.
• Create shared decision-making protocols that explicitly address the distinction between withholding and withdrawing treatments.

System Support Structures

• Develop specialized guidelines for high-frequency moral distress scenarios related to resource allocation.
• Implement transparent institutional policies regarding disinvestment decisions and drug reimbursement limitations.
• Create systematic approaches to managing transitions between active treatment and palliative care.

Post-Decision Support Mechanisms

• Establish formal processes for reviewing and processing treatment limitation decisions.
• Provide psychological support resources specifically tailored to professionals involved in treatment withdrawal.
• Implement moral distress debriefing protocols following emotionally complex cases.

Moral distress represents a significant threat to healthcare workforce stability and patient care quality, with ethical dilemmas surrounding withholding versus withdrawing treatments constituting a particularly potent source of this distress. The empirical discrepancy between ethical equivalence theories and clinical experiences creates complex challenges for healthcare professionals and researchers alike. Effective addressing of this multifaceted problem requires integrated approaches that target individual, unit, and organizational levels while acknowledging the unique moral dimensions of treatment limitation decisions in various clinical contexts.

Future research directions should include longitudinal studies tracking moral distress trajectories among healthcare professionals, intervention trials testing specific alleviation strategies, and comparative analyses of moral distress across healthcare systems with different resource allocation models. By applying rigorous methodological approaches and conceptual frameworks outlined in this technical guide, researchers and healthcare leaders can develop more effective support systems to sustain ethical practice and professional wellbeing within increasingly complex healthcare environments.

Addressing Sociodemographic Disparities in LST Decision-Making

The ethical justification for withholding or withdrawing life-sustaining treatment (LST) often centers on the doctrine of double effect, which distinguishes between intending a patient's death versus foreseeably accepting it while intending to relieve burden [10]. This moral framework underpins clinical practice and policy worldwide, asserting that LST limitation is ethically permissible when the primary intention is to avoid treatment burdens rather than to cause death [10]. However, embedded within this ethical reasoning lies a concerning reality: sociodemographic factors significantly influence how these decisions are made and for whom. Recent evidence demonstrates that unilateral clinician decisions to decline initiating or maintaining LST "are used disproportionately for vulnerable populations" [11], creating an urgent need to address these disparities within the broader moral framework governing treatment limitation decisions.

Documented Disparities in LST Decision-Making

Quantitative Evidence of Systemic Disparities

Table 1: Sociodemographic Disparities in LST Decision-Making

Disparity Domain	Documented Evidence	Regulatory Response
Vulnerable Populations	Unilateral clinician decisions to decline LST used disproportionately for vulnerable populations [11]	No state statutes explicitly address known sociodemographic disparities [11]
Decision-Maker Patterns	In South Korea, 70.6% of deceased patients had LST decisions made by families rather than patients [57]; 81.5% of LST decisions made by family members in clinical data [26]	The Korean Act allows legal representatives to make decisions when patients cannot express preferences [26]
Self-Documentation Factors	Age <65, unmarried status, malignancy, palliative care consultation associated with higher self-documentation rates [58]	Systems increasingly support patient-initiated discussions but timing remains challenging [59]
Data Collection Gaps	Disparities documented in extracorporeal membrane oxygenation selection and unilateral do-not-resuscitate orders during COVID-19 [11]	Only Texas requires tracking sex, race, age, and insurance of patients in committee reviews [11]

Cultural Dimensions in Decision-Making Processes

Cultural norms significantly influence LST decision-making dynamics. In South Korea, studies reveal that "cultural factors, such as collectivist values and societal taboos surrounding death, influence decision-making dynamics" [59]. This collectivist orientation often results in family-centered decision-making, sometimes at the expense of patient self-determination. Eastern cultures traditionally "place more importance on the family as one's guardians than the West does; hence, end-of-life decisions tend to be made by family proxy" [57]. These cultural patterns interact with sociodemographic factors, potentially exacerbating disparities when healthcare systems fail to account for these differences.

Methodological Framework for Disparity Research

Experimental Protocols for Disparity Identification

Protocol 1: Retrospective Analysis of LST Documentation Patterns

• Objective: Identify sociodemographic factors correlating with patient versus surrogate decision-making in LST documentation.
• Data Collection: Extract electronic medical records for all patients completing LST documents during study period. Variables must include: age, sex, race/ethnicity, insurance type, marital status, educational attainment, primary diagnosis, decision-maker designation, timing of decision relative to death, and palliative care consultation [58] [57].
• Analysis Method: Multivariate logistic regression to identify factors independently associated with self-documentation versus surrogate decision-making. Calculate odds ratios with 95% confidence intervals [58].
• Ethical Considerations: IRB approval with waiver of informed consent for retrospective design; compliance with Declaration of Helsinki [58].

Protocol 2: Qualitative Investigation of Decision-Making Dynamics

• Objective: Explore how sociodemographic factors influence the shared decision-making process for LST.
• Participant Recruitment: Theoretical sampling of healthcare professionals, patients, and family caregivers using snowballing chain recruitment method. Inclusion criteria should specifically ensure diversity in age, education, socioeconomic status, and cultural background [59].
• Data Collection: Semi-structured interviews using grounded theory approach. Interview guides should specifically probe how patient characteristics influence communication dynamics, decision-making authority, and timing of discussions [59].
• Analysis: Constant comparative analysis until theoretical saturation achieved. Code for emergent themes related to disparity mechanisms [59].

Protocol 3: Cross-Sectional Survey on Perceptions and Timing

• Objective: Quantize differences in perceptions of appropriate timing for LST discussions across sociodemographic groups.
• Participant Selection: Stratified sampling of health professionals, patients, and families to ensure diverse representation [26].
• Data Collection: Standardized survey instruments adapted from national awareness surveys. Include items on preferred timing for LST discussions, decision-making priorities, and perceived barriers [26].
• Analysis: ANOVA and Chi-square tests to compare awareness, participation, and preferences across groups with different demographic characteristics [26].

Analytical Framework for Regulatory Disparities

Protocol 4: Systematic Analysis of Statute Variation

• Objective: Analyze how state statutes may perpetuate or alleviate sociodemographic disparities in LST decision-making.
• Data Collection: Identify most current state and District of Columbia statutes addressing decisions to decline initiating or maintaining LST using legal databases (Fastcase, Casetext) and state websites [11].
• Analysis: Independent coding by multiple researchers to identify which statutes support unilateral clinician decisions, justifications permitted (medical reasons vs. conscience), and required procedural protections. Comparative analysis of requirements across jurisdictions [11].
• Disparity Assessment: Explicitly code whether statutes address known sociodemographic disparities or require data collection on patient demographics [11].

Visualization of Disparity Mechanisms and Interventions

Disparity Mechanisms and Intervention Pathways

The Scientist's Toolkit: Research Reagent Solutions

Table 2: Essential Research Materials for LST Disparity Investigation

Research Tool	Function/Application	Implementation Example
Electronic Health Record Data Extraction Systems	Retrieves structured and unstructured patient data for retrospective analysis	SCRAP (Severance Clinical Research Analysis Portal) system used to gather EHR data while protecting private information [57]
Standardized Survey Instruments	Quantifies perceptions, awareness, and preferences across diverse populations	Instruments adapted from national surveys of public awareness of LST decision systems [26]
Legal Database Access	Enables systematic analysis of statutory frameworks across jurisdictions	Fastcase and Casetext used to identify and compare state statutes regulating LST decisions [11]
Qualitative Analysis Software	Facilitates coding and thematic analysis of interview transcripts	Software supporting grounded theory approach with constant comparative analysis [59]
STROBE Checklist	Ensures comprehensive reporting of observational studies	Guidelines followed for retrospective cross-sectional studies to maintain methodological rigor [11] [57]

Ethical Framework and Policy Implications

The moral justification for withholding or withdrawing LST fundamentally rests on distinguishing between intended versus foreseen consequences [10]. However, this ethical framework must be reconciled with documented disparities in how these decisions are applied across sociodemographic groups. The core ethical challenge lies in ensuring that the principle of "intending to avoid treatment burdens only" [10] is applied equitably across all patient populations, regardless of age, race, socioeconomic status, or cultural background.

Current regulatory frameworks show significant gaps in addressing these concerns. A comprehensive analysis of US state statutes reveals that while 96% explicitly support unilateral clinician decisions to decline LST, "no statute addressed sociodemographic disparities associated with unilateral clinician decisions to decline initiating or maintaining LST" [11]. This regulatory silence perpetuates systemic inequities, particularly when compounded by cultural factors that influence decision-making dynamics, such as the collectivist values prevalent in many Asian societies that prioritize family-based decision-making over patient autonomy [59] [57].

Addressing sociodemographic disparities in LST decision-making requires both methodological sophistication and moral clarity. Research must move beyond documentation toward intervention development and evaluation. Priority areas include: (1) developing standardized disparity metrics for institutional self-assessment; (2) designing and testing culturally competent shared decision-making models; (3) implementing and evaluating systemic interventions like mandatory disparity monitoring; and (4) advocating for policy reforms that explicitly address equity in LST decision-making. Only by embedding equity concerns within the moral foundations of treatment limitation can we ensure that the ethical framework governing withholding and withdrawing LST serves all patients equally.

This technical guide examines the complex ethical terrain where clinical judgment, patient autonomy, and surrogate decision-making intersect and conflict. Framed within moral foundations research on withholding versus withdrawing treatment, this analysis synthesizes current empirical studies, statutory frameworks, and ethical theories to provide researchers and drug development professionals with a comprehensive understanding of decision-making protocols, conflict mediation strategies, and emerging challenges in artificial intelligence applications. The guide presents quantitative data on surrogate decision-making outcomes, detailed methodological protocols from landmark studies, and visualizations of ethical decision-making pathways to support evidence-based research and clinical policy development in end-of-life care and treatment limitation decisions.

In healthcare decision-making, particularly at end-of-life care, the convergence of clinical expertise, patient self-determination, and surrogate representation creates a complex ethical landscape fraught with potential conflicts. These tensions are especially pronounced in decisions regarding withholding or withdrawing life-sustaining treatments (LST), where moral foundations research reveals significant psychological, ethical, and practical distinctions between these two actions despite their often-equivalent outcomes [13]. Researchers and clinicians consistently report that withdrawing treatment is perceived as more psychologically difficult and ethically charged than withholding the same treatment, even when the clinical outcome is identical [13]. This perceived difference influences decision-making processes and creates barriers to appropriate care transitions.

Within this context, surrogate decision-makers—typically family members or designated agents—face enormous burdens when making treatment decisions for incapacitated patients. Recent research indicates that surrogates who prioritize patient wishes over their own preferences experience higher decision-making satisfaction, with a statistically significant correlation (r = 0.349, P < 0.01) between alignment with patient desires and post-decision satisfaction [60]. Furthermore, understanding the patient's treatment regimen correlates with reduced psychological stress among surrogates (r = -0.394, P < 0.01) [60], highlighting the critical importance of effective communication and education in mitigating conflict.

Quantitative Landscape: Empirical Data on Surrogate Decision-Making

Surrogate Priorities and Decision Outcomes

Recent cross-sectional research provides quantitative insights into the factors that influence surrogate decision-making processes and their outcomes. A 2025 Japanese study of 60 surrogate decision-makers revealed key statistical relationships that inform our understanding of conflict navigation [60].

Table 1: Key Statistical Relationships in Surrogate Decision-Making

Relationship Analyzed	Statistical Measure	P-value	Clinical Interpretation
Patient's wishes vs. surrogate's own wishes in decision-making	P = 0.005	<0.05	Surrogates significantly prioritized patient preferences over their own
Alignment with patient's desires and decision satisfaction	r = 0.349	<0.01	Moderate positive correlation: respecting patient autonomy improves surrogate well-being
Understanding treatment and psychological stress	r = -0.394	<0.01	Moderate negative correlation: education reduces surrogate distress

The same study identified critical information needs for surrogates, with 70% prioritizing knowledge about whether the patient would regain consciousness, and 66.7% considering the patient's age as essential information for decision-making [60]. These quantitative findings underscore the need for structured communication protocols that address these specific informational priorities.

Regulatory Variation in Life-Sustaining Treatment Decisions

A 2025 cross-sectional study of US state statutes revealed significant regulatory variation in clinician authority to decline initiating or maintaining LST, creating a complex legal landscape for clinical decision-making [11].

Table 2: State Statutory Justifications for Unilateral Clinician Decisions to Decline LST

Justification Category	Number of States	Percentage	Common Terminology
Medical reasons only	7	14%	"Medical standards," "medically ineffective"
Reasons of conscience only	9	18%	"Conscience," "moral," "religious"
Both medical and conscience reasons	25	49%	Combination of above terms
No specific justification stated	8	16%	Varied or absent specific language
Total	49	96%

This regulatory fragmentation creates substantial challenges for establishing consistent protocols when clinical judgment conflicts with surrogate preferences, particularly when transfer requirements vary by jurisdiction [11]. Only 28% of state statutes requiring a second medical opinion, 13% requiring ethics committee review, and a single state (Texas) mandating tracking of demographic data in these decisions [11].

Methodological Protocols: Research Frameworks for Investigating Decision Conflicts

Cross-Sectional Survey Methodology for Surrogate Decision-Making Analysis

The 2025 Japanese study on family experiences with surrogate decision-making provides a robust methodological framework for investigating these conflicts [60]:

Population & Sampling:

• Target Population: Family members with experience making surrogate decisions for hospitalized patients with conditions affecting life and prognosis (malignant tumors, neurological disorders, cardiovascular diseases, emergency diseases)
• Sampling Method: Online panel recruitment through private research company with simple random sampling from pre-screened candidates
• Sample Size Calculation: Power = 0.8, significance level = 0.05, effect size r = 0.4, requiring minimum 51 participants (actual n=60)
• Exclusion Criteria: History of diagnosed cognitive problems, inability to lead independent life

Data Collection Instruments:

• Decision Satisfaction Assessment: 10-point numeric rating scale (0-10) for satisfaction, alignment with patient wishes, and emotional burden
• Decision-Making Role Preference: Adapted Control Preferences Scale measuring preferences for patient-led, shared, or physician-led decisions
• Open-ended Qualitative Components: Resources used for decision support, desired healthcare professional support

Analytical Framework:

• Statistical Analysis: Basic descriptives, paired t-tests, χ² tests for nominal scales using SPSS v25
• Qualitative Analysis: Content analysis using NVivo software with research team verification
• Ethical Considerations: Institutional review board approval, written informed consent, data anonymization

Qualitative Meta-Synthesis Protocol for Decisional Conflict Analysis

A 2025 systematic review of decisional conflicts in kidney replacement therapy provides a methodological framework for qualitative synthesis [61]:

Search Strategy:

• Databases: CINAHL, Embase, Web of Science, Cochrane Library, MEDLINE, PubMed, OvidPsycINFO, CNKI, VIP, Wan Fang Database, Sino Med
• Search Timeline: Database inception to March 2025
• Search Methodology: Combination of subject headings (MeSH) and free-text words
• PICo Framework: Population (patients with eGFR <15 mL/min/1.73 m²), Phenomenon of Interest (decisional conflicts), Context (KRT decision-making)

Study Selection & Quality Assessment:

• Inclusion Criteria: Qualitative or mixed-methods studies with extractable qualitative data, English or Chinese language, full-text available
• Exclusion Criteria: Non-qualitative methodologies, duplicate publications, incomplete data, quality rating of "C"
• Quality Appraisal: Joanna Briggs Institute Qualitative Assessment Tool (10-item checklist) with independent review by three researchers

Data Synthesis:

• Extraction: Customized Microsoft Excel form for author details, theoretical perspective, participant characteristics, methods, original quotes
• Analysis: Import into NVivo11, identification of descriptive themes followed by development of analytical themes through synthesis and abstraction
• Validation: Iterative discussion among research team members to resolve disagreements

Moral Foundations: The Withholding Versus Withdrawing Treatment Distinction

The distinction between withholding and withdrawing life-sustaining treatment represents a critical moral and psychological dimension in treatment limitation decisions. While many ethical frameworks propose moral equivalence between these actions, empirical research reveals persistent practical distinctions that influence decision conflicts [13].

Doctrine of Double Effect Application

The 2025 philosophical analysis "Intending to avoid the treatment burdens only" provides a sophisticated framework for applying the Doctrine of Double Effect (DDE) to treatment limitation decisions [10]. According to traditional DDE formulation, withholding/withdrawing LST is justifiable when four conditions are met:

• The act itself is morally good or indifferent
• The agent intends only the good effect (avoiding treatment burden) and not the bad effect (shortening life)
• The good effect is not produced by means of the bad effect
• The good effect is proportionately grave enough to compensate for the bad effect

This framework helps resolve apparent contradictions in moral reasoning by distinguishing between intended versus foreseen consequences, particularly relevant when clinical judgment supports treatment limitation despite surrogate objections [10].

Psychological and Relational Dimensions

Interview studies with physicians and patient organization representatives reveal that while participants acknowledge theoretical ethical equivalence between withholding and withdrawing treatments, they consistently report practical and psychological differences [13]. Key distinguishing factors include:

• Prognostic Uncertainty: Withholding decisions typically occur amid greater prognostic uncertainty than withdrawing decisions
• Relational Dynamics: Withdrawing treatment often involves breaking an established treatment commitment, creating stronger psychological bonds
• Communication Challenges: Discussing treatment withdrawal requires navigating established patient expectations and previous treatment promises

These psychological factors significantly impact how conflicts manifest between clinical teams and surrogates when treatment limitation decisions are considered [13].

Visualization of Ethical Decision-Making Pathways

Ethical Decision Pathway for Conflicting Treatment Preferences

Emerging Frontiers: Algorithmic Fairness in AI Surrogates

The emergence of artificial intelligence systems designed to simulate patient preferences represents a novel frontier in surrogate decision-making research. These AI surrogates aim to infer patient treatment preferences when decisional capacity is lost, creating unique ethical challenges at the intersection of clinical judgment and autonomy preservation [62].

Algorithmic Fairness Frameworks

Current research identifies three primary fairness frameworks with distinct implications for AI surrogate systems:

• Demographic Parity: Requires algorithm outputs be independent of protected attributes, but risks moral homogenization by ignoring authentic preference variations across groups
• Equalized Odds: Demands equal true and false positive rates across groups, but fails to account for moral asymmetry in errors (false DNR recommendations carry greater ethical weight)
• Individual Fairness: Mandates similar individuals receive similar treatments, but faces challenges in defining morally relevant similarity metrics

Each framework presents distinct trade-offs for AI-assisted Do-Not-Resuscitate decision-making, where traditional fairness metrics may be ethically inadequate due to the irreversible consequences of certain errors [62].

Research Reagent Solutions: AI Surrogate Development Toolkit

Table 3: Essential Research Components for AI Surrogate System Development

Component Category	Specific Element	Research Function	Ethical Considerations
Data Sources	Electronic Health Records (EHR)	Training data for preference prediction	Documentation bias, institutional perspectives
	Natural Language Processing (Notes)	Extract unstructured preference statements	Context interpretation challenges
	Behavioral & Wearable Data	Infer values from daily life patterns	Privacy preservation, data scope
Modeling Approaches	Population-Level Models	Identify preference patterns across groups	Minority value system representation
	Individual-Level Models	Personalize predictions to specific patients	Data sparsity for individual patients
	Hybrid Modeling	Balance population and individual data	Weighting scheme transparency
Validation Frameworks	Moral Representation Metrics	Assess fidelity to patient worldview	Cultural appropriateness measures
	Error Asymmetry Analysis	Differentiate false positive/negative impacts	Contextual moral weight assignment
	Cultural Competence Audits	Evaluate performance across value systems	Pluralistic moral framework inclusion

Navigating conflicts between clinical judgment, patient autonomy, and surrogate wishes requires multidisciplinary approaches that integrate empirical evidence, ethical frameworks, and procedural fairness. The distinction between withholding and withdrawing treatment—while theoretically neutral in many ethical frameworks—retains significant psychological and relational importance that influences how conflicts manifest and resolve. Future research should prioritize developing standardized communication protocols that address surrogate information priorities, creating culturally competent conflict resolution frameworks, and establishing ethical guidelines for emerging technologies like AI surrogate systems. By understanding both the quantitative patterns and qualitative experiences of decision-making conflicts, researchers and clinicians can develop more effective strategies for honoring patient values while providing medically appropriate care.

Within the critical realm of healthcare, particularly in decisions regarding the withholding or withdrawing of life-sustaining treatment (LST), the clarity, accessibility, and usability of institutional policies are not merely administrative concerns—they are moral imperatives. Ethical analyses often grapple with the doctrine of double effect, debating whether the intention behind withdrawing treatment is solely to avoid patient burden, which some argue distinguishes it morally from actively intending death [10]. However, empirical studies reveal that healthcare practitioners and patient representatives frequently experience a significant psychological and moral difficulty with withdrawing treatments compared to withholding them, a distinction often rooted in the patient-physician relationship and communication challenges rather than abstract ethics [13]. This gap between ethical theory and on-the-ground experience underscores the vital role that well-designed, accessible policies play in supporting sound, consistent, and compassionate decision-making.

This guide provides a strategic framework for optimizing such guidelines. It moves beyond simple compliance to integrate core principles of digital accessibility, usability, and inclusive design into policy architecture. By doing so, we can create policy documents that are not only legally robust but also functionally effective, enabling researchers, clinicians, and drug development professionals to navigate complex moral landscapes with greater confidence and clarity.

Foundational Concepts: Accessibility, Usability, and Inclusion

To optimize guidelines effectively, it is essential to understand the distinct yet interconnected concepts of accessibility, usability, and inclusion. The World Wide Web Consortium (W3C) clarifies that while these areas overlap significantly, each has a specific focus [63].

• Accessibility: This addresses discriminatory aspects, ensuring that people with disabilities can perceive, understand, navigate, and interact with policies or web content. It often involves technical considerations, such as ensuring compatibility with assistive technologies like screen readers [63].
• Usability: This broader concept is about designing products to be "effective, efficient, and satisfying" for specified users in a specified context of use. When "specified users" includes people with disabilities, usability encompasses accessibility [63].
• Inclusion: Also referred to as universal design, this is the highest goal. It ensures the involvement of everyone to the greatest extent possible, considering a wide range of human diversity including disability, language, skills, and culture [63].

For policies concerning morally weighty decisions like withholding or withdrawing treatment, focusing on usable accessibility—the combination of technical standards and real-world user experience—is paramount. This approach ensures that guidelines are both technically sound and functionally practical for the diverse professionals who rely on them [63].

Strategic Framework for Optimization

Content and Structural Clarity

The complexity of the subject matter demands exceptional clarity in policy presentation.

• Use Plain Language: Avoid legal and medical jargon where possible. Define necessary technical terms like "medically ineffective" or "nonbeneficial treatment" in a simple glossary. This is crucial, as statutes often use varied and nuanced justifications for unilateral decisions (e.g., "medically inappropriate," "contrary to medical standards") [11].
• Implement Logical Information Architecture: Structure the policy with a clear, hierarchical heading structure (H1, H2, H3) and use semantic HTML elements like <nav>, <article>, and <main> to define regions. This creates a predictable and navigable document skeleton, especially for users relying on screen readers [64].
• Provide Multiple Access Pathways: Recognize that users consume information differently. Supplement dense text with structured summaries, flowcharts, and tables. For instance, a table comparing the ethical considerations and required procedures for "Withholding" versus "Withdrawing" treatment can provide immediate clarity that paragraphs of text may not.

Visual Design and Readability

Visual design directly impacts a user's ability to comprehend and process complex information.

• Ensure Color Contrast and Non-Color Cues: Adhere to WCAG 2.2 guidelines by maintaining a minimum color contrast ratio of 4.5:1 for normal text. Never convey information using color alone; use patterns, icons, or text labels to indicate status or differences [64]. This prevents miscommunication for users with color vision deficiencies.
• Design for Readability and Focus: Use typography that supports reading. Provide adequate line spacing and text size options. Crucially, do not remove the visible focus indicator on interactive elements; instead, ensure it meets contrast requirements. This is vital for keyboard navigators to understand their position within the policy document [64].
• Create Accessible Data Visualizations: All non-text content, such as graphs and diagrams illustrating decision pathways, must have text alternatives. Complex images require detailed descriptions or accessible data tables to ensure the information is available to all [65].

Technical and Functional Accessibility

The technical implementation forms the bedrock of an accessible policy.

• Ensure Keyboard and Assistive Technology Compatibility: Every interactive component must be fully operable using a keyboard alone. This includes forms, navigation menus, and any embedded interactive tools. Use ARIA (Accessible Rich Internet Applications) attributes thoughtfully to communicate roles, states, and properties to assistive technologies without creating redundancy [64].
• Build Robust and Adaptive Forms: Accessible forms are critical for any feedback or compliance tracking mechanisms. Every input must have a programmatically associated <label>. Provide clear, specific error messages and guidance for correction, moving beyond vague alerts like "Invalid entry" [64].
• Support Multi-Device and User Adaptation: Policies must be fully responsive and functional across devices (desktop, tablet, mobile). Furthermore, they should respect user-level adaptations, such as system settings for reduced motion or increased text size, without breaking the layout or functionality [64].

Quantitative Data and Experimental Insights

Empirical Data on Withholding vs. Withdrawing

A 2025 cross-sectional study of US state statutes provides critical quantitative insight into the legal landscape governing clinician decisions, revealing significant variation in how these decisions are regulated [11].

Table 1: Justifications for Unilateral Clinician Decisions to Decline Life-Sustaining Treatment (LST) Across US States

Justification Category	Number of States (n=51)	Percentage
Supported unilateral decisions for at least 1 form of LST	49	96%
Medical reasons only	7	14%
Reasons of conscience only	9	18%
Both medical and conscience reasons	25	49%
No specific medical or conscience justification	8	16%

Source: Adapted from Piscitello et al. (2025), JAMA Health Forum [11].

Furthermore, a 2024 behavioral experiment (n=1,067) explored public attitudes, finding that participants were significantly more supportive of rationing decisions framed as withholding treatments compared to withdrawing treatments. Interestingly, they were also more supportive of decisions to withdraw treatment made at the bedside level than at the policy level, highlighting the complex interplay between action type and decision context [18].

Methodologies for Studying Attitudes and Usability

Understanding how to optimize policies requires robust research into user attitudes and behaviors.

• Experimental Design for Eliciting Attitudes: The 2024 study on withdrawing vs. withholding treatments used a between-subjects experiment. Participants were randomized into different conditions (e.g., "withdrawing at policy level," "withholding at policy level") and presented with a rationing dilemma. The key outcome measure was their rating of the decision's acceptability on a scale. This method allows researchers to isolate the causal effect of how a decision is framed (withdrawing vs. withholding) on perceived acceptability [18].
• Qualitative Interview Methods for Deep Insight: A 2022 Swedish interview study with physicians and patient organization representatives used semi-structured interviews and thematic analysis. This methodology is ideal for exploring the "why" behind the numbers. Researchers transcribed interviews and iteratively developed codes and themes, uncovering factors like the importance of the patient-physician relationship and communication, which create a moral significance around withdrawal that is not present for withholding [13].
• Usability Testing with Diverse Users: As recommended by the W3C, effective usability and accessibility research involves observing people with disabilities using websites and assistive technology. This method involves empirical observation of users completing specific tasks (e.g., finding a specific policy clause). Findings are translated into concrete usability guidelines, such as those for page organization, forms, and links, which directly inform better policy design [65] [63].

Visualization of a Policy Optimization Workflow

The following diagram maps the logical workflow and key decision points for developing and testing an optimized, accessible policy, from initial audit through to final implementation and ongoing maintenance.

Professionals developing or evaluating healthcare policies require a specific set of tools to assess both content efficacy and technical accessibility.

Table 2: Key Research Reagent Solutions for Policy and Usability Analysis

Tool or Resource	Type	Primary Function
axe DevTools	Software Tool	Automated accessibility testing for identifying code-level barriers within web-based policy portals [64].
WAVE by WebAIM	Software Tool	Visual feedback about the accessibility of web content by highlighting structural and contrast issues [64].
WCAG 2.2/2.1 AA	Guideline Standard	The benchmark technical standard for testing web accessibility; often the basis for legal compliance [66].
Semi-Structured Interview Protocol	Research Methodology	A qualitative method for gathering in-depth insights from physicians and PORs on ethical dilemmas [13].
Between-Subjects Experimental Design	Research Methodology	A quantitative approach for measuring the causal impact of different policy framings (e.g., withdraw/withhold) on acceptability [18].
NVDA / VoiceOver	Assistive Technology	Screen readers used to conduct real-world testing of how a policy document is navigated and understood by users who are blind [64].

Optimizing guidelines for policy accessibility and usability is a critical, multi-faceted endeavor. By integrating strategic design and robust technical standards with a deep understanding of the ethical complexities in areas like withholding and withdrawing care, we can transform policies from static documents into dynamic tools that support ethical clarity, operational consistency, and ultimately, better decision-making. This process is not a one-time project but an ongoing cycle of evaluation, testing, and refinement, ensuring that as both ethical understanding and technological standards evolve, our guidelines remain fit for purpose.

Decision-making for incapacitated patients without advance directives represents a critical challenge at the intersection of clinical practice, biomedical ethics, and healthcare policy. This whitepaper examines the complex ethical landscape surrounding this vulnerable population, with particular emphasis on the moral distinction between withholding and withdrawing life-sustaining treatments. Through analysis of contemporary research, we explore how psychological, ethical, and practical factors create significant barriers to equitable decision-making. We further propose evidence-based frameworks to guide researchers, clinicians, and policymakers in developing more standardized approaches that respect patient autonomy while navigating the profound ethical tensions inherent in treatment limitation decisions.

Clinical decision-making for incapacitated patients without advance directives presents one of the most ethically complex scenarios in healthcare. These patients, who temporarily or permanently lack decision-making capacity due to physical or mental conditions, rely on substitute decision-makers to protect their rights and interests [67]. Contemporary medical ethics requires providing healthcare services in accordance with the patient's values, preferences, and interests based on the rights to self-determination and privacy [67]. When these preferences are undocumented, healthcare providers and surrogates face profound ethical challenges in determining the appropriate course of treatment.

This whitepaper frames these challenges within the broader context of moral foundations research on withholding versus withdrawing medical treatments. Empirical studies consistently demonstrate that clinicians and the public perceive an ethical distinction between these actions, despite philosophical arguments supporting their equivalence [18] [13] [32]. Through a synthesis of current research and ethical frameworks, this guide aims to equip researchers and drug development professionals with the conceptual tools necessary to navigate this complex landscape and contribute to more equitable, evidence-based approaches for this vulnerable population.

Moral Foundations: Withholding vs. Withdrawing Treatment

The Ethical Debate and Empirical Evidence

The equivalence thesis in medical ethics posits that there is no morally relevant difference between not starting a treatment (withholding) and stopping a treatment that has already been initiated (withdrawing) when the treatment is no longer beneficial or aligned with patient goals [32]. Normative literature has largely argued for this ethical equivalence, often characterizing perceptions of difference as irrational behaviors caused by psychological biases [13]. However, empirical research reveals a consistent discrepancy between theoretical ethics and practical application in clinical settings.

Table 1: Public Attitudes Toward Withholding vs. Withdrawing Treatments

Aspect	Withholding Treatment	Withdrawing Treatment
Public Acceptance	Higher	Lower
Psychological Comfort	Greater	Less
Policy-Level Support	More acceptable	Less acceptable
Bedside-Level Support	N/A	More acceptable than policy level

Recent experimental research involving 1,067 participants found that individuals were more supportive of rationing decisions framed as withholding treatments compared to equivalent decisions framed as withdrawing treatments [18]. This effect persisted across different decision-making contexts, though interestingly, participants were more supportive of treatment withdrawal decisions made at the bedside level compared to similar decisions made at the policy level [18]. This suggests that the perceived ethical distinction is influenced by multiple factors beyond mere outcome equivalence.

Psychological and Relational Factors

Qualitative research with physicians and patient organization representatives reveals that the distinction between withdrawing and withholding treatment is often experienced as psychologically significant, even when stakeholders acknowledge the logical equivalence in terms of patient outcomes [13]. Participants in interview studies commonly expressed internally inconsistent views on whether the two actions should be deemed ethically equivalent [13].

The patient-physician relationship emerges as a critical factor in this distinction. Withdrawing treatment typically involves breaking an established therapeutic relationship and may be perceived as violating trust that was built when initiating treatment [13]. This relational dimension carries moral significance for clinicians and ultimately makes withdrawing treatments psychologically difficult for both physicians and patients, and politically difficult for policy makers [13].

Decision-Making Framework for Incapacitated Patients

Assessing Decision-Making Capacity

Before proceeding with substitute decision-making for incapacitated patients, clinicians must first conduct a thorough assessment of decision-making capacity. Capacity is decision-specific and not an all-or-nothing state; patients may have capacity for some decisions but not others [67]. The Veterans Health Administration advocates for a sliding scale strategy that requires greater decision-making capacity for highly risky interventions and lower capacity for less risky medical interventions [67].

Table 2: Standards for Assessing Decision-Making Capacity

Capacity Component	Assessment Focus	Clinical Application
Understanding	Ability to comprehend information about medical condition and treatment	Can the patient understand the information presented to them?
Appreciation	Ability to recognize how information applies to their situation	Can the patient appreciate how this information relates to their circumstances?
Reasoning	Ability to compare options and consequences	Can the patient compare different options and infer consequences?
Expression of Choice	Ability to communicate a consistent decision	Can the patient communicate their preferences and decisions?

According to clinical standards, a patient is considered to have decision-making capacity if they can demonstrate four key abilities: understanding, appreciation, reasoning, and expressing a choice [68]. This assessment should be conducted by physicians and documented thoroughly in the medical record.

Substitute Decision-Making Standards

When patients lack decision-making capacity and have no advance directives, healthcare decisions fall to substitute decision-makers. These surrogates typically follow two primary standards:

• Substituted Judgment Standard: The surrogate attempts to make the decision the patient would have made if capable, based on the patient's known values, preferences, and prior statements [67].
• Best Interest Standard: When the patient's preferences are unknown, the surrogate decides based on what would best promote the patient's well-being and values [67].

Research indicates that approximately one in three surrogates incorrectly judges patients' end-of-life care desires [67], highlighting the critical need for systematic approaches to guide substitute decision-making. This inaccuracy rate underscores the importance of developing more robust support systems for surrogates facing these difficult decisions.

Legal and Regulatory Frameworks

The legal framework for decision-making for incapacitated patients varies by jurisdiction but generally follows similar ethical principles. In the United States, the Patient Self Determination Act of 1990 mandates that healthcare institutions receiving Medicare and Medicaid funding inform patients about their rights to participate in medical decisions and advance directives [68]. When no surrogate has been appointed, healthcare providers must act in the patient's best interest based on clinical judgment [68].

In complicated situations or when conflicts arise, ethics committees can be called upon to help resolve issues or provide guidance to medical providers [68]. These committees typically include diverse stakeholders who can consider the ethical, legal, and clinical dimensions of complex cases.

Experimental Insights and Research Methodologies

Behavioral Research on Treatment Limitation Decisions

Understanding the psychological and ethical dimensions of treatment decisions requires rigorous experimental methodologies. Recent research has employed sophisticated study designs to unpack the factors influencing attitudes toward withholding and withdrawing treatments.

Table 3: Key Experimental Findings on Withholding vs. Withdrawing Treatments

Study Focus	Methodology	Key Findings
Public Attitudes	Preregistered behavioral experiment with 1,067 participants	• People more supportive of withholding than equivalent withdrawal • Withdrawal more accepted at bedside than policy level
Practitioner Perspectives	14 semi-structured interviews with physicians and patient organization representatives	• Participants expressed internally inconsistent ethical views • Distinction carries moral significance in patient-physician relationship
Clinical Practice	Review of ICU practices	• 40-74% of ICU deaths occur after withholding/withdrawing LST • Clinicians more comfortable withholding than withdrawing

A preregistered behavioral experiment collected data from 1,404 English-speaking participants recruited through Prolific, with 1,067 included in final analysis after attention checks [18]. Participants were randomized into different conditions presenting equivalent rationing dilemmas framed as either withholding or withdrawing treatments at policy or bedside levels [18]. This methodological approach allowed researchers to isolate the effect of framing on acceptance of treatment limitation decisions while controlling for the actual outcome.

Qualitative Research Approaches

Qualitative methodologies have provided deeper insights into the experiential dimensions of treatment limitation decisions. A Swedish study conducted 14 semi-structured interviews with physicians and patient organization representatives, purposively sampling participants from healthcare areas with high influx of technology (oncology, hematology, neurology, and rare diseases) [13]. The interviews were conducted online via Zoom, audio-recorded, transcribed, and analyzed using the thematic framework method [13]. This approach allowed researchers to identify patterns in how stakeholders conceptualize and experience the distinction between withdrawing and withholding treatments.

The research identified several key themes influencing perceptions of treatment limitation decisions, including: individual patients' benefit from treatments, the relationship and communication between patients and physicians, prognostic differences, and system-level factors [13]. These findings suggest that the distinction between withdrawing and withholding treatment as unified concepts is a simplification of a more complex reality where different factors relate differently to these two actions.

Visualizing the Decision-Making Process

The following diagram illustrates the complex decision-making pathway for incapacitated patients without advance directives, incorporating key ethical considerations and potential outcomes:

Research Reagents and Methodological Tools

The study of decision-making for incapacitated patients requires specialized methodological approaches and assessment tools. The following table outlines key resources for researchers investigating this field:

Table 4: Essential Research Methodologies and Assessment Tools

Research Tool	Primary Function	Application Context
Decision Capacity Assessment Instruments	Standardized evaluation of patient understanding, appreciation, reasoning, and expression	Determining decision-making capacity in research participants and clinical populations
Vignette-Based Experiments	Presentation of controlled clinical scenarios with systematic variation of key factors	Isolating the effect of specific variables (e.g., framing as withholding vs. withdrawing) on decision outcomes
Semi-Structured Interview Guides	Flexible qualitative protocols for exploring stakeholder experiences	Eliciting nuanced perspectives from physicians, surrogates, and patient representatives
Standardized Ethical Dilemma Scenarios	Consistent presentation of complex decision-making scenarios	Comparing responses across different participant groups and cultural contexts
Survey Instruments Measuring Attitudes	Quantitative assessment of ethical perceptions and preferences	Evaluating attitudes toward treatment limitation decisions across large samples

These methodological tools enable systematic investigation of the complex factors influencing decision-making for incapacitated patients. When employing these approaches, researchers should pay particular attention to cultural variations in decision-making preferences and ensure adequate representation of diverse perspectives.

Implications for Research and Drug Development

Clinical Trial Considerations

The ethical framework surrounding decision-making for incapacitated patients has significant implications for clinical trial design and implementation. Research involving populations with potentially fluctuating or impaired capacity requires specialized protocols for informed consent and ongoing participation decisions. The sliding scale approach to capacity assessment should guide consent processes, with more rigorous standards applied for higher-risk interventions [67].

Regulatory agencies are increasing their focus on guidelines for vulnerable populations, including those who may lack decision-making capacity [69]. This evolving landscape necessitates proactive planning for capacity-related challenges in clinical trials, particularly in therapeutic areas such as neurology, psychiatry, and critical care where capacity impairment may be common.

Ethical Guideline Development

The documented distinction in perceptions of withholding versus withdrawing treatments highlights the need for more nuanced ethical guidelines that acknowledge both the philosophical equivalence and practical differences in these decisions. Policy solutions proposed in the literature include having agreements between physicians and patients about potential future treatment withdrawals, systematic evaluation of treatment effect, and national-level guidelines to support consistent practice [13].

For drug development professionals, these findings underscore the importance of considering not only whether treatments are effective but also how they might be discontinued when no longer beneficial or economically sustainable. This broader perspective aligns with growing emphasis on real-world evidence and comprehensive treatment pathway assessment in healthcare decision-making.

Decision-making for incapacitated patients without advance directives remains a profound challenge at the intersection of clinical ethics, empirical research, and healthcare policy. The documented moral distinction between withholding and withdrawing treatments represents a significant barrier to consistent, equitable decision-making for this vulnerable population. Through continued research employing rigorous methodologies and interdisciplinary collaboration, we can develop more nuanced frameworks that respect both ethical principles and practical realities.

For researchers and drug development professionals, these findings highlight the critical importance of considering the full therapeutic lifecycle—including treatment initiation, continuation, and potential discontinuation—when developing interventions for serious health conditions. By integrating these ethical considerations into research design and clinical practice, we can work toward a healthcare system that better serves all patients, regardless of their decision-making capacity.

Evidence, Equipoise, and Boundaries: Validating Practices and Distinguishing from Assisted Dying

Empirical validation serves as the cornerstone of evidence-based practice in healthcare, providing the methodological foundation for integrating scientific research into clinical and policy decision-making. This process involves the rigorous, data-driven assessment of measurement tools, theoretical constructs, and clinical practices to establish their reliability, validity, and real-world applicability. Within the morally complex domain of withholding versus withdrawing medical treatment, empirical validation provides an essential framework for moving beyond theoretical debates to evidence-based understanding. The ethical dilemmas surrounding treatment limitation decisions represent a critical area where subjective values and objective evidence intersect, creating an pressing need for validation methodologies that can synthesize diverse forms of evidence while acknowledging moral complexities.

The distinction between withholding (not starting a treatment) and withdrawing (stopping an ongoing treatment) medical interventions presents profound ethical challenges for clinicians, patients, and healthcare systems. While some argue for the moral equivalence of these decisions, empirical research reveals that both healthcare professionals and the public frequently perceive them differently, creating a discrepancy between ethical theory and practice [18] [70]. This technical guide addresses the methodologies required to validate assessment tools, synthesize evidence, and generate robust findings within this ethically sensitive research domain, providing researchers with the technical frameworks necessary to advance understanding of these critical healthcare decisions.

Methodological Foundations of Cross-Sectional Validation Studies

Core Design Principles and Considerations

Cross-sectional studies provide a foundational methodology for validating assessment tools and measuring constructs within healthcare research. When designed and executed rigorously, these studies offer efficient means of establishing the psychometric properties of instruments used to assess attitudes, beliefs, and behaviors related to healthcare decisions. The validation of International Classification of Functioning, Disability and Health (ICF) Core Sets exemplifies the application of cross-sectional methodologies in healthcare research, demonstrating both the strengths and limitations of this approach [71].

A systematic review of cross-sectional studies validating ICF Core-Sets revealed several critical methodological considerations. First, researchers must clearly articulate the consistency between study objectives and outcome variables measured. Second, sample size calculation and justification represent a frequently overlooked requirement, with up to 94.2% of Delphi studies and a significant majority of other validation studies failing to report this essential methodological detail. Third, geographical representation significantly impacts the generalizability of validation findings, with few validation studies conducted in World Health Organization regions of Africa and the Eastern Mediterranean, potentially limiting the cross-cultural applicability of results [71].

The methodological quality of cross-sectional validation studies can be enhanced through several strategic approaches. Multicenter studies strengthen validity by incorporating diverse participant populations and clinical settings. Replication of validation studies across different geographical regions and healthcare systems establishes the cross-cultural robustness of assessment tools. Finally, synthesis of existing research through systematic review and meta-analysis can strengthen the evidence base for validated instruments [71].

Technical Requirements for Validation Studies

Table 1: Key Methodological Requirements for Cross-Sectional Validation Studies

Methodological Component	Technical Requirements	Common Deficiencies
Sample Size Planning	A priori calculation with justification	94.2% of Delphi studies omit calculation [71]
Participant Recruitment	Clear inclusion/exclusion criteria; appropriate sampling strategy	Insufficient description of recruitment methods
Measurement Validity	Consistency between objectives and outcome measures	Lack of multiple validation approaches
Geographical Representation	Multicenter designs across WHO regions	Underrepresentation of African and Eastern Mediterranean regions [71]
Reporting Standards	Complete methodology description; outcome data	Omitted sample size calculations; insufficient statistical reporting

Quantitative Evidence Synthesis: Meta-Analytic Approaches

Foundational Principles and Models

Meta-analysis provides a powerful statistical framework for synthesizing quantitative evidence across multiple studies, offering enhanced statistical power and more precise effect size estimation than individual studies. The fundamental objectives of meta-analysis include estimating an overall mean effect size, quantifying heterogeneity between studies, and explaining observed heterogeneity through moderator analysis [72]. In the context of research on withholding and withdrawing treatment, meta-analytic approaches can identify consistent patterns across diverse studies while acknowledging contextual variations.

Traditional meta-analytic models include fixed-effect and random-effects models. Fixed-effect models assume all effect sizes originate from a single population with one true overall mean, represented statistically as:

$${z}{j}={\beta }{0}+{m}{j},$$ $${m}{j}\sim \mathrm{N}\left(0,{v}_{j}\right),$$

where the intercept ${\beta }{0}$ is the overall mean, $z{j}$ is the effect size from the jth study, and $m_{j}$ is the sampling error [72]. Random-effects models incorporate both within-study and between-study variance, acknowledging that each study may have different true effect sizes due to methodological or contextual differences.

Multilevel meta-analytic models represent a more flexible approach that explicitly accounts for non-independence among effect sizes, a common occurrence when multiple effect sizes are derived from the same study [72]. This approach is particularly valuable for synthesizing evidence on treatment limitation decisions, where primary studies often report multiple related outcomes from the same participant sample.

Effect Size Measures and Selection

The selection of appropriate effect size measures represents a critical decision in meta-analytic methodology. Common effect measures in healthcare research include standardized mean difference (SMD, also known as Hedges' g or Cohen's d), the logarithm of response ratio (lnRR), proportion (%), and Fisher's z-transformation of correlation (Zr) [72]. Each measure possesses distinct statistical properties and is appropriate for different types of data and research questions.

Table 2: Common Effect Size Measures in Healthcare Meta-Analysis

Effect Measure	Formula	Data Type	Interpretation
Standardized Mean Difference (SMD)	$d = \frac{\bar{X}{1} - \bar{X}{2}}{s_{pooled}}$	Continuous outcomes between groups	Difference in standard deviation units
Log Response Ratio (lnRR)	$lnRR = ln(\frac{\bar{X}{1}}{\bar{X}{2}})$	Ratio of means between conditions	Proportional difference between groups
Proportion	$p = \frac{k}{n}$	Dichotomous outcomes	Frequency or prevalence
Fisher's z	$z = 0.5 \cdot ln(\frac{1+r}{1-r})$	Correlation coefficients	Transformed correlation for analysis

For research on withholding and withdrawing treatment, SMD is often appropriate for comparing continuous outcomes (e.g., quality of life measures), while proportions may be used for dichotomous decisions (e.g., acceptance rates of treatment limitation). The transformation of effect sizes to a common metric enables quantitative synthesis across studies employing different measurement approaches [72].

Heterogeneity Assessment and Meta-Regression

Quantifying and explaining heterogeneity represents an essential component of meta-analysis, moving beyond mere calculation of an overall effect to understand variability in study findings. The I² statistic quantifies the percentage of total variability attributable to heterogeneity rather than sampling error, with values of 25%, 50%, and 75% typically interpreted as low, medium, and high heterogeneity, respectively [72].

When substantial heterogeneity is detected, meta-regression techniques can identify study characteristics that explain this variability. In the context of withholding and withdrawing treatment research, potential moderators include decision context (bedside vs. policy level), clinical setting (ICU vs. oncology), patient characteristics, and methodological features of primary studies [18]. Meta-regression extends the random-effects model by incorporating covariates:

$${z}{j}={\beta }{0}+{\beta }{1}{x}{1j}+...+{\beta }{p}{x}{pj}+{\mu}{j}+{m}{j},$$

where ${\beta }{1}$ to ${\beta }{p}$ represent regression coefficients for moderator variables $x{1j}$ to $x{pj}$ [72].

Meta-Analysis Workflow

Experimental Protocols for Empirical Validation

Behavioral Experimentation on Treatment Limitation Decisions

Empirical research on withholding and withdrawing treatment often employs behavioral experiments to understand decision-making patterns among healthcare professionals, patients, and the public. A preregistered behavioral experiment with 1,067 participants exemplifies this approach, examining variations in public attitudes toward treatment limitation decisions at both bedside and policy levels [18].

The experimental protocol employed a between-subjects design with random assignment to one of three conditions: (1) withdrawing treatment at the policy level, (2) withholding treatment at the policy level, and (3) withdrawing treatment at the bedside level. Participants received detailed scenarios describing treatment limitation dilemmas, followed by acceptability assessments of the decisions. The scenarios maintained consistency across conditions, varying only the specific elements related to withdrawal/withholding distinction and decision level, thereby enabling isolation of these specific effects [18].

This experimental approach demonstrated several key findings relevant to the moral distinction between withholding and withdrawing treatments. First, participants showed significantly greater support for rationing decisions framed as withholding treatments compared to equivalent decisions framed as withdrawing treatments. Second, contrary to theoretical predictions, participants were more supportive of treatment withdrawal decisions made at the bedside level compared to identical decisions made at the policy level [18]. These findings highlight the complex interplay between decision framing, context, and moral perceptions in treatment limitation scenarios.

Systematic Review Methodology for Mechanism Studies

Systematic reviews of implementation mechanisms provide another important methodological approach for understanding how evidence-based practices are adopted in healthcare settings, including practices related to treatment limitation decisions. A systematic review of empirical studies examining implementation mechanisms in health identified 46 relevant articles, revealing important methodological considerations for this type of research [73].

The review protocol involved comprehensive searches of PubMed and CINAHL Plus databases, using terms related to implementation science, evidence-based practice, and mechanisms (including mediator and moderator). Inclusion criteria encompassed empirical implementation studies that statistically tested or qualitatively explored mechanisms, mediators, or moderators. Quality assessment employed the Mixed Methods Appraisal Tool (MMAT), evaluating criteria such as participant recruitment strategies, measurement validity, and statistical analysis appropriateness [73].

Key findings from this methodological review highlighted substantial variation in how mechanisms are conceptualized and measured across implementation studies. Most studies employed quantitative methods (73.9%), with fewer using qualitative (10.9%) or mixed methods approaches (15.2%). The majority of studies (84.8%) met three or fewer of the seven established criteria for establishing mechanisms, indicating significant methodological challenges in this research domain [73].

Application to Withholding Versus Withdrawing Treatment Research

Empirical Evidence on Ethical Distinctions

The ethical distinction between withholding and withdrawing medical treatment represents a persistent dilemma in healthcare ethics, with empirical research revealing consistent patterns in how these decisions are perceived and implemented. Experimental evidence demonstrates that people express significantly greater support for limiting patients' access to treatments when framed as withholding rather than withdrawing equivalent interventions [18]. This preference persists despite ethical arguments for the moral equivalence of these decisions, highlighting the complex interplay between normative principles and psychological perceptions.

The context of decision-making significantly influences attitudes toward treatment limitation. Research participants show greater support for treatment withdrawal decisions made at the bedside level compared to policy-level decisions, suggesting that the proximity to individual patient circumstances affects moral perceptions [18]. This finding has important implications for healthcare policy and institutional guidelines regarding treatment limitation decisions.

In clinical practice, the distinction between withholding and withdrawing treatment often manifests differently across medical contexts. In oncology, decisions to forego additional chemotherapy lines are common when potential benefits diminish relative to burdens, with similar ethical rationales applied to both withholding and withdrawing decisions [70]. In contrast, life-sustaining treatments such as mechanical ventilation present more ethically charged decisions, where withdrawal may be perceived as more consequential than withholding, despite similar outcomes [70].

Methodological Considerations for Treatment Limitation Research

Research on withholding and withdrawing treatment decisions presents unique methodological challenges that require careful consideration in study design and interpretation. The table below outlines key methodological considerations and recommended approaches for empirical research in this domain.

Table 3: Methodological Considerations for Withholding/Withdrawing Treatment Research

Methodological Challenge	Impact on Research	Recommended Approach
Moral Intuition vs. Ethical Principle	Discrepancy between stated values and decision patterns	Mixed methods combining surveys with behavioral measures
Contextual Sensitivity	Variable effects across clinical settings	Multi-site designs across diverse clinical contexts
Emotional Intensity	Potential for biased responding due to topic sensitivity	Indirect measures and randomized vignette designs
Cross-Cultural Variation	Limited generalizability of findings	International collaboration and cross-cultural validation
Policy-Practice Gap	Discrepancy between formal guidelines and clinical reality	Multi-level analysis incorporating both perspectives

Empirical research in this domain benefits from methodological triangulation, combining quantitative approaches (e.g., surveys, experiments) with qualitative methods (e.g., interviews, focus groups) to capture both the behavioral patterns and underlying reasoning behind treatment limitation decisions. Additionally, longitudinal designs can track how attitudes and decisions evolve over time and with clinical experience.

Statistical Software and Analysis Tools

Advanced statistical analysis requires specialized software packages capable of implementing complex meta-analytic and multilevel modeling techniques. The R programming environment, with packages such as metafor, provides comprehensive functionality for conducting meta-analyses, meta-regressions, and publication bias assessments [72]. These tools enable researchers to implement multilevel meta-analytic models that appropriately handle non-independence among effect sizes, a common issue in complex healthcare research.

Other specialized software includes tools for qualitative data analysis (e.g., NVivo, MAXQDA) when investigating reasoning and decision-making processes underlying treatment limitation decisions. For behavioral experiments, platforms such as Qualtrics enable precise manipulation of scenario elements and randomization of conditions, facilitating the isolation of specific effects related to withholding versus withdrawing treatment distinctions [18].

Reporting Guidelines and Quality Assessment Tools

Transparent and comprehensive reporting represents an essential component of rigorous empirical research. Several reporting guidelines enhance the quality and reproducibility of research on treatment limitation decisions:

• PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses): Provides structured guidance for reporting systematic reviews and meta-analyses
• MMAT (Mixed Methods Appraisal Tool): Facilitates quality assessment of studies with diverse methodological approaches [73]
• STROBE (Strengthening the Reporting of Observational Studies in Epidemiology): Offers guidelines for reporting observational studies
• CONSORT (Consolidated Standards of Reporting Trials): Provides standards for reporting randomized trials

These tools help ensure methodological transparency and facilitate critical appraisal of research findings, particularly important in ethically sensitive domains like treatment limitation decisions.

Research Framework for Treatment Limitation Studies

Specialized Methodological Approaches

Research on withholding and withdrawing treatment benefits from several specialized methodological approaches tailored to the unique challenges of this domain:

• Vignette-based experiments: Enable precise manipulation of decision contexts while maintaining ethical standards
• Discrete choice experiments: Quantify trade-offs in decision-making processes regarding treatment limitations
• Longitudinal surveys: Track evolution of attitudes among healthcare professionals and the public
• Multi-level modeling: Account for nested data structures (e.g., clinicians within institutions)
• Qualitative comparative analysis: Identify complex configurations of factors influencing decisions

These methodologies facilitate rigorous investigation of the complex ethical, psychological, and contextual factors that shape decisions about withholding and withdrawing medical treatments across diverse clinical scenarios and stakeholder perspectives.

This whitepaper examines the distinct patterns of moral reasoning between practicing physicians and medical students, a critical determinant in navigating ethical dilemmas in healthcare. Empirical evidence from recent studies reveals that physicians consistently employ conventional, rule-based reasoning anchored in legality and professional codes. In contrast, medical students demonstrate greater variability, indecision, and openness to compassion-driven justifications. These differences underscore varying vulnerabilities to moral distress and highlight the imperative for structured ethics training that balances justice, compassion, and professional responsibility. Framed within the context of moral foundations in withholding versus withdrawing treatment research, this analysis provides drug development professionals and researchers with a framework for understanding how ethical decision-making evolves with clinical experience.

Moral judgment is a cornerstone of professional identity formation in medicine, extending beyond the application of clinical guidelines to the evaluation of complex dilemmas where competing values, cultural expectations, and professional responsibilities intersect [74]. In recent decades, research in psychology, philosophy, and bioethics has conceptualized moral reasoning as a multidimensional construct shaped by cognitive development, sociocultural context, and experiential learning.

The principles of autonomy, beneficence, justice, and non-maleficence provide a foundational framework for medical decision-making [75]. However, their interpretation varies across individuals and contexts. This whitepaper explores the comparative moral reasoning of physicians and medical students, with a specific lens on dilemmas concerning the withholding and withdrawing of medical treatment. The ethical rationale for these decisions often hinges on the recognition that not everything technically possible promotes the patient's best interests, a complex notion encompassing both biomedical and overall well-being [76]. Understanding these reasoning patterns is essential for improving clinical training, mitigating moral distress, and fostering ethical drug development and healthcare delivery.

Theoretical Framework and Key Concepts

Models of Moral Reasoning

Moral reasoning in healthcare is frequently analyzed through two complementary theoretical lenses:

• Kohlberg's Theory of Moral Development: This model posits a progression through three levels of moral judgment: the preconventional level (personal interest), the conventional level (compliance with rules and norms), and the postconventional level (universal principles and shared ideals) [77]. The Defining Issues Test (DIT and DIT-2) is a widely used instrument grounded in this theory [74] [77].

• Moral Foundations Theory: This theory offers a broader, pluralistic framework, highlighting intuitive domains such as care, fairness, loyalty, authority, and sanctity [74]. It helps capture the full complexity of moral decision-making, especially in diverse cultural contexts where the sufficiency of principlism has been questioned.

Moral Distress in Clinical Practice

A critical consequence of ethical challenges is moral distress, first defined by Jameton in 1984 as the psychological distress that arises when professionals recognize the ethically appropriate action but feel constrained from acting upon it [74]. This distress is frequently linked to burnout, diminished empathy, and compromised professional integrity, making it a significant concern in healthcare systems [74].

The Ethical Context of Withholding and Withdrawing Treatment

A general rationale for withholding and withdrawing medical treatment in end-of-life situations is that it respects the patient's right to refuse unwanted medical interventions, a principle distinct from voluntary active euthanasia [76]. From an ethical standpoint, the distinction between withholding and withdrawing treatment is often considered morally irrelevant. The fundamental question is whether a treatment promotes the patient's overall good, which cannot be reduced to mere biomedical benefit [76].

Methodological Approaches in Moral Reasoning Research

Core Instrument: The Defining Issues Test (DIT-2)

The primary tool for assessing moral judgment in the cited studies is the Defining Issues Test, version 2 (DIT-2), an adapted neo-Kohlbergian instrument that emphasizes moral schemas over rigid developmental stages [74].

Experimental Protocol for DIT-2 Application:

• Study Design: Cross-sectional, observational studies are typically employed to compare different groups (e.g., students vs. physicians) at a single point in time [74] [77].
• Instrumentation: Participants complete a questionnaire featuring three classical moral dilemmas:
  • The Doctor’s Dilemma: A terminally ill patient requests a morphine overdose to end suffering.
  • Jan and the Drug: A husband considers stealing a vital, unaffordable medication for his dying wife.
  • The Fugitive: A convict who has reintegrated successfully into society must be considered for reporting [74].
• Procedure:
  • Decision Task: For each dilemma, participants choose a proposed action.
  • Rating Task: Participants rate the importance of 12 statements representing different moral reasoning stages (1=not important; 5=extremely important).
  • Ranking Task: Participants select and rank the four most important statements [74].
• Data Analysis:
  • The P-score (Postconventional Index) is calculated, representing the degree to which a person judges moral problems using universal principles. A P-score <30 indicates a preconventional level, 30-40 a conventional level, and >40 a postconventional level [77].
  • Analyses use descriptive statistics and chi-square tests to identify between-group differences [74].

Research Reagent Solutions: Key Methodological Tools

Table 1: Essential Methodological Components for Moral Reasoning Research

Research Component	Function & Role in Experiment	Exemplification in Literature
Defining Issues Test (DIT-2)	Validated instrument to measure moral judgment development; presents dilemmas and captures reasoning patterns.	Adapted and translated for use in Eastern European contexts [74].
Moral Dilemma Vignettes	Standardized, hypothetical but realistic scenarios to elicit moral reasoning in a controlled manner.	"Jan and the Drug" and "The Fugitive" dilemmas [74].
P-Score (Postconventional Index)	Quantitative metric to summarize the tendency to use postconventional, principle-based reasoning.	Used to categorize participants into preconventional, conventional, and postconventional levels [77].
Semi-structured Surveys	Qualitative tool to gather free-text responses on decision criteria, enriching quantitative data.	Used to explore required information and decision criteria in intensive care settings [75].

Comparative Data Analysis: Physicians vs. Medical Students

Quantitative Differences in Moral Reasoning Profiles

Recent empirical studies provide clear evidence of divergent moral reasoning patterns between medical students and practicing physicians.

Table 2: Comparative Moral Reasoning Profiles of Medical Graduates and Other Groups

Participant Group	Preconventional Level (P-score <30)	Conventional Level (P-score 30-40)	Postconventional Level (P-score >40)	Key Reasoning Characteristics
Medical Graduates	37.5% [77]	Not Specified	34.0% [77]	Highest postconventional reasoning; relies on professional codes and legality [74].
Graduates with Other Degrees	56.0% [77]	Not Specified	18.0% [77]	Lower postconventional reasoning compared to medical graduates.
Nonprofessional Adults	70.0% [77]	Not Specified	4.5% [77]	Very high preconventional reasoning; minimal postconventional reasoning.

Table 3: Response Patterns to Specific Ethical Dilemmas (Medical Students vs. Physicians)

Moral Dilemma	Medical Students' Response Patterns	Practicing Physicians' Response Patterns	Statistical Significance
Jan and the Drug	Greater variability and openness to compassion-driven justifications [74].	Consistent endorsement of conventional, law-based reasoning [74].	p < 0.01 [74]
The Fugitive	Demonstrates indecision and consideration of empathy and justice [74].	Emphasis on legality and professional codes [74].	p < 0.01 [74]
Withholding/Withdrawing Treatment	Not explicitly reported in datasets.	Rationale based on patient's right to refuse treatment; moral irrelevance of withholding/withdrawing distinction [76].	Not Applicable

Visualizing the Moral Reasoning Workflow

The following diagram illustrates the experimental workflow and the conceptual relationship between clinical experience and moral reasoning outcomes, as revealed by the studies.

Discussion and Implications for Research and Practice

Synthesis of Findings

The data consistently demonstrates a significant divergence in the moral reasoning architecture of physicians and medical students. Physicians exhibit a more consolidated conventional reasoning profile, heavily influenced by legal frameworks and professional norms [74]. This is characterized by a higher tendency to resolve dilemmas by appealing to authority and maintaining social order. Conversely, medical students show a less consolidated profile, with a greater proportion of individuals at both the pre-conventional and post-conventional levels, indicating a transitional phase where compassion, empathy, and justice are more frequently weighed against established rules [74] [77].

This evolution in reasoning can be interpreted through the lens of professional identity formation. As physicians accumulate clinical experience, they are socialized into a profession with stringent legal and ethical accountability, which may reinforce rule-based reasoning as a protective mechanism against moral and legal transgressions.

Connection to Withholding and Withdrawing Treatment

The findings have profound implications for understanding decision-making in contexts like withholding and withdrawing life-sustaining treatment. The physician's tendency toward law-based reasoning aligns with the need for clear legal and professional guidelines when deciding to forego treatment, ensuring actions are defensible within the healthcare system [74] [76]. The student's greater openness to compassion-driven justifications mirrors the ethical argument that such decisions are morally permissible when they align with the patient's subjective good and overall well-being, not just biomedical benefit [76]. This contrast highlights the inherent tension between the ethics of action (e.g., withdrawing a ventilator) and the ethics of omission (e.g., withholding chemotherapy), a tension that is often morally irrelevant from a patient-centered perspective but can feel significantly different to the clinician [76].

Implications for Drug Development and Healthcare Research

For researchers and professionals in drug development, these insights are critical. Clinical trials and the implementation of new therapies often involve complex ethical decisions, particularly in end-of-life care or when managing severe side effects.

• Patient-Centered Outcomes: Research must incorporate patient-reported outcome measures (PROMs) to capture the patient's view of their well-being, a key component in ethical decision-making [75]. Understanding the patient's values helps align medical interventions with their overall good, mitigating moral distress for clinicians.
• Implementation Science: Employing robust experimental and quasi-experimental designs is essential for testing implementation strategies that support ethical decision-making in real-world clinical settings [78]. This ensures that new treatments are not only effective but are also adopted in an ethically sound manner.
• Ethics Training: The differences in moral reasoning underscore the need for integrated ethics education throughout medical training and continuous professional development. Training should use realistic dilemmas to help students and clinicians navigate the conflict between legal boundaries and compassionate care [74] [77].

This whitepaper delineates the contrasting moral reasoning patterns between physicians and medical students, revealing that physicians gravitate toward conventional, law-based reasoning while students exhibit more variable, compassion-driven approaches. These differences, analyzed within the framework of withholding and withdrawing treatment research, highlight different vulnerabilities to moral distress and underscore the complexity of ethical decision-making in healthcare. For the scientific and drug development community, these findings emphasize the importance of fostering a balanced ethical approach—one that harmonizes the stability of legal and professional norms with the flexibility required for patient-centered, compassionate care. Future efforts should focus on developing educational and supportive interventions that build resilience against moral distress and promote ethical reasoning that is both principled and empathetic.

This technical guide provides a comprehensive analysis of the ethical and legal distinctions between withholding or withdrawing life-sustaining treatment (WH/WD) and assisted dying. While often conflated in public discourse, these practices represent fundamentally different approaches to end-of-life care with distinct ethical foundations, legal frameworks, and clinical implications. Through systematic review of empirical studies, ethical principles, and legal standards, this paper establishes that WH/WD constitutes a recognition of medicine's limitations in altering disease trajectories, whereas assisted dying involves active intervention to terminate life. The analysis reveals significant differences in physician perceptions, psychological impacts on stakeholders, and legal permissions across jurisdictions. These distinctions carry crucial implications for research ethics, clinical practice guidelines, and drug development protocols in serious illness contexts.

The distinction between foregoing life-sustaining treatment and actively assisting in dying represents one of the most critical boundaries in contemporary bioethics and medical law. Within clinical practice and research ethics, precise understanding of these concepts is essential for protocol development, informed consent procedures, and ethical review processes. Withholding or withdrawing life-sustaining treatment (WH/WD) refers to decisions not to initiate or to discontinue medical interventions that may prolong life without reversing the underlying terminal condition [79]. In contrast, assisted dying (also termed medical aid in dying or MAiD) involves a medical professional prescribing medication that a terminally ill patient self-administers to bring about death [80].

The ethical significance of this distinction stems from different moral intuitions about action and omission, intention and foresight, and causation in death. From a legal perspective, most jurisdictions maintain a bright line between these practices, with WH/WD widely permitted while assisted dying remains legally restricted in most regions [81]. For researchers and drug development professionals, these distinctions inform clinical trial design, especially for studies involving patients with advanced illnesses where disease progression rather than treatment limitation may be the appropriate endpoint.

Quantitative Analysis of Clinical Practices and Outcomes

Empirical studies reveal significant differences in the frequency, outcomes, and perceptions of WH/WD versus assisted dying in clinical settings. The data demonstrates that these are not merely theoretical distinctions but are reflected in substantial variations in clinical practice and patient outcomes.

Table 1: Comparative Outcomes of Withholding vs. Withdrawing Life-Sustaining Treatment

Parameter	Withdrawing Therapy	Withholding Therapy	Statistical Significance
Patient mortality	99%	89% (11% survived)	P < 0.001
Median time to death	4 hours	14.3 hours	P < 0.001
Physician comfort level	26% more disturbed	Baseline comfort	Significant difference
Treatment context	Active cessation	Passive non-initiation	Conceptual difference

Source: Adapted from ETHICUS Study [79]

The near-uniform mortality following treatment withdrawal (99%) compared to meaningful survival rates (11%) when treatments are withheld highlights profound clinical differences between these approaches [79]. This divergence in outcomes suggests that patient selection criteria, disease trajectories, or physiological responses differ substantially between these cohorts, with important implications for clinical trial endpoints and survival analyses in palliative care research.

Table 2: Physician Attitudes Toward WH/WD and Assisted Dying

Attitudinal Measure	Withholding Treatment	Withdrawing Treatment	Assisted Dying
Willingness to perform	Higher willingness	26% less willingness	Highly variable by jurisdiction
Perceived ethical equivalence	34% see as equivalent to withdrawing	34% see as equivalent to withholding	Generally not seen as equivalent
Primary concerns	Prognostic uncertainty	Active causation of death	Legal, ethical violations
Psychological burden	Lower	Higher	Highest

Source: Questionnaire-based surveys of critical care professionals [79]

These attitudinal differences among healthcare professionals indicate that the psychological and moral dimensions of these practices differ substantially, potentially affecting recruitment for studies involving end-of-life interventions and data collection about care decisions.

Ethical Frameworks and Distinctions

Foundational Ethical Principles

The ethical framework distinguishing WH/WD from assisted dying rests on four key bioethical principles: autonomy, beneficence, non-maleficence, and justice [82]. Within standard medical ethics, WH/WD represents an application of the principle of autonomy, recognizing the patient's right to refuse unwanted medical interventions, while assisted dying raises distinct questions about the boundaries of beneficence and non-maleficence.

The principle of patient autonomy justifies WH/WD through the right to refuse medical interventions, even those that may sustain life [76]. This principle operates differently in assisted dying, where autonomy claims extend to requesting active assistance in dying. The critical distinction lies in whether the ethical justification derives from respecting treatment refusals or honoring requests for active life-ending interventions.

The Doctrine of Double Effect and Intention

A crucial ethical distinction concerns the role of intention. In WH/WD, the primary intention is to cease burdensome treatment without directly intending death, even if death is foreseen as a likely consequence [76]. In contrast, assisted dying involves the direct intention to bring about the patient's death through prescription of lethal medications [80]. This distinction is formalized in the doctrine of double effect, which morally differentiates between intended versus merely foreseen consequences.

Acts Versus Omissions

The acts versus omissions distinction, while debated in bioethics, continues to influence legal and clinical practice. Withholding treatment constitutes an omission—refraining from initiating an intervention—while withdrawing treatment involves an act of cessation [79]. Assisted dying unequivocally constitutes a series of acts: prescribing, preparing, and self-administering lethal medication [80]. The moral relevance of this distinction remains contested, with empirical studies indicating that healthcare professionals attribute greater moral significance to acts than omissions with similar outcomes [13].

Legal Frameworks and Jurisdictional Variations

Legal systems globally maintain fundamental distinctions between WH/WD and assisted dying, though specific regulations vary significantly by jurisdiction. Understanding these legal boundaries is essential for researchers operating across multiple regulatory environments and for drug development professionals designing international clinical trials.

Legal Status of WH/WD

Withholding and withdrawing life-sustaining treatment is legally permitted in most jurisdictions under specific conditions. The foundational legal principle is that of bodily integrity and self-determination, which grants competent adults the right to refuse any medical treatment, even life-sustaining treatments [32]. Legal standards typically require:

• Informed consent from competent patients or surrogate decision-makers for incapable patients
• Determination that treatment is medically inappropriate or futile
• Documentation in accordance with institutional policies For patients lacking decision-making capacity, decisions generally follow advance directives or substituted judgment standards [82].

Legal Status of Assisted Dying

Assisted dying remains legally prohibited in most countries, though a growing number of jurisdictions have legalized it under specific regulatory frameworks [80]. As of 2025, assisted dying is legal in 11 U.S. states and multiple countries including Canada, the Netherlands, Belgium, and Switzerland [80]. England and Wales were considering legalization as of 2024. Where legalized, assisted dying typically requires:

• Terminal illness diagnosis with specified prognosis (typically 6 months or less)
• Multiple requests with waiting periods between requests
• Mental capacity assessments
• Self-administration requirements (for assisted dying versus euthanasia) [81]

Table 3: Comparative Legal Safeguards for Assisted Dying Across Jurisdictions

Jurisdictional Requirement	Oregon (USA)	Canada	Victoria (Australia)	Proposed UK Bill
Minimum age	18 years	18 years	18 years	18 years
Residency requirement	Yes	Yes	Yes	Ambiguous
Prognosis requirement	≤6 months	Reasonably foreseeable death	≤6 months (or 12 for neurodegenerative)	≤6 months
Number of requests	2 oral + 1 written	2	3	2
Waiting period	15 days between first request and prescription	90 days (can be waived)	9 days minimum	Not specified
Mental health assessment	Required if concern about judgment	Required if concern about judgment	Mandatory for all patients	Not routinely required

Source: Comparative analysis of assisted dying frameworks [81]

Empirical Research Methodologies and Experimental Protocols

Research examining distinctions between WH/WD and assisted dying employs diverse methodological approaches, each with specific strengths and limitations for capturing the complex dimensions of these practices.

Physician Survey Methodology

Objective: To quantify and compare physician attitudes, experiences, and ethical perceptions regarding WH/WD and assisted dying.

Protocol:

• Participant Recruitment: Stratified random sampling of physicians across relevant specialties (critical care, neurology, oncology, palliative medicine)
• Instrument Development:
  • Vignette-based scenarios with systematic variation of key parameters (patient prognosis, decision-maker, treatment type)
  • Likert-scale measures of comfort, ethical appropriateness, and willingness to participate
  • Demographic and practice characteristic questionnaires
• Data Collection: Cross-sectional survey administration with reminder system for non-respondents
• Analysis Plan:
  • Multivariate regression to identify factors associated with perceived differences between WH/WD
  • Factor analysis of ethical dimensions
  • Inter-group comparisons by specialty, religious affiliation, prior experience

This methodology revealed that only 34% of physicians and nurses viewed withholding and withdrawing as ethically equivalent, with 26% reporting greater discomfort with treatment withdrawal [79].

Qualitative Interview Protocols

Objective: To explore nuanced understandings and contextual factors influencing end-of-life decision-making.

Protocol:

• Participant Selection: Purposive sampling of physicians and patient organization representatives from high-technology medical domains (oncology, hematology, neurology, rare diseases)
• Data Collection:
  • Semi-structured interviews using topic guides
  • Pilot testing and iterative revision of interview protocols
  • Audio recording and verbatim transcription
• Analytical Approach:
  • Thematic analysis following the framework method
  • First-order coding followed by iterative theme development
  • Triangulation among multiple researchers with diverse expertise

This approach identified that participants expressed "internally inconsistent views" regarding ethical equivalence, perceiving WH/WD as equivalent in terms of patient need but different in psychological impact and physician-patient relationship dimensions [13].

Observational Studies of End-of-Life Practices

Objective: To document frequencies, timing, and outcomes of WH/WD decisions in clinical practice.

Protocol:

• Setting: Multi-center cohort studies in intensive care units across multiple regions
• Data Elements:
  • Patient demographics and clinical characteristics
  • Timing and type of treatment limitations
  • Survival outcomes following decisions
  • Resource utilization metrics
• Standardization Procedures:
  • Uniform data collection instruments
  • Inter-rater reliability assessments
  • Regular data quality audits
• Statistical Analysis:
  • Survival analysis with time-dependent covariates
  • Multilevel modeling to account for center effects
  • Competing risks analysis for different outcomes

The ETHICUS study implemented this methodology, documenting that death followed treatment withdrawal after a median of 4 hours compared to 14.3 hours when therapy was withheld, with only 1% survival after withdrawal versus 11% survival with withholding [79].

Research Reagents and Methodological Tools

Table 4: Essential Methodological Tools for End-of-Life Decision Research

Research Tool	Function/Application	Key Features	Examples from Literature
Vignette-based surveys	Quantifying attitudes and ethical perceptions	Systematic variation of key parameters; between-subjects design	Physician surveys examining comfort with WH vs WD [79]
Semi-structured interview guides	Qualitative exploration of decision-making processes	Topic guides with flexible follow-up questions; pilot testing	Interviews with physicians and patient organization representatives [13]
Standardized data collection instruments	Documenting clinical practices and outcomes	Uniform definitions; reliability testing	ETHICUS study protocol for recording end-of-life decisions [79]
Capacity assessment tools	Evaluating decision-making capacity in research contexts	Structured assessment of understanding, appreciation, reasoning	Mental health evaluations in MAiD assessments [80]
Quality of life measures	Assessing patient-reported outcomes in end-of-life care	Validated instruments; sensitivity to change	Psycho-oncology assessment in MAiD evaluations [80]

Implications for Research and Drug Development

The ethical and legal distinctions between WH/WD and assisted dying carry significant implications for research design, drug development, and clinical trial implementation in serious illness contexts.

Clinical Trial Endpoints

For studies involving patients with advanced illnesses, precise definition of endpoints is critical. Overall survival analyses must account for WH/WD decisions as potential confounding factors, particularly given the documented impact on mortality trajectories [79]. Trial protocols should establish clear guidelines for distinguishing disease progression from treatment limitation decisions in outcome assessments.

Informed Consent Processes

The ethical requirement for informed consent takes on added complexity in research involving patients with progressive, life-limiting conditions. Consent processes should address:

• Potential for changing decision-making capacity over the trial period
• Procedures for surrogate decision-making
• Clarification that participation does not obligate acceptance of life-prolonging interventions
• Distinct policies regarding WH/WD versus assisted dying across trial sites

Data Collection and Reporting

Standardized data collection on treatment limitations is essential for interpreting trial results across studies. Implementation of structured documentation for:

• Timing and type of treatment limitations
• Decision-makers involved in WH/WD decisions
• Outcomes following treatment limitation decisions This permits more sophisticated analysis of how these decisions may influence observed treatment effects and safety profiles.

The distinction between withholding/withdrawing life-sustaining treatment and assisted dying remains both clinically meaningful and ethically significant despite theoretical arguments about their potential moral equivalence. Empirical research demonstrates that these practices differ substantially in their psychological impact on clinicians, their outcomes for patients, and their regulation across jurisdictions. For researchers and drug development professionals, these distinctions necessitate careful attention to study design, endpoint selection, and ethical oversight—particularly in research involving patients with advanced, life-limiting illnesses. Maintaining conceptual clarity about these boundaries remains essential for ethical research conduct, valid interpretation of clinical outcomes, and appropriate application of findings to clinical practice guidelines and policy development.

Decision-making for incapacitated patients near the end of life represents one of the most ethically and legally challenging areas of clinical practice. This analysis compares the United Kingdom and United States approaches to managing incapacitated patients, with particular focus on the ethical distinctions between withholding and withdrawing life-sustaining treatment (WWLST). The fundamental question of whether these two actions are ethically equivalent permeates legal frameworks, clinical guidelines, and bedside decisions in both jurisdictions [83]. While both nations recognize patient autonomy as a paramount principle, their application of this principle diverges significantly when patients lack decision-making capacity, leading to distinct approaches that reflect their different legal traditions and healthcare systems.

The moral tension between preserving life and respecting patient dignity forms the backdrop against which both UK and US systems have developed. Understanding these cross-jurisdictional differences is critical for researchers examining the moral foundations of end-of-life care, particularly as globalization increases the frequency of cross-cultural ethical dilemmas in healthcare [84]. This analysis explores the legal frameworks, decision-making standards, and ethical considerations that shape care for incapacitated patients in both nations, with specific attention to how these systems approach the clinically and morally significant distinction between not starting treatment versus stopping it once begun.

Ethical Foundations: Withholding Versus Withdrawing Treatment

The ethical distinction between withholding and withdrawing life-sustaining treatment represents a central tension in end-of-life care across jurisdictions. While these actions may lead to the same outcome—the patient's death—their ethical and psychological dimensions differ significantly [83].

The Ethical Debate

The conventional ethical view, supported by many guidelines including the American Medical Association, holds that there is no ethical distinction between withdrawing and withholding life-sustaining treatments [79]. This position maintains that the moral justification for both actions rests on the same principle: respecting patient autonomy and avoiding non-beneficial treatments. However, this theoretical equivalence often conflicts with clinical and psychological realities. Numerous studies demonstrate that healthcare professionals find withdrawing treatment more emotionally challenging than withholding it [79]. This psychological distinction can influence clinical decisions, with surveys showing more physicians are willing to withhold treatment than withdraw it in identical clinical scenarios [79].

The doctrine of double effect often serves as an ethical dividing line, distinguishing between what is intended (relief of suffering) versus what is foreseen (hastening of death) [83]. In WWLST, the primary intention is to avoid prolonging the dying process or causing unnecessary suffering, not to bring about death. By contrast, in assisted dying, the primary intention is the patient's death. This distinction in intention explains the different legal status of these actions across most jurisdictions.

Clinical and Outcome Differences

Significant practical differences exist between withholding and withdrawing treatment, influencing both clinical decision-making and patient outcomes:

• Mortality rates: Observational studies reveal that after withdrawal of therapy, 99% of patients die, typically within a median of 4 hours. In contrast, when therapy is withheld, 11% of patients survive, with death occurring after a median of 14.3 hours for those who do not survive [79].
• Decision-making dynamics: Withholding decisions often occur when prognosis is uncertain, allowing for a "wait and see" approach. Withdrawal decisions typically follow a trial of therapy that has proven ineffective or overly burdensome [79].
• Psychological burden: Healthcare professionals and families frequently report that withdrawing life support feels more active and intentional than withholding it, creating greater emotional difficulty despite theoretical ethical equivalence [79].

Table 1: Comparative Outcomes of Withholding vs. Withdrawing Life-Sustaining Treatment

Parameter	Withdrawing Therapy	Withholding Therapy
Mortality rate	99%	89% (11% survive)
Median time to death	4 hours	14.3 hours
Psychological impact	More emotionally difficult	Less emotionally difficult
Clinical context	After failed treatment trial	When prognosis uncertain
Perceived action	Active process	Passive process

UK Legal Framework and Approach

Mental Capacity Act 2005

The UK's approach to decision-making for incapacitated patients is primarily governed by the Mental Capacity Act 2005 (MCA), which applies to England and Wales, with similar provisions in Scotland under the Adults with Incapacity (Scotland) Act 2000 [85] [86]. The MCA establishes a hybrid best interests/precedent autonomy standard that seeks to balance objective welfare assessments with the patient's previously expressed values and preferences [86].

The Act operates on five statutory principles:

• A presumption of capacity unless established otherwise
• Practical support for decision-making before concluding incapacity
• Respect for unwise decisions
• Best interests as the sole basis for decisions for incapacitated patients
• Use of least restrictive options [85]

For end-of-life decisions, UK law starts from a presumption in favour of prolonging life but explicitly recognizes that this is not an absolute obligation [85]. The General Medical Council guidelines emphasize that decisions must not be motivated by a desire to bring about death and must focus on whether treatment would be of "overall benefit" to the patient [85].

Best Interests Standard

The UK's "best interests" standard requires a broad assessment that extends beyond medical factors to include:

• The patient's past and present wishes and feelings
• Their beliefs and values that would have influenced their decision
• The views of anyone engaged in caring for the patient or interested in their welfare [86]

This approach is particularly significant for patients with disorders of consciousness, such as those in minimally conscious state (MCS), where the courts have sometimes permitted withdrawal of clinically assisted nutrition and hydration (CANH) based on a holistic assessment of best interests that incorporates the patient's prior values [86]. The UK Supreme Court in Airedale NHS Trust v. Bland (1993) established that withdrawal of life-sustaining treatment could be lawful when not in the patient's best interests, creating an important precedent for subsequent cases involving incapacitated patients [83].

US Legal Framework and Approach

Legal Hierarchy and State Variations

The United States lacks a unified federal approach to decision-making for incapacitated patients, resulting in significant variation across state jurisdictions. The US system prioritizes patient autonomy over best interests in decision-making, employing a hierarchical approach to surrogate decision-making [86]:

• Precedent autonomy: When patients have previously expressed clear treatment preferences through advance directives or living wills
• Substituted judgment: When surrogates attempt to determine what the patient would have decided based on their known values and preferences
• Best interests: When patient preferences are unknown and unknowable, requiring an objective assessment of benefits and burdens [86]

This hierarchy reflects the strong emphasis on self-determination in American healthcare law and ethics. However, in practice, U.S. courts frequently prohibit the withdrawal of life-sustaining treatment from conscious but incapacitated patients, such as those in minimally conscious state, even when surrogates argue it aligns with the patient's values [86].

Limitations in Practice

The application of these standards faces several challenges:

• Statutory limitations: Many state laws specifically address only permanent unconsciousness (often using the outdated term "persistent vegetative state") as a triggering condition for surrogate decisions to withdraw life-sustaining treatment [86].
• Conscious patient dilemma: For conscious but incapacitated patients (including those with MCS, dementia, or severe disabilities), surrogates may be legally blocked from deciding to withdraw LST even with evidence of the patient's prior preferences [86].
• Procedural hurdles: Some states require clear and convincing evidence of the patient's wishes, creating significant barriers for surrogates seeking to refuse life-sustaining treatment on behalf of incapacitated patients [86].

Table 2: Comparison of Legal Frameworks for Incapacitated Patients

Decision Element	UK Approach	US Approach
Governing legislation	Mental Capacity Act 2005 (England/Wales)	State-specific legislation
Primary standard	Hybrid best interests/precedent autonomy	Hierarchical: precedent autonomy → substituted judgment → best interests
Advance decisions	Must be specific, written, signed, and witnessed for life-sustaining treatment	Varies by state; generally respected if meet statutory requirements
Court involvement	Court of Protection for contentious cases	Variable; often required for conscious patients without clear advance directives
Withdrawal from MCS patients	Sometimes permitted based on holistic best interests	Generally prohibited without clear prior patient instructions

Cross-Jurisdictional Analysis

Decision-Making Standards

The fundamental difference between UK and US approaches lies in their application of decision-making standards for incapacitated patients. The UK employs a single, unified best interests standard that incorporates the patient's values and preferences as part of a broader assessment, while the US uses a hierarchical approach that prioritizes patient self-determination through precedent autonomy and substituted judgment before resorting to best interests [86].

Paradoxically, despite the US system's stronger theoretical commitment to autonomy, UK courts have been more willing to permit withdrawal of life-sustaining treatment from conscious incapacitated patients when evidence suggests it aligns with their values and best interests [86]. This divergence highlights how similar ethical principles can yield different outcomes when implemented through distinct legal frameworks.

Clinical Application and Consequences

The practical implications of these legal differences are significant:

• Evidence requirements: The UK system allows for more flexible consideration of a patient's values and preferences, even without formal advance directives, while many US states require formal documentation for treatment refusals, particularly for conscious patients [86].
• Vulnerable populations: Patients who never expressed preferences or cannot express them face particular vulnerability in the US system, where the absence of clear evidence of their wishes may default to continued treatment regardless of their current quality of life [86].
• Role of surrogates: UK surrogates provide information to inform the best interests determination but do not necessarily have final decision-making authority, whereas US surrogates typically have stronger legal authority when acting under substituted judgment standards [86].

Research Implications and Methodological Considerations

Key Research Reagents and Materials

Research into cross-jurisdictional analysis of healthcare ethics requires specific methodological approaches and conceptual frameworks:

Table 3: Essential Research Framework for Cross-Jurisdictional Ethical Analysis

Research Component	Function	Application Example
Comparative legal analysis	Identifies statutory and case law differences	Analyzing MCA 2005 (UK) vs. state surrogate decision-making laws (US)
Ethical framework	Provides normative structure for evaluation	Applying principles of autonomy, beneficence, non-maleficence, justice [84]
Case law database	Source of judicial reasoning and precedent	Examining Airedale NHS Trust v. Bland (UK) and comparable US cases
Qualitative interview protocols	Captures stakeholder perspectives	Studying physician attitudes toward WWLST across jurisdictions
Outcome metrics	Measures practical impact of different approaches	Comparing mortality, time to death, and family satisfaction [79]

Experimental Protocols for Ethical Research

Research into the moral foundations of withholding versus withdrawing treatment requires rigorous methodological approaches:

Protocol 1: Healthcare Professional Attitudes Survey

• Based on established questionnaires from North American and European studies [79]
• Utilizes clinical vignettes with random assignment to withholding vs. withdrawal scenarios
• Measures willingness to engage in each action and perceived ethical distinctions
• Controls for demographic factors, clinical experience, and cultural background

Protocol 2: Cross-Jurisdictional Case Law Analysis

• Systematic review of judicial decisions involving incapacitated patients
• Coding for: legal standards applied, evidence considered, ultimate outcomes
• Comparative analysis of how different jurisdictions handle similar fact patterns
• Particular focus on cases involving minimally conscious state patients

Protocol 3: Clinical Outcome Studies

• Observational studies of actual end-of-life decisions in ICU settings
• Documents: mortality rates, time to death, family distress indicators, staff moral distress
• Enables comparison of practical outcomes between withholding and withdrawal [79]

Diagram 1: Decision Pathways for Incapacitated Patients

The comparison of UK and US approaches to decision-making for incapacitated patients reveals both convergence on fundamental ethical principles and divergence in their practical application. While both jurisdictions recognize the importance of patient autonomy and the ethical permissibility of forgoing non-beneficial life-sustaining treatments, their legal frameworks lead to meaningfully different outcomes for vulnerable patient populations.

The distinction between withholding and withdrawing treatment remains both clinically and morally significant despite theoretical arguments for their equivalence. This distinction manifests differently across jurisdictions, influenced by legal standards, evidence requirements, and cultural factors. The UK's unified best interests standard offers greater flexibility for holistic decision-making that incorporates patient values without requiring formal advance directives, while the US approach provides stronger protection for previously expressed wishes but may default to overtreatment when such wishes are not formally documented.

For researchers examining the moral foundations of end-of-life care, these cross-jurisdictional differences represent natural experiments that can illuminate the practical implications of various ethical frameworks. Understanding how different legal systems navigate the tension between protecting vulnerable patients and respecting individual autonomy provides valuable insights for developing more ethically robust approaches to care for incapacitated patients across healthcare systems.

The determination of medical futility represents a critical juncture in patient care, marking the contested transition from life-sustaining intervention to merely life-prolonging measures. Within clinical practice and research ethics, this distinction carries significant moral weight, particularly when framed within the broader debate on the ethical equivalence of withholding versus withdrawing treatment. For researchers and drug development professionals, understanding these concepts is essential not only for trial design but also for navigating the complex ethical landscape of therapeutic innovation. Medical futility is broadly categorized into two distinct concepts: quantitative futility, which refers to physiologic ineffectiveness wherein an intervention has an exceedingly low likelihood of achieving its stated physiologic goal, and qualitative futility, which questions whether an intervention reasonably achieves a proper goal of medicine and provides a benefit of value to the patient [87].

The clinical determination of futility necessitates a shift in the goals of medicine—from curing disease, relieving symptoms, or improving function to easing suffering near the time of death. As Jonsen et al. postulate, healthcare providers have a moral obligation to the goals of medicine, and many argue that prolongation of life "in itself" is not a proper goal [87]. This is particularly relevant for drug development professionals designing trials for end-stage diseases, where the line between meaningful therapeutic effect and mere biological prolongation becomes blurred. Treatments that delay death—such as dialysis, mechanical ventilation, repeated transfusions, and parenteral nutrition—may compound suffering and impede efforts to palliate, thereby running counter to the fundamental goals of medical practice [87].

Ethical Frameworks: Withholding Versus Withdrawing Treatment

Conceptual Distinctions and Moral Relevance

The ethical debate surrounding treatment limitation centers substantially on the distinction between withholding life-sustaining treatment (a decision not to initiate or escalate a therapy) and withdrawing life-sustaining treatment (a decision to cease or remove an ongoing intervention) [88]. Traditionally, these concepts have been defined within the context of terminal illness and in accordance with the expressed wishes of patients or their surrogates. From a moral perspective, a significant body of ethical analysis argues for the moral irrelevance of the distinction between withholding and withdrawing treatments, particularly in the context of pharmaceutical interventions such as chemotherapy in oncology [76].

The ethical rationale for not employing all technically possible interventions in patients near the end of life rests on the principle that not everything medically possible promotes the patient's best interests or overall good. This is especially evident when the patient's medical interest does not align with their comprehensive well-being, giving rise to the ethical dilemmas characteristic of end-of-life medicine [76]. In the context of oncology, for instance, patients frequently face decisions about whether to pursue additional lines of chemotherapy with minimal potential benefit or transition to palliative care. The same ethical rationale that supports withholding chemotherapy initially also supports its subsequent withdrawal when experience demonstrates that the treatment fails to improve the patient's condition or unacceptably diminishes their quality of life [76].

Empirical Research on Perceptions and Decision-Making

Recent experimental research has quantified attitudes toward withholding and withdrawing treatments, revealing significant psychological biases that influence decision-making at both bedside and policy levels. A 2024 preregistered behavioral experiment involving 1,067 participants demonstrated that acceptance toward limiting patients' access to treatments was lower when withdrawing treatments compared with withholding treatment, confirming that people are more supportive of rationing decisions presented as withholding rather than withdrawing treatments [18].

Contrary to the researchers' initial hypothesis, the study also found that participants were more supportive of decisions to withdraw treatment made at the bedside level compared with similar decisions made at the policy level [18]. This finding suggests that the contextual framing of decisions—whether as individualized clinical judgments or broader policy directives—significantly impacts their perceived acceptability. The experimental design manipulated both the rationing type (withdrawing versus withholding) and decision level (bedside versus policy), revealing complex interactions between these variables in shaping ethical perceptions [18].

Table 1: Experimental Findings on Attitudes Toward Treatment Limitation

Experimental Condition	Key Finding	Ethical Implication
Withholding treatment	Higher acceptance compared to withdrawal	Perceived as less active intervention
Withdrawing treatment	Lower acceptance compared to withholding	Perceived as more morally significant act
Bedside decision-making	Higher acceptance for treatment withdrawal	Contextual factors increase legitimacy
Policy-level decision-making	Lower acceptance for treatment withdrawal	Perceived as more impersonal and restrictive

Quantitative Assessment of Futility in Clinical Research

Statistical Methodologies for Futility Analysis

In clinical trials, futility analysis provides a statistical framework for determining when a study is unlikely to achieve its primary objectives, allowing for early termination to conserve resources and protect participants from ineffective interventions [89]. Various methodological approaches have been developed for assessing futility, including stochastic curtailment, predictive power, predictive probability, and group sequential methods [89] [90]. These approaches allow researchers to determine whether continuing a trial is scientifically justified given the interim results.

Multi-stage designs with futility stopping are widely employed in single-arm Phase 2 oncology trials where the probability of positive response is compared to historical response rates [90]. A survey of oncology trials published between 2010-2015 found that 40% of Phase 2 trials in oncology used Simon's two-stage design, which incorporates futility stopping criteria [90]. These statistical frameworks are equally valuable in other therapeutic areas, particularly in Phase 2 trials evaluating novel therapies, where early stopping can prevent exposure to ineffective treatments.

Table 2: Futility Stopping Rules in Clinical Trials

Stopping Rule	Statistical Approach	Decision Criterion	Application Context
Conditional Power [90]	Probability of achieving significance given current trend	Stop if conditional power < cutoff γ	Adapts to observed treatment effect
Test Statistic for H₀ [90]	Interim test statistic for treatment effect	Stop if Zt < c(γ)	Maintains Type I error control
Test for Alternative Hypothesis [90]	Tests H₀,F: μY-μX-δ≥0	Stop if ZtF < cF	Controls stopping probability under HA

Optimal Timing and Decision Boundaries

The timing of futility analyses significantly impacts their utility and efficiency. In two-stage trials, recommendations emphasize optimal timing in terms of information fraction and the probability of stopping under the alternative hypothesis [90]. The information fraction (t) represents the proportion of data collected at the interim analysis relative to the planned total sample size. For a two-arm clinical trial with n subjects per arm, the first interim analysis is typically performed when outcome data from n₁ subjects in each arm are obtained, with corresponding information fraction t₁ = n₁/n [90].

The selection of futility stopping rules often follows optimality criteria proposed by Simon (1989), which minimize the expected sample size under the null hypothesis [90]. Alternative approaches minimize the weighted average of the maximum total sample size and the expected sample size under the null hypothesis [90]. In practice, statistical stopping rules and boundaries often serve as guidelines rather than rigid rules, allowing sponsors flexibility in following or ignoring futility boundaries without inflating Type I error rates [90].

Hermeneutic Approaches to Futility Determinations

Integrating Patient Perspectives and Physician Expertise

Recent phenomenological research suggests that determinations of medical futility extend beyond statistical probabilities to encompass the divergent value orientations and temporal understandings of patients and physicians. A 2025 interpretative phenomenological analysis drawing on Heidegger's concept of being-in-the-world and Gadamer's fusion of horizons reveals that decisions to continue aggressive treatment, even when medically futile, often emerge from fundamentally different existential structures between patients and clinicians [91].

This hermeneutic framework proposes a three-step approach to shared decision-making in contexts of medical futility: (1) attunement to the patient's existential situation, (2) fusion of horizons between patient and physician, and (3) respect for irreducible differences [91]. This approach acknowledges that a clinically "correct" decision may be ethically inadequate if it fails to integrate the patient's lived experience and values. The analysis highlights how patients' decisions are shaped by their "thrownness" (Geworfenheit)—their already-being-in a world of factual conditions not of their choosing, including bodily states, disease trajectories, family roles, and cultural contexts [91].

Temporal Understanding and Clinical Decision-Making

Heidegger's concept of temporality provides crucial insights into futility determinations, suggesting that human existence is not lived in abstract, linear time but as a temporal unity where past experience and future projection shape present understanding [91]. For patients facing terminal illness, decisions made in the present are influenced by memories of suffering and unfinished life projects while being oriented toward an anticipated future. This temporal structure gives clinical choices existential weight that purely statistical assessments of futility may overlook.

The hermeneutic approach emphasizes that physicians and patients may inhabit different temporal horizons when interpreting the same clinical situation. Where physicians may perceive biological inevitability, patients may envision opportunities for meaningful experiences or relational completion. This divergence explains why determinations of futility are not merely binary or unilateral judgments but deeply complex interpretive negotiations that require acknowledging both medical expertise and patient values [91].

Practical Frameworks for Clinical Decision-Making

Communication Strategies and Conflict Mitigation

Effective communication between healthcare providers and patients/families represents a critical component in navigating futility determinations. Evidence suggests that discussions fundamentally should comprise: (1) eliciting the patient's values and goals, (2) communicating which interventions serve those values and which do not, and (3) offering only those interventions whose likely outcomes align with stated values and goals [87]. This approach shifts the focus from specific interventions to overarching objectives of care, potentially reducing conflicts arising from divergent expectations.

Proactive communication is essential, as reactive approaches often lead to scenarios where families feel compelled to request "everything" be done due to insufficient understanding of medical limitations or inadequate insight into patient values [87]. Palliative measures should be framed affirmatively rather than as treatment cessation, and clinicians should maintain transparency about the inherent limits of medical interventions [87]. This is particularly important given that an estimated 20% of Americans die in ICUs, with more than 20% of ICU care administered to patients with poor prospects for survival or functional recovery [87].

Institutional Policies and Systemic Biases

The practical implementation of futility judgments is significantly influenced by institutional policies and systemic biases within medical culture. The management of cardiopulmonary resuscitation (CPR) provides a illustrative example—in most American hospitals, CPR is performed by default unless a Do Not Resuscitate (DNR) order is explicitly documented, a policy that differs markedly from the United Kingdom, where physicians are legally empowered to sign DNR orders against patient/surrogate wishes if resuscitation is deemed unlikely to succeed [87].

Additional biases include "surgical buy-in," a documented practice pattern wherein surgeons are less likely to withdraw care for patients who have undergone difficult procedures or experienced complications following elective operations [87]. Disparities in the aggressiveness of end-of-life care also exist across racial, ethnic, and socioeconomic dimensions, highlighting the need for conscious examination of potential biases in futility determinations [87]. Institutional policies that protect clinicians from legal liability when withdrawing nonbeneficial treatments may help reduce practice variation and support ethically justified decisions.

Research Reagents and Methodological Tools

Table 3: Essential Methodological Tools for Futility Research

Research Tool	Function	Application Context
Simon's Two-Stage Design	Minimizes expected sample size under H₀	Single-arm Phase 2 oncology trials
Conditional Power Analysis	Estimates probability of trial success given interim data	Adaptive clinical trial designs
Predictive Probability Method	Bayesian approach to futility assessment	Trials with substantial outcome variability
Group Sequential Methods	Controls Type I error in multiple looks	Randomized controlled trials
Interpretative Phenomenological Analysis (IPA)	Explores lived experience of futility	Qualitative research on decision-making
Delphi Method	Establishes consensus on definitions and guidelines	Development of institutional policies

The determination of when treatment transitions from life-sustaining to life-prolonging remains a complex interplay of statistical probability, clinical expertise, and patient values. The futility debate underscores the limitations of purely empirical rationality in medical decision-making and highlights the need for hermeneutic frameworks that acknowledge the ontological depth of patient experience [91]. For researchers and drug development professionals, this integrated approach necessitates both methodological rigor in trial design and ethical sensitivity in contextualizing therapeutic goals.

Future progress in this domain will require continued refinement of statistical methods for futility assessment alongside deeper philosophical engagement with the goals of medicine. As biomedical technologies advance, creating increasingly powerful interventions at the margins of life, the ethical imperative to distinguish between meaningful therapy and mere biological prolongation will only intensify. By integrating quantitative assessments with qualitative understanding of patient values, the medical community can develop more nuanced approaches to this fundamentally human dilemma.

Conclusion

The moral foundation for withholding and withdrawing life-sustaining treatment is firmly rooted in their ethical equivalence, a principle supported by core bioethical tenets. However, a significant implementation gap persists, driven by psychological barriers, uneven policy awareness, and systemic vulnerabilities in decision-making processes. For biomedical researchers and drug development professionals, these findings underscore the critical need to integrate ethical foresight into clinical trial design, particularly for studies involving critically ill patients where end-point decisions are paramount. Future directions must focus on developing standardized, accessible protocols that mitigate moral distress, explicit training to address implicit clinician biases, and rigorous ethical frameworks for research at the interface of life-sustaining therapies and end-of-life care. Closing the gap between theoretical equivalence and clinical practice is essential for upholding patient autonomy and ensuring equitable, compassionate care.

References

• 1. Principles of Bioethics [https://depts.washington.edu/bhdept/ethics-medicine/bioethics-topics/articles/principles-bioethics]
• 2. Exploring the ethical issues posed by AI and big data ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12581208/]
• 3. Principles of Clinical Ethics and Their Application to Practice [https://pmc.ncbi.nlm.nih.gov/articles/PMC7923912/]
• 4. Guide to medical law and ethics in healthcare [https://www.medicalprotection.org/uk/guidance/medical-ethics]
• 5. Researchers Highlight Ethical Concerns When Clinical ... [https://www.bu.edu/sph/news/articles/2025/researchers-highlight-ethical-concerns-when-clinical-trials-are-cut-short/]
• 6. Researchers Highlight Ethical Concerns When Clinical Trials ... [https://nursing.iu.edu/news-events/vital-signs/2025/2025-10-researchers-highlight-ethical-concerns-when-clinical-trials-are-cut-short.html]
• 7. Intensivists' ethical perceptions about decisions to withhold ... [https://pubmed.ncbi.nlm.nih.gov/39426181/]
• 8. Ethical Principles [https://www.cdc.gov/niosh/learning/safetyculturehc/module-5/11.html]
• 9. The 2025 Tennessee Medical Ethics Defense Act is ... [https://blogs.bmj.com/medical-ethics/2025/08/21/the-2025-tennessee-medical-ethics-defense-act-is-leading-to-unethical-healthcare/]
• 10. Intending to avoid the treatment burdens only [https://link.springer.com/article/10.1007/s11017-025-09712-7]
• 11. US State Statutes Addressing Unilateral Clinician ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12397882/]
• 12. Quantitative and Qualitative Data in Clinical Trials [https://www.gcp-service.com/quantitative-and-qualitative-data-in-clinical-trials/]
• 13. Withdrawing or withholding treatments in health care rationing [https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-022-00805-9]
• 14. The Influence of Hospital Policies on Clinicians' Decisions ... [https://www.sciencedirect.com/science/article/pii/S0012369225008220]
• 15. Moral foundations theory and the narrative self [https://pmc.ncbi.nlm.nih.gov/articles/PMC10248973/]
• 16. Crafting Richer Messages: Moral Foundations Theory and ... [https://www.networkforphl.org/news-insights/crafting-richer-messages-moral-foundations-theory-and-communication-strategies-for-public-health/]
• 17. The impact of withholding and withdrawal life-sustaining ... [https://www.nature.com/articles/s41598-025-98584-x]
• 18. Withdrawing versus Withholding Treatments in Medical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11346081/]
• 19. Family Health Care Decisions Act (FHCDA) Resource Center [https://nysba.org/fhcda-resource-center/?srsltid=AfmBOoorQpl4s0ADg0Zh8Lmx27QEY7j0aBs3jIhQ4IfZ9vjMlRKFY6lR]
• 20. Post-Trial Access to Treatment & Expanded Access Solutions [https://mytomorrows.com/blog/biopharma/post-trial-access-treatment-how-expanded-access-may-offer-strategic-solution/]
• 21. Legislation - The Laws of New York [https://www.nysenate.gov/legislation/laws/PBH/2994-G]
• 22. Nuanced Public Support for Rationing Treatments by ... [https://link.springer.com/article/10.1007/s11673-025-10469-w]
• 23. Withdrawing or withholding treatments in health care ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC9233323/]
• 24. Distinctions and Controversies in End of Life Care [https://bioethics.umn.edu/events/withdrawing-and-withholding-distinctions-and-controversies-end-life-care]
• 25. Hospital Policy Variation in Addressing Decisions to ... [https://www.sciencedirect.com/science/article/abs/pii/S0012369224000011]
• 26. Issues and implications of the life-sustaining treatment ... [https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-024-01088-y]
• 27. Withdrawal/Withholding of Life-Sustaining Therapies in the ... [https://www.intechopen.com/chapters/1220671]
• 28. Physicians' experiences and perceptions about withholding ... [https://bmcpalliatcare.biomedcentral.com/articles/10.1186/s12904-024-01511-6]
• 29. Hospital Policy Variation in Addressing Decisions to ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11026167/]
• 30. Ethical and Legal Concerns Associated With Withdrawing ... [https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.897955/full]
• 31. Finding Data: Types of Health Data - Guides [https://guides.hshsl.umaryland.edu/finding-data/health-data-types]
• 32. Withdrawing and withholding life-sustaining treatment [https://www.sciencedirect.com/science/article/abs/pii/B9780444535016000123]
• 33. Outcome Predictions at Two Time Points among Surrogates ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11949294/]
• 34. Substituted Judgment: The Limitations of Autonomy in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC2518005/]
• 35. Clinical Decision Support Innovation Collaborative 2024 ... [https://www.ncbi.nlm.nih.gov/books/NBK618402/]
• 36. Advancing Oncology Trials: MMS and Friends of Cancer ... [https://mmsholdings.com/mms-friends-cancer-research-oncology-os-framework/]
• 37. AI for Surrogate Decision Making?!? Dave Wendler, Jenny ... [https://geripal.org/ai-for-surrogate-decision-making-dave-wendler-jenny-blumenthal-barby-teva-brender/]
• 38. Predictive Healthcare 2025: Transforming Patient Outcomes [https://www.omdena.com/blog/predictive-healthcare-2025]
• 39. New Report Uncovers Structural, Cultural Barriers Prevent ... [https://drlornabreen.org/new-report-uncovers-barriers/]
• 40. Medication Adherence in 2025: A Hidden Healthcare Crisis [https://www.pharmdlive.com/blog/medication-adherence-2025/]
• 41. Rethinking Medication Adherence: A Stakeholder Blueprint [https://www.ispor.org/heor-resources/news-top/news/2025/05/12/rethinking-medication-adherence--a-stakeholder-blueprint]
• 42. Clinicians' view on non-adherence: sharing expert opinion [https://pmc.ncbi.nlm.nih.gov/articles/PMC12396120/]
• 43. Barriers and Facilitators to Accessing Primary Care in ... [https://pubmed.ncbi.nlm.nih.gov/41060817/]
• 44. From Ethics to Palliative Care: A Community Hospital ... [https://www.sciencedirect.com/science/article/abs/pii/S0029646508000182]
• 45. First-Ever Global Ranking of Palliative Care: 2025 World ... [https://www.sciencedirect.com/science/article/pii/S0885392425007481?via%3Dihub]
• 46. Human research ethics committees: issues in palliative ... [https://pubmed.ncbi.nlm.nih.gov/12560792/]
• 47. Real-world ethics in palliative care: A systematic review of the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7897798/]
• 48. Current status of knowledge, attitudes, and practices ... [https://www.nature.com/articles/s41598-025-18909-8]
• 49. Ethical issues in palliative care: nursing and quality of life [https://bmcnurs.biomedcentral.com/articles/10.1186/s12912-024-02530-7]
• 50. Examining the implementation of home-based palliative ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12530434/]
• 51. Moral Distress [https://www.aacn.org/clinical-resources/moral-distress]
• 52. Withholding and Withdrawing Life-Sustaining Treatment [https://www.aafp.org/pubs/afp/issues/2000/1001/p1555.html]
• 53. Managing moral distress | NACNS [https://nacns.org/managing-moral-distress/]
• 54. Levels of Moral Distress among Health Care Professionals ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC8701919/]
• 55. Moral Distress as a Critical Driver of Burnout in Medicine [https://pmc.ncbi.nlm.nih.gov/articles/PMC11915272/]
• 56. Newly graduated nurses' experiences of moral distress during ... [https://bmcnurs.biomedcentral.com/articles/10.1186/s12912-025-02863-x/tables/4]
• 57. Life‐Sustaining Treatment Decision in Palliative Care ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10078701/]
• 58. Factors Affecting Life-Sustaining Treatment Decisions and ... [https://www.e-crt.org/journal/view.php?doi=10.4143/crt.2024.360]
• 59. Navigating shared decision-making after the Life-Sustaining ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11568970/]
• 60. Families' Experiences of Surrogate Decision-Making and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC11959204/]
• 61. Decisional Conflicts in Kidney Replacement Therapy for ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12551440/]
• 62. Algorithmic Fairness in AI Surrogates for End-of-Life ... [https://arxiv.org/html/2510.16056v1]
• 63. Accessibility, Usability, and Inclusion [https://www.w3.org/WAI/fundamentals/accessibility-usability-inclusion/]
• 64. Web Accessibility Best Practices 2025 Guide [https://www.broworks.net/blog/web-accessibility-best-practices-2025-guide]
• 65. Usability Guidelines for Accessible Web Design [https://www.nngroup.com/reports/usability-guidelines-accessible-web-design/]
• 66. Accessibility in 2025: What Every Institution Needs to Know [https://www.oho.com/blog/accessibility-2025-what-every-institution-needs-know]
• 67. Protecting Incapacitated Patients' Rights and Best Interests [https://jpalliativecare.com/protecting-incapacitated-patients-rights-and-best-interests/]
• 68. Advance Directives - StatPearls - NCBI Bookshelf - NIH [https://www.ncbi.nlm.nih.gov/books/NBK459133/]
• 69. New Predictions for 2025 [https://globalforum.diaglobal.org/issue/january-2025/additional-predictions-for-2025/]
• 70. On the ethics of withholding and withdrawing medical treatment [https://mrmjournal.biomedcentral.com/articles/10.1186/2049-6958-9-39]
• 71. Methodological considerations in cross-sectional studies ... [https://pubmed.ncbi.nlm.nih.gov/39162291/]
• 72. Quantitative evidence synthesis: a practical guide on meta ... [https://environmentalevidencejournal.biomedcentral.com/articles/10.1186/s13750-023-00301-6]
• 73. A systematic review of empirical studies examining ... [https://implementationscience.biomedcentral.com/articles/10.1186/s13012-020-00983-3]
• 74. Moral Distress in Ethical Dilemmas: A Comparative Study of ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12524078/]
• 75. Presentation of ethical criteria during medical decision-making ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC10430832/]
• 76. On the ethics of withholding and withdrawing medical treatment [https://pmc.ncbi.nlm.nih.gov/articles/PMC4107538/]
• 77. Differences in moral reasoning among medical graduates ... [https://bmcmededuc.biomedcentral.com/articles/10.1186/s12909-022-03624-z]
• 78. Experimental and Quasi-Experimental Designs in ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC6923620/]
• 79. Withdrawing and withholding life-sustaining therapies are not ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC1175875/]
• 80. Medical aid in dying brings a compassionate close to life [https://www.apa.org/monitor/2025/07-08/compassion-medical-aid-dying]
• 81. Strengthening Safeguards in the Assisted Dying Bill [https://pmc.ncbi.nlm.nih.gov/articles/PMC11994194/]
• 82. Navigating Ethical and Legal Decisions in Serious Illness [https://www.nationalcoalitionhpc.org/navigating-ethical-and-legal-decisions-in-serious-illness/]
• 83. Is withdrawing and withholding of life sustaining treatment ... [https://www.sciencedirect.com/science/article/abs/pii/S2352552525001793]
• 84. Ethical principles across countries: does 'ethical' mean the ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC12188308/]
• 85. Guidance: Treatment and care towards the end of life [https://www.gmc-uk.org/professional-standards/the-professional-standards/treatment-and-care-towards-the-end-of-life/guidance]
• 86. Best Interests and Decisions to Withdraw Life-Sustaining ... [https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/best-interests-and-decisions-to-withdraw-lifesustaining-treatment-from-a-conscious-incapacitated-patient/D7B07A98D5DD1FB2BCBC948AD9929E30]
• 87. Addressing Futility: A Practical Approach - PMC [https://pmc.ncbi.nlm.nih.gov/articles/PMC9257305/]
• 88. Definition of Terms Used in Limitation of Treatment and ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC5930529/]
• 89. Assessment of futility in clinical trials [https://pubmed.ncbi.nlm.nih.gov/17128426/]
• 90. Futility stopping in clinical trials, optimality and practical ... [https://pmc.ncbi.nlm.nih.gov/articles/PMC7954786/]
• 91. Medical futility and the ethics of continuing treatment [https://peh-med.biomedcentral.com/articles/10.1186/s13010-025-00200-3]